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ABSTRACT
The experiments in this thesis were designed to
investigate the modification of oxytocin secretion by
mechanisms acting at the posterior pituitary gland and
on centra 11y-projecting oxytocin neurones.
Electrical stimulation of the neurohypophysial stalk
to release oxytocin combined with autobioassay of
oxytocin secretion was used in anaesthetized,1actating
rats to compare actions of opioid-receptor subtype
specific agonists on oxytocin neurone terminals in the
posterior pituitary.The kappa-receptor was identified
as the opioid-receptor subtype responsible for
inhibition of oxytocin secretion at the posterior
pituitary by the use of the selective opioid-receptor
agonists U50.488H and morphine.It was determined that
in rats with oxytocin neurones made tolerant to
morphine there was no cross tolerance to the actions
of kappa-opioid agonists at the posterior pituitary.
Electrically-stimulated isolated posterior pituitaries
in vitro were used to study effects on oxytocin of
opioid—antagonists with different receptor
aff inities: the non-selective antagonist naloxone was
more effective than the relative ^-selective RX8008M
and x—selective MR2266.
Cerebrospinal fluid (CSF) samples were collected from
the cisterna magna, for oxytocin radioimmunoassay from
anaesthetized rats,which were also blood sampled to
monitor opioid actions on centrally-projecting
oxytocin neurones.It was found that oxytocin neurones
projecting centrally and to the posterior pituitary
could not be made dependent upon the kappa-agonist
U50,488H,as assessed by lack of withdrawal excitation
of oxytocin secretion after naloxone.Dependence upon
the p-opioid receptor agonist,morphine,could be
(i)
acheived for oxytocin neurones releasing into CSF as
well as oxytocin neurones secreting into blood;it was
concluded that both centrally-releasing and
magnocellular neurones can be inhibited by
opioids.Studies on morphine dependent rats with
ablated paraventricular nuc1ei, ind i cated that
magnocellular supraoptic neurones could release
oxytocin into CSF during morphine withdrawal.
The effects of a synthetic, fx-selective
opiate,pethidine,upon the progress of parturition was
determined by monitoring the timecourse of parturition
and ensuing maternal behaviour.P1asma samples taken
during parturition shows oxytocin secretion was
decreased following administration of the
opiate,indicating how pethidine slows parturition.
Finally,the opioid receptors involved in the control
of oxytocin secretion were examined more
c 1 ose 1 y. Changes in receptor density of p. and x
receptors in the posterior pituitary during the
development of morphine tolerance were sought by
specific in situ s'H-receptor 1 igand binding
autoradiography and computer assisted image
ana 1ysis.Anima 1s were also treated with i.e.v.
pertussis toxin, known to inactivate G, proteins in
order to investigate the role of these proteins in
post-receptor mechanisms involved in the inhibitory
action of opiates on oxytocin secretion.
(ii)
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THE DISCOVERY OF OXYTOCIN.
Understanding of the pituitary gland and physiology
of the hormones it secretes has progressed far since
the days when it was described as a filter for the
excretion of ' pituita' or 'brain waste" into the
nasophar ynx.
The pressor function of a pituitary body extract
administered intravenously into a dog was noted by
Oliver & Schafer in 1895.The rise in blood pressure
produced was rapid,the fall slow and the maximum
pressure maintained for many minutes if the dose given
was sufficient. The rise was attributed to contraction
, of arterioles and augmentation of heart beats.The
mechanism of action was concluded to be
periphera 1,since when added to Ringers circulating
fluid and perfused through a frog with the nervous
system destroyed,the flow of fluid was greatly
diminished.
In 1901 this study was extended by SchSfer & Magnus to
demonstrate that the pituitary extract caused a marked
'expansion' of the kidney and a prolonged diuresis.The
'active* substance responsible for these described
actions was documented to be present in the
infundibular or nervous portion of the pituitary
gland.
In 1906,Sir Henry Dale was investigating the
physiological actions of ergot in the cat.He had noted
that the actions of adrenaline on blood pressure and
uterine activity was reversed by ergot so that a fall
in arterial blood pressure and relaxation of the
uterus was seen.The pressor activity of posterior
pituitary lobe extract was now familiar and he decided
to see if this action was reversible by ergot.The cat
being recorded from happened to be in the early stages
of pregnancy and injection of the extract not only
showed that it retained its pressor activity in the
-1-
presence of ergot but that the extract could also
produce a strong contractile response of the uterus in
the pregnant animal not hitherto described.This
fortunate experimental 'accident' led to the
systematic studies that were then carried out on
neurohypophyseal extracts, and the hormone oxytocin
was characterized.Oxytocin is now known to play a




Oxytocin is made as part of a large precursor molecule
together with the neurophysin polypeptide which is
associated with the hormone in the neurosecretory
granules found in oxytocin neurones.The precursor is
processed en-route from its site of synthesis in the
cell bodies of the hypothalamic magnocellular neurones
in its passage along the axons through the median
eminence and neurohypohysia 1 stalk, to the granule
sites in the pituitary nerve endings (Ivel1 &
Richter,1984).
In the rat,oxytocin and vasopressin are encoded by
separated genes.The two genes do not appear to be
expressed together — thus a cell produces either
oxytocin or vasopressin but not both.This has been
confirmed immunocytochemica11y (Dierickx,1980) and by
in-situ hybridization studies (Coghlan,Aldred et
al,1984).The biosynthesis of oxytocin and neurophysin
I are shown in Figure <i>.
<ii> Co—localization
One third of oxytocin neurones projecting to the
posterior pituitary produce both oxytocin and
corticotrophin releasing factor <CRF>
(Swanson,Sawchenko et al,1983).CRF is also located in
parvoce11u1ar vasopressin neurones (Whitnal1,Mezey et
al,1985).The hormones co-exist within neurosecretory
GENE










Biosynthesis of oxytocin and neurophysin I based on data
obtained from the cow and rat.
From 'Oxytocin': Clinical and Laboratory studies,Excerpta




Cholecystokinin-8 (CCK) is an abundant regulatory
peptide found in the brain and posterior pituitary of
the rat (Deschapper, Lotstra et al,1983).
Immunocy t ochemi ca 1 studies on CCK have shown that it
is co—localized with oxytocin (Kiss, Wi11iams et
al,1984).Oxytoein and CCK appear to be co-localized in
the same neurosecretory granules (Martin,Gels et
al,1983).Since one third of magnoce11u1ar oxytocin
neurones contain CRF there may be a population of
oxytocin/CRF/CCK containing cells.CCK is not co-
produced with vasopressin.
Opioid peptides have also been isolated within
oxytocin and vasopressin neurones.Met-enkephalin has
been shown to be present in oxytocin containing
neurosecretory granules (Martin,Geis et al,1983) but
is undetectable by immunocytochemica1 methods in the
SON/PVN (Weber,Roth et al,1982>.
Pro-enkephal in A has been isolated in bovine SON and
PVN (Vanderhaegen, Lotstra et al, 1983) and it has been
suggested that pro-enkephalin A could be processed to
met-enkephalin in the rat magnocellular system.
Leu-enkephalin is found in the posterior pituitary in
much greater amounts than met-enkephalin
(Giraud,Castanas et al, 1983) .It is likely that at
least some of this is derived from pro-enkepha 1 i n B
and possibly some from pro-enkephalin A.The product of
pro—enkepha1 in B.dynorphin co-exists and is co-
secreted with vasopressin in magnocel1ular neurones
(Watson, Akil et al, 1982).The significance of these
endogenous opioid peptides in the regulation of
oxytocin secretion will be discussed later.
ELECTROPHYSIOLOGY.
Oxytocin and vasopressin neurones can be distinguished
by their contrasting patterns of electrical
activity.The characteristic firing patterns of the
cells in part reflect their secretory activity and
-4-
also their afferent synaptic inputs.
The first determination of magnoce11u1ar oxytocin
neurone firing came from an experiment that initially
set out to investigate oxytocin release in the
anaesthetized lactating rat following dilatation of
the uterine cervix.Oxytoein secretion was to be
quantified by milk let-down in response to oxytocin
secretion and subsequent weight gain of the litter of
pups suckling at the nipples of the anaesthetized dam.
It was noticed that in the absence of any stimulus
from the experimenters that the pups showed a
stretching reflex and increased vigorous suckling for
about 10 seconds every 5-10 minutes (Wakerley &
Lincoln,1971>.This phenomenon was the milk-ejection
reflex,and coincided with a sharp increase in
intramammary pressure.
Following these observations,electrophysiological
recordings were made from a population of neurones in
the paraventricu1ar nucleus CPVN) that were
continuously firing but showed explosive firing bursts
for 2— 4 seconds prior to mi 1k—ejection.These were
classified as putative oxytoeinergic neurones (Lincoln
& Wakerley, 1971;Wakerley & Lincoln, 1973) .Neurones with
a similar firing pattern were subsequently recorded
in the supraoptic nucleus (SON) (Lincoln &
Wakerley, 1974).
All these early experiments were performed on
anaesthetized animals but identical electrical
recordings were eventually made in unanaesthetized
rats (Summer lee & Lincoln, 1981).
Initially the mammary gland autobioassay was used as a
measure of oxytocin secretion during
electrophysiological recording experiments.Plasma
oxytocin measurements have now been achieved by RIA on
blood samples withdrawn during suckling in conscious
rats (Higuchi,Tadokoro et al,1986) and has confirmed
the release of a 'bolus' of oxytocin after each burst
of electrical activity by the cell bodies of putative
-5-
oxytocin neurones.
Therefore,putative oxytocin neurones were identified
as those cells in the SON/PVN which had a continuous
background firing rate on which were superimposed
synchronous,short duration bursts of high frequency
(10-80Hz) electrical activity.Convers1ey,neurones
which displayed an asynchronous phasic firing-pattern
were classified as putative vasopressinergic cells.
These patterns of firing are also seen during
recording from hypothalamic slices in—vitro (Hatton,Ho
& Mason,1983).Dye injection and immunohistochemistry
following intracellular recording, demonstrated that
the phasically firing neurones contained vasopressin
(Yamashita, Inenaga et al, 1983).By exc1 usion, the
continuously firing cells,in vitro,are classified as
oxytocinergic.
Oxytocin neurones only display their bursting pattern
of firing in response to certain physiological
stimuli.The suckling stimulus,as described
previously,leads to high frequency cell firing
synchronized within all four magnoce11u1ar nuclei
(Lincoln & Russel1,1985).There is summation of the
afferent input in that 5 — 7 pups must be attached to
the nipples for expression of the milk ejection reflex
in the anaesthetized rat (less in the conscious
anima1) .
These synchronous bursts of oxytocin neurones are also
seen upon dilatation of the cervix,for example during
labour (Summerlee, 1981)
Vasopressin cells are not seen to be activated under
these conditions-the stimuli are oxytocin specific.
Changes in osmotic pressure stimulate oxytocin cell
body firing and hence oxytocin secretion but by
Increasing the rate of continuous background firing
rather than by induction of high frequency bursting
(Poulaln,Wakerley & Dyball ,1977).
The phasic firing of vasopressin neurones is believed
to promote a continuous profile of vasopressin
-6-
secretion.The amount of vasopressin secreted is
related to the ratio of the mean 'on phase' (during
firing bursts) to the mean 'off phase' (during silent
periods) and also to the firing rate of the neurones
during the 'on phase'.
The continuous background activity of oxytocin
neurones reflects the nature of the background
secretion of the hormone whilst the high frequency
bursts of electrical activity provide the pulses of
oxytocin which stimulate uterine contractility during
parturition and the mammary gland for the milk-
ejection reflex during 1actation.There is a non-linear
relationship between firing-rate and oxytocin
seeretion,such that at higher frequencies there is a
disproportionate increase in oxytocin secretion
(Lincoln & Russel1,1985).
There is evidence that oxytocin released centrally in
the vicinity of the magnocellular nuclei may act as an
autoregu1 ator upon oxytoeinergic neurones and
synchronize bursting between the four magnocellular
nuclei (Moos,Freund-Mercler et al,1984;Mason,Hatton et
al,1986).
There is extensive neuronal linkage between the four
nuclei (Si 1verman, Hoffman & Zimmerman, 1981) and
oxytoein—containing terminals have been reported in
contact with oxytocin neurone cell bodies
(Theodosls, 1985).Oxytoe in is found to excite
continuously firing but not phasically active neurones
in the SON in vitro (Yamashita,Okuya et al,1983).
Administration of oxytocin into the third ventricle
enhances the neurosecretory bursts associated with
milk-ejection and reduces the interval between them.An
oxytocin antagonist administered to the same site has
the opposite effect (Freund-Mercler & R1chard,1984>.
A background of oxytocin secretion
is,therefore,maintained by the continuous firing of
magnocel1ular oxytocin neurones in the SON/PVN.High
frequency,synchronized bursts of electrical activity
-7-
of these neurones leads to pulses of oxytocin seen
during parturition and 1actat 1 on.Th1s bursting
phenomenon is a gated response with centrally released
oxytocin acting to augment the high frequency bursting
patterns seen.
PROJECTIONS & PATHWAYS.
The cell bodies of oxytocin and vasopressin-containing
neurones are mainly located in two discrete groups, the
supraoptic <SON> and paraventricular CPVN) nuclei.The
neurones in the PVN comprise two
types,magnocellular neurones with cell body diameter
15-35pm and parvoce11u1ar neurones with cell body
diameter 10-15 prn.
There is also a topographic segregation of oxytocin
and vasopressin neurones which has been extensively
described (Sokol,Zimmerman et al, 1976;McNei11 &
SIadek,1980;Swanson,Sawchenko et
al,1981;Rhodes,Morrel1 & Pfaff,1981;Hou-Yu,Lemme et
al,1986).
In general,the magnoce11ular neurones of the
hypothalamus are located in the SON,PVN and anterior
commissural nuclei CACN),a number of accessory nuclei
and also as individual cells within this region.
The SON is divided by the optic tract into the
principal and retrochiasmatic SON regions.The former
is found to contain oxytocin cells rostrally and
dorsally whilst vasopressin neurones are located
caudally and ventra11y.The latter region contains
almost exclusively vasopressin cells.
The PVN is divided into three main regions, the
medial, lateral and posterior subnuclei on the basis of
cellular morphology and peptide content (Swanson &
Kuypers,1980;Armstrong,Warach et al,1980>.
The medial PVN contains mainly oxytoein-secreting
cells.The lateral PVN has a core of vasopressin—
producing cells surrounded by a rim of oxytocin-
containing cells.The posterior PVN contains mainly
-8-
oxytoein-producing eel Is.The accessory nuclei are
found to contain both oxytocin and vasopressin
producing cells.
Magnocellular oxytocin neurones of the principal
portion of the SON project to the posterior pituitary
gland (Scherlock,Field & Raisman,1975)
The projections of oxytoein-containing neurones in the
PVN are more complex. In essence, a core of
magnoce11u1ar neurones project to the posterior
pituitary gland whilst in the parvoce11u1ar regions
oxytocin neurones project to the bra instern, spina1 cord
and the external lamina of the median eminence.
The magnocel1ular portion consists of three relatively
dense cell groups projecting to the posterior
pituitary.The posterior group contains both oxytocin
and vasopressin cells whilst the medial and anterior
groups contain oxytocin only.
Cells from the anterior,media 1 and lateral
parvocellular PVN project to the dorsal-vagal
comp1 ex; 10-15% of these cells project to the medulla
and spinal cord (Swanson & Kuypers,1980).Some oxytocin
fibres from the PVN pass through the dorso-vagal
complex to the central gray of the spinal cord
(Swanson & W=Keller,1979).The dorsal parvoce 11u1ar
region has oxytocin cells which project to the spinal
cord whereas the other regions of the PVN contain
approximately equal numbers of cells which project to
the spinal cord and/or the pituitary gland.
A medial parvoce11u1ar group projects to the median
eminence, where the nerve terminals abut onto
capillaries located In the external lamina and they
release their neurohumoura 1 content into the portal
capillary system which irrigates the anterior
pituitary (Wiegand & Prise,1980).
Oxytocin projections from the PVN have also been
traced to innervate the locus coeruleus and
parabrachial nucleus in the pons
(Swanson, 1977).Oxytoe in-stained fibres also form a
-9-
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plexus in the marginal zone of the spinal nucleus of
the trigeminal nerve in the medulla (Swanson &
Hartman,1980).
In a study by Taniguchi,Yoshida et al,1988 using
retrograde horseradish peroxidase and
immunohistochemi ca1 tracing techniques, 'CSF-contacting
neurones' which have been reported in the subependymal
layer with their cytoplasmic processes projecting to
the ventricular lumen were observed (Vich & Vich-
Teichman,1973).This study however located neuronal
perikarya not only beneath the ependymal layer but
also within the ependymal layer.The existence of these
CSF—contacting,oxytoe in-containing neurones implies
that some of the neurones which project to the
posterior pituitary have a direct connection with the
CSF and may be a source of the detectable CSF
oxytoe in.
The anterior commissural nucleus contains many
magnoce11u1ar oxytocin perikarya which project to the
posterior pituitary but not to the brainstem or spinal
cord and have one or two dendrites which project to
the third ventricle (Armstrong,Warach et
al,1980).These too may contribute to the oxytocin
measured in CSF.
STIMULI FOR INCREASED OXYTOCIN SECRETION.
<i> Parturition
Oxytocin is a potent uterotonic agent and has
therefore been recognized as a possible trigger for
the activation of uterine contractions during
parturition.The action of oxytocin on the myometrium
is dependent upon the presence of extracel lular Cas""
and is inhibited by Ca2'" channel blocking agents
(Forman, Gandrup et al, 1982) . Ca2 is probably the
second messenger involved.
Oxytocin binds to specific binding sites on the muscle
sarcolemmal membrane (Crankshaw,Branda &
Mat 1ieb, 1978).These receptor sites may be linked to
-9-
Ca2"*" channels or gates, thus controlling the influx of
Ca2+ Into the muscle cells (Mironneau,1976).
Oxytocin is also found to inhibit the activity of a
Ca2* extrusion pump which consequently leads to an
increase in intrace 11u1ar Ca2+ CSoloff & Sweet, 1982).
In the rat,uterine responsiveness to oxytocin is
rapidly increased in late gestation so that it is
maximal for the impending parturition (Fuchs,1985).
In this species,oxytoein receptor density on
myometrial cells is increased with oestrogen
(Fuchs,Periyasami et al,1983) an effect which is
inhibited by progesterone. In rats, this steroid-
mediated increase in oxytocin receptors is a major
factor in uterine responsiveness to oxytocin at term.
The electrical activity of antidromica11y identified
magnocellular oxytocin neurones has been recorded
during parturition in unanaesthetized rats
(Summerlee, 1981).Preceding any signs of delivery such
as abdominal contractions, the oxytocin neurones show a
gradual increase in their basal continuous firing
pattern upon which is superimposed rapid bursts of
high frequency activity.These bursts tend to occur
just prior to delivery of individual pups.Vasopressin
cell firing was also increased.
The stimulation of neurosecretory cells in the
posterior pituitary occurs well before delivery of the
pups and is not therefore due to reflexes from the
birth canal during foetal-expulsion.
Measurements of plasma oxytocin and uterine activity
by intra-uterine pressure recordings have shown that
plasma oxytocin does not change in the few hours
before expulsion of the pups (Higuchi,Honda et
al, 1985;Higuchi,Tadokoro et al , 1 986).This would imply
that increased oxytocin secretion is not the critical
element for triggering parturition.Frequent blood
samples taken around the time of foetal expulsion show
a sma11,gradua1 increase in plasma oxytocin which




high frequency bursting of oxytocin neurones during
the abdominal contractions prior to the foetus-
expu1sion.
The apparently different findings with
e 1 ectrophysio1ogy and RIA could be due to several
reasons;the foetus-expulsion reflex may not be the
trigger for the burst like release of oxytocin or
maybe the frequency of sampling was not high enough to
detect the rapid,sharp increase in plasma oxytocin.
There is some speculation that the bursting pattern of
oxytocin neurones seen at this time is not synchronous
unlike milk ejection and that not all of the oxytocin
neurones are activated under these conditions.
Disruption of oxytocin secretion during parturition
and its effect on the time course of pup delivery will
be discussed later.
(ii) The milk—ejection reflex
Suckling is a major stimulus for the increased
secretion of oxytocin.The mechanism of this is as
fo11ows.Pressure sensitive receptors located in the
nipple are activated by the pups suckling
<Find1 ay, 1966) .Nerve impulses travel via segmental
nerves,via the spinal cord and brainstem to the
supraoptic and paraventricular nuclei.The
magnocellular oxytocin neurones in these nuclei fire
intermittently as described above and oxytocin is
released in pulses from their axon terminals in the
pituitary into blood to bind to oxytocin receptors on
myoepithelial cells in the mammary gland (Soloff &
Schwarz,1973).Binding of oxytocin to these receptors
leads to contraction of the myoepithelial cells and
milk from the mammary glands is forcibly ejected to
the suckling pups.This is called the milk ejection
ref1 ex.
Concomitant with the observed extensor reflex of the
-11-
suckling pups,there is a pulsatile release of oxytocin
which decreases rapidly once into the circulation due
to its short half life (ca. 100 sec) (Higuchi,Honda et
al,1985;Higuchi,Tadokoro et al , 1986)
The frequency of milk ejections or the time spent
suckling by the pups seems not to affect the amount of
oxytocin released at mi Ik-ejection.This suggests that
the amount of oxytocin released is strictly
contro11ed.The effect of endogenous opioid peptides on
the release of oxytocin during the milk-ejection
reflex will be discussed later.
<i11> Maintenance of hydromlnera1 balance
For oxytocin to have a role in salt/water balance as a
putative natriuretic hormone,it would be expected to
be released in response to increased plasma
osmolality,Na" concentration and/or decreased blood
vo1ume.
In experiments that involved measurements of intra¬
uterine pressure and urine flow in dogs,hypertonic
saline gave rise to the release of 10-20 times as much
oxytocin as vasopressin (Abrahams & Plckford,1954).
In the rat, it was shown that dehydration by means of
water deprivation or saline intake causes similar
depletion of neurohypophysial oxytocin and vasopressin
content (Jones & Pickering,1969).
To investigate changes in plasma osmolality upon the
firing rate of neurones in the SON and PVN, hypertonic
saline was injected intraperitoneal1y in order to
elevate plasma osmolality without changes in blood
volume <Brimble & Dyba11,1977).
An elevation in firing rate of the oxytocin and
vasopressin neurones was seen but it was low and
sustained compared to that observed during milk-
eject i on . Oxy toe i n neurones responded with an increase
in their continuous firing rate rather than high
frequency burst pat terns.P1asma oxytocin was elevated
in parallel with the firing rate-a rapid response
-12-
immediately following the hypertonic stirnulus,which
was maintained 35-40 minutes after the stimulus
(Brimble,Dybal1 & ForslIng,1978).
As well as a peripheral release of oxytocin following
osmotic stimulation,centra1 release of
oxytocin,presumably from centrally projecting
processes of hypothalamic and extrahypotha1 amic
neurones has been shown (Landgraf,Neumann and
Schwarzberg,1988).
Following hyperosmotic stimulation,an elevation of
oxytocin was seen in plasma and CSF.Using push-pull
perfusion techniques,an elevation of oxytocin in the
septum and dorsal hippocampus was detected
simultaneous with the changes seen in CSF and plasma.
This shows that osmotic stimulation leads to the same
secretory response from two separate oxytocin
pathways,one inside,and one outside the blood-brain
barrier.As mentioned in the anatomical description of
oxytocinergic pathways some neurones appear to project
to the region close to the third ventricle <" CSF-
contacting neurones").These neurones may well be
responsible for the similar response of central and
peripherally projecting neurones.
The question must be raised - how is oxytocin
secretion elevated following hypertonic saline ? What
stimulates the neurones ?
It is possible that, like vasopressin neurones,oxytoe in
neurones are osmosensitive (Mason,1980) but there is
now evidence to suggest that hyperosmotic or
hypernatremic effects are relayed to oxytocin neurones
from elsewhere and angiotensin II is a likely
candidate as a neuroregulator in this pathway.
Angiotensin II receptors are found in the subfornical
organ CSFO) and the organ vasculosum of the lamina
terminal is (OVLT),which are part. of a
circuraventricular system (Simpson,1981).Receptor sites
are also found in the SON and PVN (Mendelsohn, Quirion
et al,1984).
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Angiotensin II i.e.v. stimulates vasopressin release,a
response mediated via the region anterior and ventral
to the third ventricle <AV3V region) (Sladek,1983).
There is now evidence that angiotensin II stimulates
oxytocin secretion.Plasma oxytocin is elevated rapidly
(within one minute) of injecting angiotensin II
i.e.v.—this response is blocked by saralasin,an
angiotensin II antagonist (Lang,Rascher et al,1981),
Lesions of the AV3V region inhibit both oxytocin and
vasopressin release following water deprivation
(Russe11,Hat ton & Robinson, 1984).
The OVLT and SFO project to the SON and PVN as well as
having interconnections between themselves indicating
that the stimulation of oxytocin could involve all of
these structures.
Interruption of the pathway between the SFO and the
SON/PVN reduces the increased electrical activity of
oxytoeinergic neurones following i . p. hypertonic
saline or angiotensin II i.e.v. (Dyball &
PrHusky, 1981) .
This lesion may remove the angiotensin II influence on
the AV3V oxytocin pathway thus removing any input from
the SFO.This results in a decreased secretion of
oxytocin following water deprivation,for example.In
addition,the AV3V region may also contain
osmoreceptors projecting to the magnocellular nuclei,
although ruagnocel lular neurones in the SON and PVN may
themselves be osmosensitive, they apparently require
the AV3V input to express this (Leng, Blackburn et
al,1989).
(iv) Stress
Stress can be defined as activation of the
hypotha1amo-hypophysia 1-adrena1 axis <Gibb,1984).
CRF-41 is believed to be the hypothalamic hormone
which mediates the ACTH response to 'stress'.CRF-41 is
present in hypophys i a 1-por ta 1 blood in sufficient-
amounts to stimulate ACTH secretion.There is increased
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secretion of CRF into portal blood following
haemorrhagic stress and,fo11 owing passive immunization
against CRF-41 the stress response is nearly
abo1ished.
Oxytocin and vasopressin are now thought to be
involved in the modulation of ACTH secretion probably
by a facilitatory effect on the action of CRF-
41.Oxytocin is present in portal blood along with CRF-
41 and CRF-41 is also found co-localized in
magnocellular oxytocin neurones and in parvoce11ular
vasopressin neurones.
The pathways for stress-evoked oxytocin secretion are
not yet known.Oxytoein secretion from the posterior
pituitary appears to be affected differently by
different kinds of stress.
Disturbance of parturition is found to disrupt the
progress of pup delivery due to an inhibition of
oxytocin secretion (Leng,Mansfield et al,1987> and
release of oxytocin during suckling is also blocked by
emotional stress (Lincoln,Hi 11 et al,1973>.
It has been shown that stress-evoked increases in
oxytocin secretion are diminished in lactating rats
(Schlein, Zarrow et al, 1974) which may be due to high
levels of circulating pro1actin.Hyperpro1actinaemia
(produced by the administration of either dopamine
agonists or ovine prolactin) reduces the oxytocin
response to stress. This effect is not seen in
ovariectomized rats but is restored upon replacement
of oestradiol and progesterone.The effect of
hyperpro 1actinaemia on oxytocin secretion is not
mediated by steroids however,sinee oestradiol and
progesterone have no modulatory effect on oxytocin
secretion (Carter & Lightman, 1987) .The mechanisms by
which hyperpro 1actinaemia modifies oxytocin secretion
is not known.
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OPIOID INTERACTION WITH OXYTOCIN SECRETION.
<i> Opioid receptors
There are three main opioid receptor subtypes - a
'classic' morphine receptor called the mu receptor <p>
and two 'non-classic' receptors termed kappa (x) and
delta (5> (Martin,Eades et al,1976>.
Peripheral organ bioassays have shown that the potency
of opioid agon i s t and an t. agon ists varies according to
which tissue is used in the assay, demonstrating that
opioid receptors represent a heterogeneous population
(Chang,Hazum &Cuatrecasas 1980).
There are three endogenous opioid precursor
mo 1 ecu1es, pro-opiome1anocortin (Nakanishi, Inoue et
al, 1979), pro-enkepha1 in (Gubler,Seeberg et al,1982)
and pro-dynorphin (Fischli, Goldstein et
al,1982;Kilpatrick,Wahlstrom et al,1982).
Pro-opiome 1 anocort in gives rise solely to the (3-
endorphin fragment,whereas pro—enkephalin A gives rise
five peptide f ragments;t Met] and [Leul
enkepha1in, 1 Met! enkepha1y1—Arg-Phe, CMet] enkephalyl-
Arg—Gly-Leu and [Met] enkephaly 1-Arg-Arg-Val-NH:;!. Pro-
dynorphin gives rise to pro-dynorphin A and B,a and p—
neoendorphin and dynorphin A (1—8).These fragments of
the precursor molecules have different affinities for
the different opioid receptor subtypes.
p-endorphin binds with approximately equal affinity at
both p. and 5 sites. Leu and Met—enkepha 1 in bind with
highest affinity at the 5 site but the other pro
enkephalin derived fragments bind at both p and 5
s i tes.Fragments of the pro-dynorphin precursor
molecule bind at the x—receptor,dynorphin A and B
having the greatest affinity at this site
(Kosterlitz,1985).
The distribution of opioid receptors has been
determined by specific 1igand-binding autoradiographic
techniques.
A dense distribution of p-receptors has been located
in the neocortex, caudate putamen,nuc1eus
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accumbens,thalamus,hippocampus,amygdala,inferior and
superior co11iculi,nuc1eus tractus so1itarius,spina1
trigeminal nucleus and the dorsal horn.There is a
moderate distribution of p-receptors observed in the
periaqueductal gray and raphd nucleus whilst a sparser
distribution is observed in the hypothalamus,preoptic
area and globus pa 1 1 i dus . Th i s distribution of p—
receptors corresponds well with their putative
function in pain regulation and sensorimotor
integration (Mansour,Khachaturian et al,1988>.
There is a less widespread distribution of 5-receptors
in the CNS. They are most densely located in olfactory-
related areas, neocortex,caudate putamen, nuc1eus
accumbens and amygdala with a very sparse distribution
in the thalamus,hypothalamus and brainstem.the
function of the 5-receptor is not yet known but from
its distribution it is thought that it may play a role
in motor integration and olfaction
(Mansour,Khachaturian et al,1988>.
There is a dense distribution of x-receptors in the
caudate-putamen,nucleus accumbens-
amygdala,hypothalamus,neural lobe of the
pituitary,median eminence and the nucleus tractus
solitarius.A less dense but significant population of
x-receptors are found in the periaqueductal
gray,raphd nuclei,spinal trigeminal nucleus and the
dorsal horn.This distribution is consistent with the
probable role of x-receptors in water balance and
food-intake control,pain perception and neuroendocrine
functions (Mansour,Khachaturian et al,1988>.
Activation of p or 5 opioid-receptor subtypes causes
an increase in potassium conductance.This effect has
been characterized for p-receptors on rat locus
coeruleus neurones (Williams & North,1984) and for the
5—receptor in cell of the submucosal plexus (Mihara &
Nor th, 1986) . It has not yet been demonstrated if p and
5- receptors co-exist on the same neurone
(North,1986).
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Activation of x-receptors leads to a reduction of
voltage dependent calcium conductance.This is believed
to be through the N but not the L-type calcium
channels (Xiang,Adamson et al,1990>.
The results of all these channel events is a reduction
in the rate of neuronal discharge and a reduction in
the amount of transmitter or hormone released by each
action potential.
<ii> Opioid—mediated modulation of oxytocin secretion.
The secretion of oxytocin is inhibited by the action
of endogenous and exogenous opiates.
Autoradiographic studies on the rat brain have shown
that there is a distribution of opioid receptors in
close association with oxytocin neurones.There is a
high density of x-opioid receptors located in the
neural lobe with a few p—receptors but virtually no 6—
receptors present (Herkenham,Rice et al,1986).These
opioid receptors may be located on the oxytocin nerve
terminals or on surrounding pituicytes
(Lightman,Ninkovic et al,1983).In the SON,both x and p
receptors are found (Sumner,Coombes et al,1990>.
As described previous1y,both oxytocin and vasopressin
are co-localized with opioid peptides.Vasopressin with
dynorphin,derived from pro-dynorphin (Watson, Aki1 et
al,1982> and oxytocin with Met (and possibly Leu)
enkephalin (Martin,Geis et al,1983).
Endogenous opioids have a modulatory interaction with
oxytocin neurones which acts at the level of the cell
bodies in the hypothalamus and at the nerve terminals
in the pituitary.
Opioids inhibit the mi Ik-ejection reflex by decreasing
oxytocin secretion.This was first observed in mice
(Haldar & Sawyer,1978) when morphine (a p—opioid
receptor agonist) and its analogues butorphanol and
oxilorphan inhibited the suck 1ing-induced release of
oxytocin.Evidence was also provided that opiates could
inhibit carbachol induced,as well as electrically or
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osmotically stimulated oxytocin release (Clarke,Wood
et al, 1979;Wright,PI 11 et al,1983>.
It was believed that the opiates were acting on or
close to the nerve terminals in the posterior
pituitary although now,the actions of morphine on
oxytocin neurones is believed to be a centrally
mediated effect due to the lack of p-receptors at the
posterior pituitary (Coombes & Russel1,1988)
Environmental disturbance is found to prolong
parturition in the rat and this is partly due to a
decrease in plasma oxytocin (Leng,Mansfield et
al, 1985).Naloxone (a general opioid-receptor
antagonist) administration was found to prevent the
disruption of parturition,presumably by reversal of
endogenous opioid actions,sinee it was observed to
elevate plasma oxytocin content.
It was shown that naloxone did not potentiate oxytocin
secretion in non-pregnant rats or on Day 1 post—partum
but did potentiate oxytocin secretion on Day 22 of
pregnancy,even before the onset of parturition.This
suggests a tonic opioid-inhibition of oxytocin on Day
22 immediately prior to parturition which is absent in
non—pregnant or immediately post-parturient rats
(Leng,Mansfiel d et al,1988).
Which opioid system may be responsible for maintaining
a regulatory opioid tone on oxytocin neurones during
pregnancy is not known.Re 1 ease of oxytocin from
terminals in the posterior pituitary is postulated to
be inhibited by x-opioid agonists,possib1y dynorphin
co-released from neighbouring vasopressin neurones
(Bicknel1,Chapman & Leng,1985;Suramy-Long,Denlinger et
al,1986).E1evated vasopressin ( and hence dynorphin)
is found during pregnancy in the rat
(Lindheimer,Barron et al,1985) but compared to
oxytocin seeretion, the release of vasopressin during
pregnancy is not significant (Hartman,Rosel1 a—Dampman
and Summy-Long, 1987) .
Oxytocin secretion is also under the control of
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opioids acting at the cell bodies of magnocellular
oxytocin neurones (Bicknel1,Leng et al,1988);these
receive g-endorphin projections from the arcuate
nucleus (Sawchenko, Swanson et
al,1982).Interestingly,central g-endorphin levels are
elevated during late pregnancy until 1-2 days post¬
partum (Wardlaw & Franz,1983).
Relaxin concentrations are also elevated during late
pregnancy and relaxin administration to rats
apparently inhibits oxytocin secretion by an
endogenous opioid mechanism (Summer lee,O*Byrne et
al, 1984;O*Byrne & Summer lee, 1985;O*Byrne,EltrIngham et
al,1986).
Endogenous opioid control of oxytocin secretion may be
mediated both centrally and at the neural lobe,and
which is important in various circumstances is not
presently clear.
Oxytocin secretion can also be inhibited during
parturition by the acute administration of exogenous
opiates such as morphine,resu1ting in a prolongation
of litter delivery (Russel1,Gosden et
al, 1989).Morphine is effective when administered
subcutaneous 1y (s.c.) or i ntracerebroventricu1ar1y
(i.c.v.).The i.c.v. dose was however,ineffective when
administered periphera11y,favouring a central site of
action for the opiate.Morphine was found to inhibit
foetal ejection—the movement of pups through the
uterus to the cervix-by decreasing circulating
oxytocin.Infusion of oxytocin in physiological
concentrations <5mU for one minute and then 2mU/min
until delivery was comp 1 ete,reversed the interruption
of parturition by i.e.v. morphine,showing that
morphine was inhibiting oxytocin release from the
neural lobe of the mother rat. It also showed that
physiological concentrations of oxytocin are necessary
for the normal progress of parturition.
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Ciii> Tolerance and dependence.
Oxytocin neurones can be made tolerant to and
dependent upon morphine;this has been demonstrated by
infusing rats i.e. v. with morphine, in increasing
doses,over a period of five days (Rayner,Robinson &
Russel1,1988).
Tolerance is demonstrated by the fact that subsequent
acute doses of morphine have less effect on the
electrical or secretory activity of oxytocin
neurones.Dependence is revealed by a characterized
withdrawal response in which removal of the opiate
with the opioid antagonist naloxone leads to a
dramatic increase in oxytocin neurone firing rate with
a coincident hypersecretion of oxytocin into plasma
(Rayner,Robinson & Russell,1988;Bicknel1,Leng et
al,1988;Leng,Russel1 & Grossman ,1989).
Chronic morphine treatment initially blocks the
suck 1ing-induced mi Ik-ejection reflex in lactating
rats but this returns to normal within three
days,whilst still receiving the morphine infusion
(Russel1,1984).These results demonstrate the
development of to1erance;evident 1y,during infusion of
the opiate,the oxytocin neurones modify their activity
to restore a normal state of electrical and
neurosecretory activity.When the opiate action is
acutely reversed by naloxone administration,the
oxytocin cells are left in a hyperexcitable
state,revea1ing dependence.
This overview of oxytocin biosynthesis,the pathways
regulating secretion and its regulation by opioids
demonstrate the complexity of the magnoce11u1ar and
parvoce 11u1ar oxytocin system.This thesis now attempts
to elucidate the acute and chronic actions of opioids
on the regulation of oxytocin from certain pathway




CHAPTER 1 : General methods.
1.1 ANIMALS
Unless otherwise stated,all the animals used in the
following experiments were supplied by Bantin &
Kingman (Hull,U.K.) and were Sprague-Dawley
straIn.Pregnant and lactating animals were always
primiparous and housed under controlled temperature
(22—23°C> and light cycle conditions (13hrs
light/llhrs dark, lights on 8a.m GMT).Non-pregnant
animals were virgin females which were kept under the
same temperature but a slightly different lighting
schedule (12hrs light/12hrs dark,lights on 8.50a.m.
GMT) . Rat breeder diet and tap water were freely
available to all the animals.
1.2 ANAESTHESIA AND ROUTINE CANNULATION
Surgical procedures to be followed by recovery were
performed under ether anaesthesia,maintained
throughout surgery by means of a gauze mask for
inhalation of the solvent.For all terminal surgical
procedures,the rats were anaesthetized with urethane
(ethyl carbamate),administered intraperitonea11y as a
25% weight/vo1ume so 1ution,0.5ml/1OOg bodyweight.
For experiments in which blood sampling was necessary
and/or drugs were given intravenous 1y,rats were fitted
with polythene cannulae (Portex Ltd.,Hythe,Kent.OD
O.75mm. ).Vesse1s routinely cannulated were the femoral
ar tery, f emora 1 vein and a side branch of the external
jugular vein.Three abdominal mammary gland main milk
ducts were cannulated when the experiment necessitated
recording of intramarnmary pressure. The cannulae were
composed of a syringe needle (Becton-Dickinson
microlance 25 gauge) connected to =10cm length of
polythene tubing (OD 0.7mm).In experiments where it
was possible that surgery could interrupt
respiration,the rats were fitted with a tracheal
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cannula made from polythene tubing bent to a 90° angle
( OD 2,Omm/ID 1. 7raa) to keep the trachea patent.
1.3 INFUSION OF MORPHINE SULPHATE SOLUTION INTO A
LATERAL CEREBRAL VENTRICLE.
To investigate morphine tolerance and dependence in
relation to oxytocin secretion in the rat,an
intracerebroventricular (i.e.v.) infusion of morphine
sulphate in increasing doses was given over 5 days
from a subcutaneous osmotic minipump via a stainless
steel i.c.v. cannula.
The animals were anaesthetized with ether and placed
in a stereotactic frame to keep the head immobi1ized.A
skin incision was made in the midline to expose the
sagittal suture and the dorsal surface of the skull
exposed.
Using bregma,a well known anterior intersection of the
sagittal and coronal skull sutures as a reference
point,a hole (to fit a 21 gauge needle) was drilled
through the parietal bone 2mm lateral and 3mm
posterior to bregma to a depth of 1mm (the skull
thickness) .
A stainless steel cannula (Becton—Dickinson 21
gauge,1cm length bent at 90°, 4.5mm from the tip) was
lowered vertically through this hole into the right
lateral cerebral ventric1e.Before insertion,the
cannula was attached to an 18cm coil of sterile
polythene tubing (ID 0.7mm/OD 1.2mm) and the whole
assembly filled with 40jjl1 of 10p.g/pl morphine sulphate
solution closest to the steel cannula separated by a
lpl air bubble from 40p.l of 20fjtg/pl morphine sulphate
so 1ution.
All morphine solutions were made up in sterile pyrogen
free water and sterilized by passage through a
Millipore filter <Q.22juu).
The other end of the polythene coil was attached to a
Hamilton microsyringe (lOOpl) which allowed the small
volumes of morphine solutions to be drawn up into the
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tubing coil.Once the cannula was secured in position,
the tubing was severed from the microsyringe and
connected to a sterile osmotic minipump (Alzet 2001)
filled with 50pg/pl morphine sulphate solution.
The minipump was filled a few hours previously and
allowed to equilibrate in sterile isotonic saline at
room temperature.The minipump pumping rate was Ipl/hr
and the rats were left for 120hrs <5 days) to develop
dependence, finally receiving 4-Op.l 1 Opg/p 1 , 4-0p 1
20p.g/jj.l and 40jj.1 50pg/pl morphine sulphate solution.
Two other holes were drilled in the skull antero¬
lateral and postero— 1 atera 1 to the cannula. Into each
of these was inserted a stainless steel screw <3.2mm
x 10 BA) which provided anchor points for the dental
acrylic which was finally applied to the skull
surface in order to hold the cannula in place.
The minipump and polythene coil were placed
subcutaneously in the subscapular space and the
incision closed with skin sutures.The animals were
immediately returned to their cages,the whole
procedure lasting approximately 20 minutes.
For vehicle infused control animals,the minipump and
polythene tubing were filled with sterile water.
In an experiment where animals were infused with the
x-opioid receptor agonist U50,488H,the polythene,
tubing length was increased to 32cm and was filled
with 40jj. 1 lOpg/pl U50.488H, 40pl 20jj.g/pl U50,488H and
80pl 50jjg/pl separated by 1 jjl 1 air. The minipump was
filled with sterile pyrogen free water so that it
would puinp the contents of the polythene coil into the
lateral cerebral ventricle.This alternative method was
used to avoid using large volumes of U50,48SH solution
to fill the minipump which would be wasted.All
U50,488H solutions were made up in sterile water and
filtered through a Millipore filter.
Russell (1984);Rayner,Robinson & Russell (1988)
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1.4 CENTRAL RELEASE OF OXYTOCIN:COLLECTION OF
CEREBROSPINAL FLUID <CSF> SAMPLES UNDER URETHANE
ANAESTHESIA.
The release of oxytocin into CSF was measured in some
experiments as well as plasma oxytocin content. In
order to do this the rats were fitted with a cannula
which allowed CSF samples to be obtained via the
cisterna magna.The CSF samples collected were free
flowing and care was taken not to accumulate samples
that were too large and would disrupt the dynamics of
CSF production (normal rate of production 150p 1 /hr > .Cserr, 1965
The rats were anaesthetized with urethane.The atlanto-
occipital membrane covering the cisterna magna was
cannulated and the fluid allowed to collect under
gravity.
The animals were held In a head frame to keep the head
immobilized with the neck flexed for access to the
region of the cisterna magna.A midline dorsal skin
incision was made starting between the ears and
extending * 1.5cm caudal ly. The posterior dorsal
surface of the skull was exposed by clearing away the
overlying muscle (cranial portion of the levator auris
longus) with fine curved forceps.The external
occipital crest was located and traced along its
length to the rostral attachment of the occipital
foramen.Using curved forceps the first cervical
vertebra was located and the overlying muscle gently
cleared away; this bone marks the caudal attachment of
the membrane.The muscle layers overlying the membrane
were retracted and any connective tissue remaining
gent 1y freed.
The cannula was constructed from a 4mm length of
stainless steel tubing (Becton—Dickinson microlance,23
gauge) which had been ground to a 45° bevel at one
end; the other end was attached to a length of silicon
rubber tubing through which the CSF could be
col 1ec ted.
To secure the cannula once it had pierced the membrane
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and to render it immobile, especially during
respiratory movement,a silicon rubber flange was
placed at the joint of the cannula and tubing.This was
trimmed to the size and shape of the at 1anto-occipita1
membrane and was secured to the surface using a
cyanoacrylic adhesive (Perma Bond C2:Permabond
Adhesives Ltd. , East 1eigh,Hants. ) . As well as securing
the cannula this method sealed the membrane and
prevented loss of CSF from 1 eakage. Robinson & Jones, 1982
1.5 EXPOSURE OF THE NEURAL STALK IN THE ANAESTHETIZED
RAT AND SUBSEQUENT STIMULATION OF DESCENDING OXYTOCIN
NEURONES.
For investigation of opioid-rnediated regulation of
oxytocin release from nerve terminals in the
neurohypophysis any opioid manipulation of oxytocin
secretion must take place solely at the terminals and
be isolated from any facilitatory or inhibitory
actions at the cell bodies in the hypothalamus.
This is achieved in an in—vitro system where an
iso1 ated,perifused,neura1 lobe preparation can be
induced to secrete oxytocin by means of electrical
stimulat ion,any changes in secretion being attributed
to effects at the nerve terminals.
In—vivo,by stimulating descending oxytoeinergic nerve
axons in the neural stalk, the cell bodies are for the
mostpart,effective1y bypassed and any changes seen in
secretion are likely be mediated via receptors located
on or in the vicinity of the nerve termina 1 s. The
following method was used in such studies.
1.5 (i> SURGERY demonstrated by G. Leng
For this procedure the animal was anaesthetized with
urethane and transferred to a stereotactic headf rame
(Narishige) where it was immobilized in a supine
position for ventral exposure of the neural stalk.The
lower jaw was split with scissors in the midline
between the lower incisors and both the jaw and tongue
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retracted laterally to expose the soft palate (Fig
1<a)) .
Overlying soft tissue was removed by cautery,with care
not to disrupt blood vessels lateral to the midline
and near the junction of the hard and soft palate,thus
avoiding unnecessary blood loss.
Underlying bone was gently drilled away with a dental
burr .repeated applications of bonewax
(Ethicon,Edinburgh,Scot land.) preventing bleeding from
the sinus which lies ventral to the pituitary stalk.
The bone was drilled away until the final layer could
gently be lifted off with fine forceps revealing the
neural stalk within its dural membrane beneath.Once
this had been exposed the animals were left for an
equilibration period of at least 1 hr.
1.5 <11> STIMULUS
In order to stimulate oxytoeinergic (and
vasopressinergic> axons descending from the
hypothalamus through the neural stalk to terminate in
the neural lobe,a concentric bipolar stimulating
electrode was lowered into the pituitary stalk with a
micromanipulator under visual control with a
dissecting microscope.
The stimulus delivered to the neural stalk was
generated from a Neurolog pulse generator system. The
number of pulses in individual trains and their
frequency were controlled by a DIgitimer D4030.
The final stimulus was a train of matched biphasic
pulses (usually between 60—240 pulses in a
train),0.5mA peak to peak, 1ms duration and at a
frequency of 50Hz.
These parameters were chosen since they represented
activity similar to that seen during the synchronous
bursting of oxytocin neurones during the milk-ejection
reflex and would result in a near maximal stimulus




The bottom left-hand picture is a schematic
representation of the hard and soft palate of the
rat.The dotted oblong on the soft palate demarkates
the area surgically exposed and is enlarged in the top
right-hand picture.The stimulating electrode was
positioned on the stalk,as shown,to deliver trains of









Set up for stimulation of the neural stalk.Two
abdominal mammary glands are cannulated for the
recording of intramammary pressure; the femoral and
jugular veins cannulated for injection of oxytocin
and opiates and the electrode positioned as labelled.
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experimental set-up for neural stalk stimulation of
oxytocin neurones is shown in Plate 1.
1.6 MAMMARY GLAND AUTOBIOASSAY
For all experiments involving stimulation of the
neural sta 1k,oxytocin release was quantified using a
mammary gland autobioassay which utilizes the response
of myoepithelium to oxytocin.
Cannulation of three abdominal gland milk ducts
allowed measurement of intramammary pressure
changes,in response to oxytocin secretion, by
connecting the cannulae to force transducers (Gould
P231D) which converted pressure variations (rnrnHg) to a
deflection on a chart recorder <J&J Instruments CR652S
Recorder).
Recordings were taken from two mammary glands
simultaneously so that pressure changes arising from
spontaneous contractile activity rather than a defined
stimulus could be detected.
Bolus doses of synthetic oxytocin 0.25.0.50,0.75 and
1. OmU from a 12.5mQ/ml stock so 1ution,were injected
via the femoral vein with a Hamilton 1ml glass syringe
attached to a Hamilton PB600 dispenser,set to deliver
20pl per strike,a 11owing construction of an oxytocin-
dose intramammary—pressure response curve.
Stimulation of the neural stalk via a stimulating
electrode results in a bolus release of oxytocin,the
amount of which can be determined by extrapolation
from the dose-response curve.
In experiments where the effect of opioid receptor
agonists and antagonists on oxytocin release from
nerve terminals in the neurohypophysis were to be
measured,the number of pulses within a stimulus train
was set for an optimal release of oxytocin into the
circulation; i . e. at the top or bottom of the steep
slope on the dose-response curve so that a small
change in oxytocin secretion would be represented by a
larger change in intramammary pressure.
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Dose response curves were obtained before and after
each drug injection so that any changes in mammary
gland sensitivity could be taken into account.Once the
amount of oxytocin evoked upon neural stalk
stimulation had been determined for a control period
and after each drug administration, the results were
expressed as the percent of the initial amount of
oxytocin released on stimulation of the neural stalk
during the control period.All final results are
expressed as the mean ± standard error of the mean for
these values.
1.7 RADIOIMMUNOASSAY TECHNIQUE FOR OXYTOCIN
DETERMINATION IN PLASMA AND CEREBROSPINAL FLUID
SAMPLES.
1.7.1 The method developed by I.C. A. F. Robinson <1980)
was used for oxytocin determination in arterial blood
samples and cerebrospinal fluid samples taken during
experiments described in this thesis
1.7.1 <1> PLASMA SAMPLES
Blood samples were drawn up into heparinized syringes
and cooled over ice before being centrifuged <3000rpm
for 3 mins) to obtain plasma.The resulting plasma
aliquots were immediately frozen and stored at -20°C
un til assayed.
1.7.1 <ii) ASSAY PROCEDURE
The buffer used in the following assay procedure was a
lOOmM tr is buffer (tris-(hydroxymethy1)-
methyl amine,BDH chemicals) with 3mg/ml bovine serum
albumin added (Fraction V.Sigma) and adjusted to pH
7.4 with 5M hydrochloric acid.
The antibody was RIIIS which was used at a final
dilution of 1:230,000 in the assay volume.
Oxytocin was iodinated by the iodogen method
(Salacinsky,Hope,McLean et al,1979> and purified by
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HPLC . 1 32 s I-oxy toe in stock <3,000 000 cpm/lOOpl) was
diluted in assay buffer to give ^ 7000 cpm/100pl i.e.
7000 cpm per tube.
For the plasma assay, the standard curve was made up
using human plasma which did not cross react with the
assay.The standard curve was set up in the following
way: -
Tc tubes: lOOpl tracer
Ab tubes: lOOpl tracer , lOOpl buffer, IOOjj.1 50% plasma
Bo tubes: lOOpl tracer, lOOpl 50% plasma, lOOpl RIII.S
The stock oxytocin standard was 5ng/ml . IOOjj.1 of this
was added to lOOpl 100% plasma in tube S-, .This was
vortexed thoroughly and lOOp.1 removed and placed in
tube with lOOpl 50% plasma. After vortexing, 100p.l
was taken from S-, and placed in S:s, with lOOpl 50%
plasma.This procedure was repeated so that there were
ten doubling dilutions < S ^ — S, , > giving a range of
standards from 250-0.25 pg/ml.
Antibody (lOOp.1 at a final dilution of 1:230,000) and
tracer <7000cpm/lOOpl) were also added to these
tubes.The standard curve was pipetted in triplicate.
Experimental plasma samples <50pl) were set up in
duplicate.Added to this was 50pl buffer <so that there
was a total of 50% plasma present in the tube plus
IOOjjI RHIs (1:230,000) and IOOjj.1 tracer
<7000cpm/ lOOp.1 )
All tubes had a total volume of 300pl and were
vortexed thoroughly before incubation.Two incubation
procedures were possible,
a) simultaneous addition
Antibody and tracer were added at the same time and
the tubes incubated overnight at room temperature.
b) delayed addition
Antibody was added on Day 1 and the tubes incubated
overnight at 4°C. On day 2, the tracer was
added,vortexed to mix well and incubated overnight at
4°C before separation on Day 3.
The latter method gives a more sensitive assay and is
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often used if low levels- of oxytocin are expected in
the samples.
The method of separation of bound oxytocin from free
oxytocin for this assay was with polyethylene glycol
6000 CBDH Chemicals).An 18% polyethylene glycol <PEG>
solution is made up in tris buffer from a 27% PEG
stock solution with bovine y globulin (Sigma,Cohn
fraction II).600p.l PEG was added to all the tubes
except the Tc tubes.The tube contents were vortexed to
enure thorough mixing and left for 30 minutes.After
this they were centrifuged at SOOOrpm for 10 minutes
at 4°C.The resulting supernatant was aspirated
carefully and the the remaining pellet counted in a
gamma counter (LKB Wallac 1260 Multigamma II).
1.7.2 CEREBROSPINAL FLUID SAMPLES
The basic assay procedure for oxytocin determination
in CSF was the same as for plasma. Only 50pl CSF was
collected per sample so,the standard curve was set up
using 50jj.1 of standard, the top standard being 125
pg/ml with ten doubling dilutions to 0. 125 pg/rnl . The
total volume of the assay was 150pl.
Antibody dilution was 1:230,000 but calculated for a
final volume of 150pl and the tracer was diluted to
give no more than 4000cpm/50p1 (per tube).
To dispense 50pl accurately a Hamilton dispense 200
was used to add antibody and tracer to the relevant
tubes.
This time,assay buffer (as previously described) was
added in place of 50% p1asma.Leve1s of basal oxytocin
in CSF samples are sometimes much lower than that
found in plasma and the volume assayed much smaller so
a delayed addition protocol was always followed to
give the maximum sensitivity.
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1.7.3 Modified Higuchi radioimmunoassay <1984) used at
AFRC,Babraham for detection of oxytocin In In vitro
perfusates and plasma samples.
Prior to aliquoting into assay tubes,the samples were
centrifuged briefly in a bench centrifuge to spin down
any precipitate.The assay buffer used in this
procedure was a phosphate buffer Q.01M P04",0.5%
bovine serum albumin (Sigma — No A—8022),lmg/ml bovine
Y globulin (Sigma — No G5009) and lmg/ml thiomerosol.
The antibody used was Higuchi THF-3 used at a final
assay dilution of 1:300,000.
Oxytocin was iodinated using the chloramine-T
method,the 12GI-oxytocin being stored in 0.2% acetic
acid/0,25% BSA at -20°C until used.The tracer was
diluted in assay buffer to give 8000-10000 cpm/50jal.
A standard curve was set up with the top standard
10000 pg/ml and ten doubling dilutions to 9 pg/ml.
On day 1 antibody (50pl) was added to sample (50pl) or
standard (50pl) tubes.These were incubated for 24hrs
at 4°C.On day 2,50pl tracer was added to all the tubes
which were incubated for a further 48hrs at 4°C.
Separation was achieved with polyethylene glycol 6000
(PEG) 30% weight/vo1ume.The tubes were vortexed
thoroughly and then centrifuged at 3000rpm for 30
minutes at 4°C.The supernatant was aspirated and the




The following list of materials and drugs were
routinely used in the experiments described.
CHEMICALS AND DRUGS
Isotonic sterile saline: "Steriflex",sodium chloride
intravenous infusion BP <0.9% w/v>,The Boots Company
pic,Nottingham, U.K.
Sodium chloride: BDH Chemicals Ltd.,Poole,Dorset,U.K.
U50,488H, trans— <±>—3,4,dichloro-N-methyl—N—<2—1 1 —
pyrroldiny11—eyelohexy11 benzene acetamide (methane
sulphonate salt) :




Morphine sulphate: Supplied by the Pharmacy,Edinburgh
Royal Infirmary.
Naloxone hydrochloride:
<i)A gift from Endo Laboratories Inc..Garden
City,New York,USA.
(ii)Product no.N7758,Sigma Chemical
Co. Ltd . , Poo 1 e , Dorset., U. K .
MR2266, b, 9—of-diethy 1 — 2— <3—furylmethyl > — 2* -hydroxy—
6, 7, benzomorphan: A gift f rorn Boehringer Ingelheim.
RX8008M, 16—Me—cyprenorphine: A gift from Reckitt. &
Colman Pharmaceuticals Division,Hu11,U.K.
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Propranolol: "Inderal" propranolol injection BP
(lmg/ml>,Imperial Chemical Industries
pic,Pharmaceuticals Division,Macc1esfield,Cheshire,UK
Oxytocin: "Syntocinon" oxytocin injection BP
(lOunits/ml),Sandoz
Pharmaceuticals,Feltham,Middlesex, UK .
Pethidine: pethidine (meperidine) injection BP
(100mg/2ml> Roche Pharmaceuticals.
Heparin: "Monoparin" heparin injection BP
<5000units/ml>,CP Pharmaceuticals, Wrexham,UK.
SURGERY
Urethane,ethyl carbamate: Fisons Laboratory
Reagents,Loughborough, UK.
Anaesthetic ether: Fisons Laboratory
Reagents,Loughborough,UK.
Osmotic minipumps: ALZET 2001,ALZA,Pa 1o
A1to,California. (European Distributors,Scientific
Marketing,67.Mi 1dmay Grove,London, UK. >
Bone wax: Ethicon,Edinburgh,UK.
Surgicel: sterile oxidized
eellulose,Ethicon,Ed inburgh, UK .
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CHAPTER TWO
INVESTIGATION OF A KAPPA-OPIOID RECEPTOR
AGONIST,U50,488H AND A MU-OPIOID RECEPTOR AGONIST
MORPHINE,ON ELECTRICALLY-EVOKED OXYTOCIN RELEASE
FROM THE NEURAL LOBE OF THE ANAESTHETIZED LACTATING
RAT.
CHAPTER 2 : Investigation of a *—opioid receptor
agonist,U50,488H and a p-opioid receptor
agonist,morphine,on electrically evoked oxytocin
release from the neural lobe of the anaesthetized
lactating rat.
INTRODUCTION
Oxytocin is secreted from nerve terminals situated in
the neural lobe of the rat, as a result of electrical
activity arising in the cell bodies of magnocellular
neurones located in the supraoptic nuclei of the
hypothalamus (Lincoln & Wakerley,1974;Poulain &
Wakerley,1982;Bourque & Renaud,1985).Oxytocin is
released into the circulation where it is transported
to its target organs.
Regulation of oxytocin by endogenous opioids can be
effected at several sites;the oxytocin neurone cell
bodies,nerve terminals and their afferent synaptic
input.At the cell bodies,oxytoein secretion may be
inhibited by enkephalins co-produced and released by
oxytocin neurones (Martin,Geis et
al,1983;Vanderhagen,Lotstra et al 1983),dynorphin co-
produced and released by vasopressin neurones
(Watson,Akil et al,1982> and P~endorphin from
projections of the arcuate nucleus (Sawchenko, Swanson
& Joseph, 1982; Finley,Maderdrut & Petrusz, 1983) .These
peptides may act directly on the cell bodies or on
their afferent synaptic input.
At the neural lobe,inhibition of oxytocin secretion
may be inhibited by enkephalins and dynorphiri co-
produced and released from oxytocin and vasopressin
nerve terminals respectively (Van Leeuwen,Pool &
Sluiter, 1983;Summy—Long,Denlinger, 1984) . p-endorphin
from the intermediate or anterior pituitary lobes may
also be responsible for modification of oxytocin
secretion.
Autoradiographic studies have shown that,in the
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rat,the predominant opioid receptor subtype located at
the neural lobe are x-receptors with a few fi-receptors
at this site; S-receptors are virtually undetectable
(Herkenham,Rice et al, 1986;Brady &
Herkenham,1987;Bunn,Hanley &
Wi1kins,1985;Zukin,Eghba1i et a 1,1988;Sumner,Coombes
et al,1988)).The x-opioid receptors are at their
densest on the rim of the neural lobe indicating close
proximity to or location on oxytocin nerve terminals.
There is however, evidence to suggest that opioid
receptors may be located on the specialized astrocytic
glial ce11s,pituicytes,which have a close positional
relationship with oxytocin nerve terminals in the
neural lobe.Transect ion of the neural stalk and
subsequent nerve degeneration does not lead to a loss
of ligand binding to opioid receptor subtypes
indicating this alternative site (Lightman,Ninkovic et
al,1983;Bunn,Hanley & Wi1kin,1985>.
Pituicytes have been suggested as one possible
mediator for regulating oxytocin seeretion.They are in
close proximity to the nerve termina1s, some
encapsulating the terminals entirely and changes in
their morphological arrangement have been noticed
during times of high oxytocin and vasopressin
secretion i.e. dehydration and lactation
(Hatton, Perlmutter, , 1984; Perlmutter,Tweedle &
Hatton,1985).These changes may lead to variation in
the immediate extracellular enviroment of the oxytocin
nerve terminals which lead to a change in oxytocin
release.
In—vitro experiments using the isolated neural lobe
preparation have indicated through use of selective
opioid receptor subtype antagonists MR2266 and
naloxone that it is mainly opioids acting via x or p
receptors respectively that suppress electrically
evoked oxytocin secre t. i on, a 1 though inclusion of
specific opioid receptor agonists fi-endorphin
<p),dynorphin 1-13 and bremazocine <x> was
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unsuccessful at Inducing significant inhibition of
oxytocin secretion (Bicknel1,Chapman &
Leng,1985).Vasopressin secretion was not affected by
naloxone or MR2266 indicating that its release is not
controlled by endogenous opioids . Later experiments
showed significant inhibition of oxytocin and
vasopressin by the selective x-agonist U50,488H in a
naloxone reversible manner indicating the effect to be
opiate receptor mediated.
Since the predominant type of opioid receptor at the
neural lobe is kappa whose endogenous ligand is found
to be dynorphin (Corbett,Paterson et
al,1982;Kosterlitz,1985)) it seems likely that
dynorphin-binding to opiate receptors on or around
oxytocin nerve terminals could play a role in the
modulation of oxytocin secretion.
In the following experiments, modulatory effects of
the x and p-opioid system on oxytocin secretion at the
neural lobe in the anaesthetized lactating rat in vivo
was investigated.The neural stalk was stimulated
electrically in order to elicit oxytocin release from
nerve terminals in the neural lobe.This ensured that
any inhibitory effects of opioids seen would be
isolated to the neural lobe since the cell bodies were
no longer involved in generation of action potentials
normally associated with oxytocin release and the
neural lobe was in effect isolated.
The x- opioid receptor ligand used to try and modify
oxytocin release was U50,488H (trans-3,4-dichloro-N-
me thy1—N—t2-(1-pyrroldinyl>-cyclohexy1 benzene—
acetamide) which has been shown to be a relatively
selective x-ligand with poor affinity for p, , p;?. and 8
sites (Pasternak & Wood,1986;Clarke & Pasternak,1988).
Evidence has been put forward that intrathecal
administration of U50,488H,in the rat,acts through a
g—adrenergic mechanism originating in the adrenal
medulla (Clarke & Wright,1987).An intact,fully
functioning adrenal medulla has been shown to be
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necessary for x-opioid agonist induced diuresis in the
rat (B1ackburn,Boronski,1986;Borkowski,1989).A P~
adrenergic antagonist propranolol was used as
pretreatment prior to U50.488H intravenous injection
to determine whether a p-adrenergic system has any
contribution to opioid modification of oxytocin
secretion at the level of the neural lobe.
Initial studies on opiate actions on oxytocin
secretion indicated that morphine acts on the neural
lobe although there are few ^-receptors at this
site. However, (^-opioid receptors, located in the
supraoptic nucleus respond to opiates and influence
oxytocin secretion by changes in electrical activity
at the neurone cell bodies (Wakerley,Noble & Clarke (1983)
To distinguish these two sites of action, the effects
of a kappa agonist on oxytocin secretion was
investigated in rats which were morphine
dependent.Dependence on morphine in relation to
oxytocin secretion is centrally mediated,in the
hypothalamus, since peripheral infusion of morphine at
the same dose is ineffective in producing
dependence.Na1oxone injection leads to a withdrawal
response involving excitation of oxytocin neurone cell
bodies and subsequent hypersecretion of oxytocin into
the blood.This response denotes dependence on the
opiate (Rayner,Robinson & Russel1,1988).
In addition morphine tolerance deve1 ops,since the
milk-ejection reflex returns and oxytocin neurone
activity and secretion are within normal
limits.Intravenous injection of U50.488H was used in
conjunction with measurement of electrically-
stimulated oxytocin secretion to establish whether
there is any cross tolerance to opiates acting via
kappa receptors conferred at the neural lobe when the
cell bodies are tolerant to and dependent on morphine.
The structures of U50,488H,morphine .naloxone and
propranolol are shown in Fig 2.1(a)
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* .CH3 S02 OH
U50,488H : trans (±) -3,4-dichloro-N-Me-N-
[2-( 1 -pyrrolidinylcyclohexyl)]



















Adult female Sprague-Dawley rats 7-14 days post. —partum
in their first lactation,with litters standardized to
10 pups 2 days post-parturn were used. The lactating
rats weighed ca.400g and were housed as described in
1.1.
2. 1< i i) SURGERY
The dam was separated from all but one of her litter
overnight in order to encourage milk accumulation into
the mammary glands which would subsequently be used in
an oxytocin autobioassay (Lincoln,Hi 11 &
Waker1ey,1973).On the morning of the experiment,under
urethane anaesthesia a tracheal cannula was
fitted.Insertion of a femoral arterial cannula allowed
blood sampling; a femoral venous cannula for injection
of graded doses of oxytocin,a jugular venous cannula
for injection of opiates and three abdominal mammary
gland cannulae for the measurement of intramammary
pressure and hence a method of quantifying oxytocin
release were fitted.With the animals' head immobilized
in a stereotactic frame,the neural stalk was exposed
by ventral surgery as described in detail in 1.5 and
the animal left for at least one hour so that
circulating oxytocin which may have been elevated due
to surgical 'stress' could equilibrate to a steady
basal secretion.
For the morphine dependent animals,five days prior to
the experiment they were anaesthetized with ether and
fitted with an i ntracerebroventricu1ar infusion device
to deliver graded doses of morphine into a lateral
cerebral ventricle as described fully in 1.3
2.1(iii> STIMULUS
Trains of pulses were delivered to the exposed neural
stalk via a concentric bipolar stimulating
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e1ectrode.The stimulus consisted of matched biphasic
pulses CO.5mA,lms duration at 50Hz> as described in
detail in 1.5<ii>.
2.1 Civ) OXYTOCIN AUTOBIOASSAY
The amount of oxytocin released on stimulation was
extrapolated from a dose response curve constructed
from the rises in intramammary pressure resulting from
intravenous injection of graded doses of synthetic
oxytocin (see 1.6 for details).A dose-response curve
was constructed before and after each drug addition so
that changes in mammary gland sensitivity due to
direct actions of opiates on the mammary gland or
other systems affecting sensitivity (e.g. the adrenal
medulla) could be accounted for.
2.1<v) DRUGS AND ADMINISTRATION PROTOCOL
Once a sub-maximal secretion of oxytocin had been
achieved in response to stimulation of the neural
stalk <0.7-0.8mU,see 1.5 for rationa1e),U50,488H or
morphine were given intravenously at different doses,
to see if they had any inhibitory action on oxytocin
secretion from the neural lobe
All drugs were made up in sterile isotonic saline and
were injected via the jugular vein.The dose range of
U50.488H tested was 10-5000jj.g/kg <n=9) . In animals that
were morphine dependent the dose range of U50.488H
tested was 10-1OOOpg/kg <n=6).Animals treated with
acute injections of morphine were exposed to a dose
range of 100—5000pg/kg <n=ll).
Drugs were given in increasing doses, with time for
recovery between doses,typically - 20mins,as judged by
recovery of stimulus evoked oxytocin release.Summaries
of the drug administration protocols \_ised in morphine
naive and morphine dependent rats are shown in Figs
2. 1<b) & 2.1< c ) .
To investigate the involvement of j3-adrenergi c
receptors in kappa mediated effects on oxytocin
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Dose response curve 1
Exogenous oxytocin injection of 0.25.0.50.0.75 and




Pulse train sufficient to elicit ~ 0.8mU oxytocin from
the neural lobe delivered to the neural stalk.
4
Drug administration
Intravenous injection of opioid receptor agonists
U50.488H or morphine in appropriate dose.
4
Dose response curve 2




Same pulse train as previously used to determine any
inhibition of oxytocin secretion due to the presence
of the opiate agonist.
Repetition of the above sequence.
Fig 2.1 <b>
Protocol showing oxytocin does—response curve
construction and administration of opioid agonists in
neural stalk stimulation experiments.
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t = —2 mins Blood sample 1 <basal oxytocin
secretion)
t = O mins lmg/kg naloxone i.v.
t — 5 mins Blood sample 2 (withdrawal oxytocin
secretion)
t = 8 mins 5 or lO mg/kg U50,488H i.v.
t = 14 mins Blood sample 3 (post-agonist
oxytocin secretion)
t = 17 mins 1 or 5 mg/kg naloxone i.v.
t = 25+ mins Blood sample 4 (re—initiated with¬
drawal oxytocin—
secret ion)
Fig. 2. 1 (c)
Approximate timing protocol of opiate injections and
blood samples from morphine dependent rats undergoing
withdrawal from morphine with naloxone.
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secretion,a group of animals were pretreated with the
p-adrenergic antagonist propranolol <n=6).It was hoped
to determine whether the antagonist would affect
modification of electrically stimulated oxytocin
release by the x-opioid receptor agonist, at the level
of the nerve terminals in the neural Iobe.Propranolol
was given as a dose of Img/kg (lmg/ml) , approximately
20 mins prior to commencing the sequence of U50,48<3H
administration.
For the experimental group which were morphine
dependent naloxone CI or 5rog/kg> was administered
intravenously at the end of the experimental protocol
in order to precipitate a withdrawal response from
chronic morphine infusion.Withdrawal was characterized
by hyperventi1 ation,vibrissae and jaw twitching and a
hypersecretion of oxytocin recorded as a large and
sustained rise in intramammary pressure.In n=3 animals
U50.488H (5 or lOmg/kg) was given during the
withdrawal period and timed blood samples withdrawn
<2.1<c>).
In n=3 an i ma 1 s, U50, 488H was applied directly to the.
neural stalk at doses of l|j.g,5jj.g, 10pg and 20pg/5p.l
isotonic saline using a 50pl Hamilton syringe.Direct
application of the opiate onto the tissue was intended
to give a more precise application of the drug and any
effects could be attributed solely to actions at the
neural lobe and distinguish indirect from direct
effects of the opiate.The dural membrane overlying the
neural stalk was gently cut to allow distribution of
the drug onto the neural stalk surface in these
anima 1s.
In n=4 animals,before the neural stalk was exposed,the
rats were fitted with a stainless steel
in tracerebrovent ricular guide cannula into the right
lateral cerebral ventricle (Rayner,Robinson &
Russel1,1988 ) through which acute injections of
morphine could be made.Morphine solutions were made up
in sterile isotonic saline and adrn i n i s t ered as four
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doses 1 pg, 5pg, 1 Op.g and 20pg/5pl saline. The drug was
injected using a 25 pi Hamilton syringe connected to
the i.c.v. cannula by means of a length of polythene
tubing.
2.2 EXPRESSION OF RESULTS
Amounts of oxytocin released upon electrical
stimulation of the neural stalk were extrapolated from
the relevant dose response curve <in mi 11iunits),see
1.6 for details.The effects of morphine (intravenous
and intracerebroventricular),U50,488H (intravenous and
direct stalk application) and U50,488H with
propranolol pretreatment (intravenous) and U50.488H in
morphine dependent animals were expressed as a
percentage of the initia 1,pre-drug amount of oxytocin
released upon stimulation of the neural stalk.
Statistical comparisons:
Comparisons of responses within groups of animals were
made using a paired t-test and between groups of
animals by an unpaired t-test.
The raw data from individual animals of log dose
opiate vs. intramamrnary pressure response was used to
obtain a linear regression line from which the ID30
was calculated.
X«^=5Q—a a: y intercept
b b: gradient
The standard error range was calculated as foilows:-
s.e. Xso = Var <a) + Var (b) + 2Cov <a.b)
(50-a>= b^ b <50—a)
where Var (a) = variance a
Var (b) - variance b
Cov (a, b) =; covariance (a,b>




< i > EFFECT OF U50.488H ON EL.ECTRICALLLY—EVOKED
OXYTOCIN SECRETION.
The x-opioid receptor agonist U50.488H administered
intravenously and tested over the dose range lOpg/kg-
5mg/kg inhibited the release of stimulus evoked
oxytocin in a dose dependent manner.
A typical intr arnarnmary pressure recording trace from
an animal that had received an inhibitory dose of
U50,488H is shown in Fig 2.3<a>.
U50.488H did not alter the sensitivity of the mammary
gland to any great extent as shown in Fig 2.3(b) which
depicts typical dose response curves and stimulus
response to 60 pulses before and after 500pg/kg
U50,488H.A slight shift in sensitivity of the mammary
gland to oxytocin at the lower range of the dose-
response curve was noted.The profound inhibitory
effect of U50.488H can be seen by the response to 60
pulses) closed squares) which shift to the left on the
curve after U50,488H.
Naloxone <lmg/kg i.v. ) admini stered at the end of the
experiment fully reversed the inhibition of stimulus
evoked oxytocin secretion without potentiation of the
response.
The dose response relation of electrically stimulated
oxytocin release to U50.488H is shown in Fig 2.3(c).At
doses above 500pg/kg the inhibition by U50.488H was
significant with respect to the initial amount of
oxytocin elicited upon stimulation of the neural stalk
<p<0 . 05>0.01,paired t — test).Using the raw data,a
linear regression line was calculated from which the
IDSO)the dose of U50,488H to Inhibit the initial
release of oxytocin by 50% was obtained.Using
covariance values as described in 2.2 the standard
errors for this value were calculated. The ID,30 for


















Figs. 2.3 <a> & <f>
Intramammary pressure recording traces from two rats
that received 500pg/kg U50,488H <2.3 a) or morphine
<2.3f ) i.v..U50,488H can be seen to completely
inhibit oxytocin released in response to a pulse
train of 75 pulses and profoundly reduce the response
to 90 pulses without a loss in sensitivity of the
mammary gland to oxytoe in.Morphine appears to slightly
reduce the response to 90 and 120 pulses but this is
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Dose-response curves to illustrate changes in sensitivity
of the mammary gland that occur following i.v. injection




1 1 1 1
10 100 1000 10000
Dose U50,488H or morphine (pg/kg)
Fig 2.3 (c)
Graph to show the inhibition of electrically-evoked oxytocin
release in urethane anaesthetized,lactating rats following i.v.
administration of the opioid agonists U50,488H or morphine.
Values shown are mean ± sem.Filled circles represent rats
that received U50,488H (n=9) and filled squares the rats
which received morphine (n=l 1).
Statistical comparisons:
*
p < 0.05 > 0.01 with respect to initial response to stimulation
(paired t-test).
t p < 0.05, ft P < 0.01 with respect to rats treated with the same
dose ofmorphine (unpaired t-test).
IDso U50,488H 441 (+194,-136) pg/kg.
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< I i > EFFECT OF PROPRANOLOL ON ELECTRICALLY-STIMULATED
OXYTOCIN SECRETION.
Pretreatment with propranolol approximately 20 minutes
prior to the U50.488H administration protocol,
firstly, resulted in an enhancement of mammary gland
sensitivity to oxytocin as shown by the
representative dose response curves constructed before
and after propranolol injection in Fig 2.3<d>.
U50.488H still caused a dose dependent inhibition of
electrically-stimulated oxytocin following propranolol
pretreatment but a change in sensitivity to U50, 48811
was noted.The dose/response relation appears to have
been shifted to the right,as seen in Fig 2.3<e)
indicating propranolol to reduce the inhibitory effect
of U50.488H on oxytocin secretion.Significant
inhibition of electrically evoked oxytocin was
achieved at doses of 500pg/kg and above (p=0.01,paired
t-test>.Comparison of the two experimental
groups,proprano1o1 pretreated and propranolol naive
receiving i.v. U50.488H only showed significant
differences at U50.488H doses of 100pg/kg and
lOOOpg/kg (p<0.05 unpaired t-test;p=0.05 unpaired t-
test).Using regression analysis the IDso for U50,488H
in propranolol pretreated rats was found to be 1585
jag/kg <+ 603/— 437p.g/kg> .This was significantly
different from the IDso obtained from rats that
received only U50,488H (pi0.05,derived from regression
statistics.
Naloxone restored the stimulus evoked oxytocin reponse
in this experimental group to initial values without
any potentiation.
<iii> EFFECT OF MORPHINE ON ELECTRICALLY-STIMULATED
OXYTOCIN SECRETION.
Intravenous morphine sulphate in the dose range
1OOpg/kg-5mg/kg had no significant effect on stimulus
evoked oxytocin secretion when compared to initial






















O Response to pulse
































□ Response to pulse







Dose-response curves to illustrate changes in sensitivity
of the mamary gland that occur following i.v. injection
of lmg/kg propranolol (2.3 d) or 500|ig/kg U50,488H


































Graph to show the inhibition of electrically-stimulated oxytocin
release in urethane-anaesthetized,lactating rats following i.v.
administration of the opioid agonist U50,488H.Values shown
are mean ± sem.Filled circles represent rats that received
U50,488H (n=9),open circles represent rat that were pre-
treated with propranolol prior to U50,488H injection (n=6).
Statistical comparisons:
*
p < 0.01 with respect to initial response to stimulation
(paired t-test)
t p < 0.05 with respect to inhibition caused by U50,488H alone
(unpaired t-test).
IDso U50,488H + propranolol 1585 (+603,-437) |ig/kg (p < 0.05
with respect to IDso U50,488H alone.
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elevated oxytocin secretion slightly but not in a
significant manner.
A typical intramammary pressure recording trace during
the morphine drug administration protocol is shown in
Fig 2.3(f).
Mammary gland sensitivity to oxytocin was depressed by
i.v. morphine as demonstrated in Fig 2.3<g> where a
shift in the dose response curve to the right after
500pg/kg can be seen.
(iv) EFFECT OF U50,488H ON ELECTRICALLY-STIMULATED
OXYTOCIN SECRETION IN MORPHINE DEPENDENT RATS
In the morphine dependent group of animals U50,488H
effectively inhibited stimulus evoked oxytocin
secretion in a dose-dependent manner as seen in Fig
2.3(h).
A typical intramammary pressure recording trace from a
morphine dependent animal receiving i.v.U50,488H is
shown in Fig 2.3<i>.
Dose response curves constructed before and after each
drug administration in this group of animals showed
that there was no change in mammary gland
sensitivity.This is illustrated in Fig 2.3(j).At a
dose of 50pg/kg and above from a dose range of 10 —
1000pg/kg there was significant inhibition of oxytocin
with respect to i nitia 1,pre-drug values <p ( 0.01,
paired t-test).The IDso for U50.488H was found to be
170pg/kg <+ 78/- 54pg/kg).This was significantly
different from the morphine naive group
(p(0.05,derived from the regression statistics).
In all morphine treated animals naloxone caused a
sustained elevation of intramammary pressure response
sufficient to satisfy that the animals were morphine
dependent.A typical elevation of intramarcmary pressure
seen upon naloxone induced morphine withdrawal is
shown in Fig.2.3(k).The sustained elevation of




Dose of U50,488H (|ag/kg)
Fig 2.3 (h)
Graph to show the inhibition of electrically-evoked oxytocin
release in urethane-anaesthetizedjactating rats following i.v.
administration of the opioid agonist U50,488H.Values shown
are mean ± sem.Filled circles represent morphine-naive rats
that received U50,488H (n=9) and the open squares morphine-
dependent rats that received U50,488H(n=6).
Statistical comparisons:
*
p < 0.01 with respect to initial response to stimulation (paired
t-test)
IDso U50,488H (morphine dependent rats) 170 (+78,-54) (tg/kg
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Figs 2. 3(i> & 2. 3<k>
Fig 2.3<i> shows an intramammary pressure recording
'trace from a morphine dependent rat which received
0.5mg/kg U50,488H i.v.This dose effectively inhibits
the release of oxytocin evoked by a stimulus train of
150 pulses without loss of sensitivity of the mammary
gland to oxytocin.
Fig 2.3 <k> shows a the typical sustained elevation of




































Fig 2.31 <i & ii)
[ntramammary recording traces from two morphine
dependent rats,withdrawn with naloxone dmg/kg), and
then subsequently challenged with the x-opioid agonist
J50.488H at lOmg/kg <2.31<i>> and 5mg/kg <2.31<ii>>
i.v..In both cases the withdrawal hypersecretion of
pxytocin is re-initiated with 5mg/kg naloxone
i.v..Plasma oxytocin at the times indicated is shown
by the solid bars.
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In those animals that received U50.488H during
withdrawal it would appear that the hypersecretion of
oxytocin can be inhibited by a U50.488H mediated
action as demonstrated in the traces shown in Fig 2.3
1 <i & i i> .
In trace (i) injection of Img/kg naloxone i.v. was
able to precipitate withdrawal from morphine as seen
from the elevation in intrarneimmary pressure and
elevation of plasma oxytoe in.Once the response was
maximal,lOmg/kg U50,488H was injected i.v. and a rapid
decrease in intramammary pressure was seen over the
next 3—4 minutes after which it had reached basal,pre-
naloxone values.Plasma oxytocin was also
deer eased. Subsequent injection of 5rng/kg naloxone was
able to re-initiate the withdrawal response although
to a lesser degree than the initial response.
Circulating levels of oxytocin in peripheral plasma
are also increased.
In trace Cii) the rat was given lmg/kg naloxone
i.v.which precipitated a sustained rise in
intramammary pressure due to the hypersecretion of
oxytocin into plasma following withdrawal from
morphine.Once the response had reached a 'plateau'
5mg/kg U50,4S8H was injected i.v.Intramammary pressure
decreased rapidly over a period of about 5
minutes,although it did not reach initial basal
values.The animal was then given 5mg/kg naloxone
i.v.There was a rapid elevation of intramammary
pressure over about 2 minutes indicated withdrawal to
have been re-initiated,
Blood samples were taken from the rat at the points
indicated in Fig 2.3(1).These showed naloxone to
Increase plasma oxytocin and U50.488H to decrease
circulating oxytocin.
<v> THE EFFECT OF STALK APPLICATION OF U50,488H ON THE
ELECTRICALLY-STIMULATED RELEASE OF OXYTOCIN.
Application of a dose range of U50,488H <1-20pg/5p1
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isotonic saline) directly onto the neural stalk gave
no conclusive results.Due to the inconclusive results
obtained this method was abandoned for further
experiments into the effects of different opioid
agonists and antagonists on oxytocin secretion from
the neural lobe.
(vi) THE EFFECT OF INTRACEREBROVENTRICULAR MORPHINE ON
ELECTRICALLY-STIMULATED RELEASE OF OXYTOCIN.
Acute injection of morphine sulphate (1 -20pg/5p 1
isotonic saline) directly into the right lateral
cerebral ventricle also presented inconsistent results
and this method of drug delivery abandoned for further
experiments.
2.4 DISCUSSION
Results from this series of in—vivo experiments
complement autoradiographic ligand binding opiate
receptor studies (Bunn,Hanley &
Wi lkin, 1985;Herkenham, Rice et al, 1986;Zukin,Eghbali et
al,1988) and in vitro experiments using the isolated
neural lobe preparation (Bicknell et
al, 1985;Zhao,Chapman & Bicknell , 1988a;Zhao,Chapman &
Bicknel1,1988b) which have indicated the predominant
opioid receptor present at the neural lobe to be of
the x-subtype.
When examining stimulus-evoked oxytocin release in the
presence of a x or p opioid receptor agonist,only the
x-agonist U50,488H was able to show an inhibitory
influence on oxytocin secretion.Morphine sulphate,the
p-opioid receptor agonist showed no influence on
stimu1 us—evoked oxytocin release from the neural lobe
although it is known to act at opioid receptors in the
hypothalamus to modify oxytocin secretion as
demonstrated by studies on oxytocin
seeretion,e1ectrophysio1ogia 1 and tolerance and




This would indicate that there are (a) virtually
negligible numbers of functionally-coupled p-receptors
in the neural lobe of the rat either on or around
oxytocin nerve terminals which contribute to the
endogenous opioid tone influencing oxytocin release
or Cb) p-receptors detected at the neural lobe are of
a different subtype and binding affinity than those
which predominate at the hypothalamus.
The p-opioid receptor comprises of two subtypes p-, and
Ps», of which Pt^ is the highly selective morphine
receptor (Pasternak & Wood, 1986) . It may be the case
that at the hypothalamus the population of p receptors
comprises of mainly the high affinity morphine p-);
receptors whilst those at the neural lobe are mainly
of the p, subtype.
U50.488H is a selective ligand for the x-type receptor
and although ethy1ketocyc1azocine is approximately
five times more potent at the x receptor than U50,488H
it is much less selective and will compete at both p-,
and ps. sites (Vonvoigt lander, Laht i & Ludens, 1983) . In
fact,it has been found to label p1 receptors ten times
more effectively than x-sites.U50,488H therefore,was a
more suitable agonist for investigating opioid
receptor mediated modification of oxytocin secretion
since it is thirty-fold more potent at x than p,
receptors and forty-fold more potent at x than p~». Any
inhibition of oxytocin secretion could be attributed
more confidently to actions via kappa opioid
recept ors.
Autoradiographic evidence now suggests that there are
two kinds of kappa receptors - x , and x.;t which bind
endogenous x—opioids and U50.488H (Clark and
Past ernak , 1988;ZukIn,Eghba1i et a 1 , 1988). In the
latter st.udy, homogenates from guinea pig brain and
ratbrain were taken and a species difference in
distribution of these receptors was noted/a single
population of high affinity x, being present in guinea
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pig brain whilst in the rat brain homogenate two
populations of receptors were characterized:-high
affinity sites at low density (x , ) and low affinity
sites at high density <x:;>> .
The two sites show different 1igand selectivity
profiles U50.488H being much more potent at the x
than the xs site. It is thought that the two subtypes
of x receptors may either couple to different membrane
channels or perhaps the same channel but a different
second messenger.
There is also evidence for a third type of x—
receptor,x3.This is insensitive to U50,488H binding
and can therefore be distinguished from x •, and x*.
receptors(Clark,Lui et al,1989).
When naloxone was given at the end of the experiments
where the animals had undergone a U50,488H or morphine
administration protoco1,oxytoe in secretion was only
restored to its initial value, in the case of the x-
receptor agonist U50.488H which had caused an
inhibitory response, or remained unchanged as in the
case of morphine injected animals.This was an
unexpected result as it was thought that as well as
reversing any inhibition mediated by exogenously
applied opiates that there would be reversal of
endogenous opioid tone acting at oxytocin nerve
terminals.
It isbe1ievedthat the endogenous ligand for the x —
receptor is dynorphin AC1-17) which is co-secreted and
co-released with vasopressin from vasopressin nerve
terminals also in the neural lobe (Watson,Akil et
a 1 , 1982>.Dynorph i n has been shown to be potent at the
x;:;; Clow affinity site) whilst U50,488H is more potent
at the xl (high affinity site ) (Zuk in, Eghbal i et
al , 1988).Competitive binding studies have shown that
U69,593,a x-agonist can displace 85% of x-, receptor
binding but only .15% of x:;L. binding. It is possible that
under the conditions of the experiment that naloxone
preferentially binds to the x,-type opioid receptor to
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reverse the effects of U50,488H but not the endogenous
x-ligand binding at x:-> receptors.
Oxytocin secretion is elevated by naloxone in both in
vivo and in vitro studies demonstrating its ability to
reverse endogenous opioid tone acting on oxytocin
neurones.If U50,488H was inhibiting vasopressin
secretion, as has been shown (Forsl ing & Wells, 1989)
then dynorphin secretion would also be reduced so that
there would be less endogenous opioid tone acting at
these neurones and naloxone is just reversing the
effect of U50,488H.
Another proposal is that endogenous opioid tone has
been reversed and there is incomplete antagonism of
U50,488H, which leads to restoration of oxytocin
secretion to pre—drug values but without superceding
them.E1ectrophysio1ogica1 recordings from putative
oxytocinergic neurones in the SON show that U50.488H
will profoundly inhibit firing rate of these neurones
but that naloxone only restores this to control values
whereas morphine inhibition of oxytocin neurone cell
body activity is reversed by more than 100% by
naloxone.The inhibitory actions of U50,488H at the
cell bodies in the SON are ther ef ore, mi rror ed by its
effects on oxytocin secretion at the neural lobe
(Leng,Pumford & Russel1, 1990).
By pretreating a subsection of the experimental
animals receiving U50.488H with the g-adrenergic
antagonist propranolol it had been hoped to elucidate
the contribution of a f3-adrener g i c system to x —
mediated inhibition of oxytocin secretion.In the
suckled rat it has been shown that intraperitoneal or
intrathecal U50.488H interupts the mi Ik-ejection
ref1 ex.Fo1 1 owing injection of propranolol, intrathecal
U50.488H was ineffective whilst the action of
intraperitoneal U50,488H was significantly reduced
thus suggesting that there may be two sites of action
for x-agonists,one within the spinal cord acting
through a p-adrenergic mechanism and one at a
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supraspinal level (Clarke & Wright,1987).
Using radio1igands,opiate receptors have been
localized at the bovine adrenal medullary membranes of
which a high percentage are identified as x-receptors
(Castanas,Giraud et al,1983).
In our experiments,pretreatment of the rats with
propranolol did not prevent the inhibitory action of
U50.488H on oxytocin secretion from the neural lobe
but it did reduce its effects, as judged from
comparison of the IDs;0 values obtained from
propranolol pretreated rats and propranolol naive
anima 1s.
From this it is concluded that the adrenergic system
may be partly involved in x-opioid modification of
oxytocin secretion from the neural lobe of the rat but
that some of the inhibitory actions of U50.488H are
not mediated by an adrenergic mechanism.
In the morphine dependent group of animals there was
no cross tolerance to the effects of i.v.
U50, 488H .Converse 1 y> morph ine dependency led to a
significant enhancement of x- mediated inhibition of
electrically evoked oxytocin secretion.
Previous experiments which have addressed this
question fom another viewpoint i.e. does U50.488H
administration affect the development of morphine
tolerance and dependence in rats,have produced a
mixture of results.
Yamamoto, Ohno & Ueki,1988, reported that the
development of tolerance to morphine analgesia was
blocked by intraperitoneal U50,488H,which did not
block the analgesic effect of morphine when
administered with a single acute injection in the
morphine naive rat.In morphine tolerant
anima1s,U50,488H restored the analgesic effect of
morphine.These results led to the suggestion that
development of morphine tolerance can be blocked by a
x-mediated action but that once tolerance has
developed,U50,488H,which has previously shown no
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analgesic properties,expressed an analgesic effect
through up-regulation of x-receptors.
Fukagawa, Katz et al,1989 made rats morphine dependent
by food admixture which were subsequently challenged
with naltrexone to precipitate withdrawa1.U50,488H
administered prior to withdrawal had no effect on the
visible signs of withdrawal and concommitant
administration during chronic morphine exposure also
had no effect on withdrawal indicating tolerance and
dependance to have developed normally.The analgesic
effect of morphine was used as an index to demonstrate
tolerance and dependence.
Rats chronically exposed to U50.488H and subsequently
challenged with morphine were used by
Bhargarva,Hemendra et al,1989 to examine the cross-
tolerance of p and x receptor systems.They concluded
that there was tolerance to some effects of U50,488H
but not to the x—agonist induced diuresis and found no
cross-to 1 erance properties were conferred to the p—
system as demonstrated by morphine induced analgesia.
In the urethane anaesthetized rat model used in the
present study there was no sign of cross tolerance
between p and x-receptors.U50,488H appeared to be more
effective at inhibiting stimulus evoked oxytocin
secretion which would tend to comply with the idea of
upregulation of the kappa system put forward by
Yamamoto, Ohno & Ueki.This would have to be at the
neural lobe since neural stalk stimulation isolates
the inhibitory action of IJ50,488H to this site.
However we have no other evidence to support this
theory as autoradiographic studies on receptor changes
at the neural lobe during chronic morphine exposure
showed no change in the x—opioid receptor density (see
chapter 7).
There can be independent control of oxytocin by means
of p and x-opioid receptors demonstrated by the
ability of U50.488H to inhibit the withdrawal
hypersecretion of oxytocin from the neural lobe
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following naloxone administration. We cannot say from
this study the site of the x-receptors involved in
this;they could be located at either the neural lobe
or hypothalamus . It does however show that x-opioid
receptor modification of oxytocin secretion can take
place when the p-opioid receptors are inactivated
The unreliable results obtained from direct
application of U50.488H onto the neural stalk arose
from the problems in cutting the dural membrane
overlying the sta1k.Cutting the membrane led to
release of CSF at the site of drug application.It was
difficult to tell whether the drug reached the tissue
or was washed away in the flow of CSF. It was also
impossible to quantify the concentration of U50.488H
reaching the tissue since it was immediately diluted
in CSF.
Intracerebroventricular injection of morphine proved
difficult due to the rats being held in a supine
position.During injection,morphine solution tended to
leak out of the i.e.v. cannula making it impossible to
deliver a precise amount of drug to this compartment.
In conclusion, it seems that in the urethane
anaesthetised rat,inhibition of stimulus evoked
oxytocin at the site of the nerve terminals is
mediated by x rather than p-receptors. The effect may
partly but not entirely involve a f3-adrenerg i c
component at this site and there is no cross-tolerance
between the morphine and U50,488H at the neural
1obe.Specu1 ative1y,endogenous opioid tone which
modifies oxytocin secretion under physiological
conditions would appear to act at a different subset
of x-receptors <X2) than the x-opiate receptor agonist
U50,488H.Binding affinity studies have shown dynorphin
to be a potent agonist at these sites and this would
further emphasize its possible role as the endogenous
ligand acting to modify oxytocin secretion at the




INVESTIGATION OF THE ACTIONS OF MORPHINE AND OPIOID-
RECEPTOR ANTAGONISTS ON OXYTOCIN SECRETION FROM THE
POSTERIOR PITUITARY GLAND OF THE RAT IN VIVO AND IN
VITRO.
CHAPTER 3 : Investigation of the actions of morphine
and opioid-receptor antagonists on oxytocin secretion
from the posterior pituitary gland of the rat in—vivo
and in—vitro.
INTRODUCTION
In the rat,the magnocellular oxytocin secretory system
can be influenced by both endogenous and exogenous
opioids which exert their actions at the cell bodies
in the hypothalamus (Gosden,Humphreys et
al, 1985),demonstrated by changes in electrical
activity (Bicknel1,Leng et al , 1984) and at the
neurosecretory terminals in the neural lobe (Bicknell
& Leng,1982;Bicknel1,Chapman & Leng,1985;Coombes &
Russe11,1988) .
Naloxone,an opioid receptor antagonist,active at all
receptor subtypes (Paterson,Robson & Kosterlitz,1983)
is found to enhance oxytocin secretion in the urethane
anaesthetized rat of either sex (Hartman, Rose!I a—
Dampman & Surnmy—Long, 1987) but without alteration of
recorded electrical activity from identified
oxytoeinergic SON neurones (Clarke,Wood et
al,1979).This action is assumed to be from reversal of
endogenous opioid tone acting at oxytocin nerve
terminals as a pre-synaptic mechanism in the posterior
pituitary (Bicknel1,Chapman & Leng,1985).
As described in the introduction,immunoreactive
dynorphin,the endogenous ligand for the x-opioid
receptor subtype (Chavkin,James &
Goldstein,1982;Corbett,Paterson et al,1982) has been
found in magnoce11u1ar vasopressin neurones and
terminals (Watson, Aki I et al,1982) and is colocalized
within neurosecretory granules (Martin,Geis et
al,1984).
The predominant opioid receptor subtype localized at
the neural lobe is the x-receptor although a small
number of jj.—receptors have been reported
c
(Bicknel1,Chapman & Zhao, 1988 ; Herkenham,Rice et
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al,1986).F rorn our own studies, the presence of jjl—
receptors in the posterior pituitary remains
unresolved (Sumner,Coombes et al,1990).In the SON both
p. and x—receptors are found (Sumner, Coombes et
al,1990).
Inhibitory endogenous opioid effects have been
attributed to dynorphin released from vasopressin
nerve terminals acting via x—receptors located on
oxytocin nerve terminals or pituicytes in the
posterior pituitary (Lightman, Ninkovic et
al,1983;Bunn,Hanley & WilkIn,1985).
Acute intracerebroventricular (i.e. v.) injection of
morphine (2-4p.g) , wh i ch is considered to be a
relatively selective p-opioid agonist (Paterson,Robson
et al, 1983), inhibits oxytocin secretion and hence the
mi 1k-ejection reflex in
suck 1ed,anaesthetized, lactating rats (Clarke,Wood et
al, 1979).The characteristic,high frequency synchronous
bursting pattern associated with mi 1k—ejection
activity (Poulain & Wakerley,1982),recorded from
identified oxytoeinergic SON cells,is unaffected.
This indicates morphine to act by un-coupling
electrical activity in the hypothalamus from events
leading to hormone secretion in the neural lobe.The
effect was found to be naloxone reversible and
attributed to the actions of morphine on oxytocin
nerve terminals in the neural lobe.
More recent 1y,acute i.v. injection of morphine has
been found to be inneffective at inhibiting
electrically-evoked secretion from oxytocin nerve
terminals (Chapter 2 this thesis,Coombes &
Russel1, 1988>,a1 though it inhibits the spontaneous
firing activity from putative oxytocin neurones on the
SON in hypothalamic s1ices,indicating its actions to
be mediated at the cell bodies (Pittman,Hatton &
Bloom,I960;Wakerley,Noble & Clarke,1983).
In the following experiment,morphine was given as an
acute i.v. injection to occupy (i-receptors and to test
-68-
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Structures of the opioid antagonists naloxone,MR2266 and RX8008M
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whether it decreased plasma oxytocin.The animals were
then given the opioid antagonists naloxone or MR2266
i . v.
Naloxone acts at all opiate receptor subypes but has a
higher relative affinity for ^-receptors and therefore
may be selective for p-receptors at low
concentrations.
MR2266 is a benzomorphan derivative with ~ 40 times
greater affinity for x than p-receptors (derived from
binding studies using guinea-pig brain membranes
(Kosterlitz,1985)
MR2266 and naloxone have similar affinity at p~
receptors and in the in-vitro neural lobe preparation
are equipotent at reversing endogenous opioid peptide
inhibition of oxytocin secretion.At low concentrations
MR2266 and naloxone may have different effects on
oxytocin secretion according to whether p or x —
receptors are involved in its regulation.
In this case, using low concentrations of both
antagonist,MR2266 would be expected to reverse
endogenous opioid tone acting via x-receptors at
oxytocin nerve terminals In the neural lobe (Coombes &
Russel1,1988) to increase oxytocin secretion and
naloxone would be expected to reverse the effects of
morphine,believed to be a p-receptor agonist and hence
acting centrally on oxcytocin neurone cell bodies.The




Virgin female Sprague-Dawley rats of mean bodyweight
286.5 ± 7.3g,as described in 1.1 were used.
3. 1. 1 ( i i ) SURGERY
On the morning of the experiment the animals were
anaesthetized with urethane <1.25g/kg i.p.) and fitted
with a femoral arterial and femoral venous cannula for
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blood sampling (see 1.2 for details).The animals were
left for two hours to allow equilibration of oxytocin
secretion after surgery.The animals body temperature
was maintained at 37°C using a thermostatically
controlled blanket connected to a rectal probe.
3.1.1(111) SAMPLING/TREATMENT PROTOCOL
The sampling protocol is shown in Fig 3.1(b). .Half
the rats received 500pg/kg morphine i.v. after sample
2,the first two samples being a measure of basal
plasma oxytocin.At this dose,morphine has profound
inhibitory effects on the milk ejection reflex in the
urethane anaesthetized rat and is analgesic (Clarke &
Wright,1984).Control rats received isotonic sterile
saline (0.5ml/kg) i.v.
After plasma sample 4, by which time any changes in
plasma oxytocin would have been detected, both morphine
treated and control rats received 50pg/kg of naloxone
or MR2266.It was hoped that by using this low
concentration of antagonist,that their relative
abilities to antagonize a predicted p.—mediated
inhibition of oxytocin secretion would be
discrimina ted.
Blood samples (0.3ml) were taken and plasma separated
as described in 1.7.1(1) and oxytocin content,
determined by the Higuchi radioimmunoassay (for
details see 1.7.3).The first plasma sample was
replaced with an equivalent volume of sterile isotonic
saline,subsequent samples were replaced with
resuspended red cells in an equivalent volume of
isotonic saline.
3.1.1(Iv) DRUGS
Morphine sulphate and naloxone hydrochloride were made
up to the required concentration in an appropriate
volume of isotonic sterile sa1ine.MR2266,5,9 a —
diethyl—2-(3-fury1 me thy1> — 2-hydroxy-6,7-benzomorphan
(originally a gift from Boehringer-Ingelheim) , was
Surgery completed t = 120 mins
Plasma sample 1 t = 0 mins
Plasma sample 2 t = 10 mins
Morphine <500pg/kg> i.v. t = 15 mins
or saline <0.5ml/kg> i.v.
Plasma sample 3 t = 20 mins
Plasma sample 4 t = 30 mins
MR2266/na1oxone <50pg/kg i.v.) t = 34 mins
Plasma sample 5 t = 40 mins
Plasma sample 6 t = 50 mins
Plasma sample 7 t = 60 mins
Fig 3.1<b>
Sampling protocol showing the schedule for timed
arterial blood sampling for the measurement of
oxytocin concentration in urethane anaesthetized rats.
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initially dissolved in 0.1N HCl.lmg MR2266: 30p 1 0.1N
HC1 . The resulting solution was then made up to the
required concentration in isotonic sterile saline.
3. l.Mv) STATISTICS
Values of plasma oxytocin from radioimmunoassay are
mean ± sem.Significant changes within a group were
determined by a paired t-test and between groups by an
un—paired t-test.
3.1.2 RESULTS
Graphs 3.1(c) and 3.1(d) show plasma oxytocin values
in the four groups of animals used.For construction of
these graphs,the plasma oxytocin concentrations for
the two groups of morphine animals have been combined
(samples 1-4),until the animals received either
naloxone or MR2266 i.v.,when the results have been
plotted separately for each experimental
group.Simi 1ar1y, the plasma oxytocin concentrations in
the control groups were combined until after sample 4
when the animals received one of the two opioid
antagonists.
In graph 3.1(c),oxytoein content in plasma sample
4,taken at t=30 minutes,15 minutes after morphine
administration was significantly decreased compared to
basal levels Cp < 0.05,paired t-test).Both naloxone
and MR2266 caused a significant elevation in oxytocin
seeretion.P1asma oxytocin was elevated from 11.5 ± 2.2
pg/ml post morphine injection to 52.7 ± 19.9 pg/ml by
naloxone and to 78. 1 ± 27. 6 pg/ml by
MR2266.Statistical comparisons using a paired t-test
show that oxytocin content in samples 6 and 7 <t=16
and t=26 mins post antagonist) were significantly
elevated with respect to oxytocin content pre-
antagonist (p < 0.05 for both naloxone and
MR2266>.A1 though MR2266 would appear to have caused a
greater elevation in plasma oxytocin content than








Plasma oxytocin in arterial blood samples taken from urethane
anaesthetized rats.Morphine (500p.g/kg) was administered i.v.
at t=15 mins.At t=34 minutes the rats were given naloxone
(50|ig/kg) i.v. represented by the filled squares or MR2266
(50|ig/kg) i.v.,shown by the open squares.
Statistical comparisons:
* p< 0.05 with respect to sample 1 (paired t-test)




Plasma oxytocin in arterial blood samples taken from urethane
anaesthetized rats.Saline (0.5ml/kg) was administered i.v.
at t=15 mins.at t=34 minutes the rats were given naloxone
(50(ig/kg) i.v.represented by the filled circles or MR2266
(50pg/kg) i.v.,shown by the open circles.
Statistical comparisons:
t p< 0.05 with respect to sample 1,morphine group (unpaired
t-test).
* 0.005 > p < 0.05 with respect to sample 4 (paired t-test)
** p< 0.05 with respect to sample 4 (paired t-test).
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significant difference in the magnitude or time course
of their antagonism against morphine using an
unpaired t-test.
In control anima 1s,shown in graph Fig 3. 1 (d>, the basal
concentration of oxytocin in peripheral plasma started
off higher than in the group of rats that received
morphine <p < 0.05,unpaired t-test).Intravenous
injection of isotonic saline (0.5ml/kg) had no
significant effect on oxytocin seeretion.Both naloxone
and MR2266 caused significant elevation in oxytocin
secretion,plasma oxytocin being elevated from 18.3 ±
4.8 pg/ml post saline injection to 45.8 ± 14.5 pg/ml
by naloxone and 59.3 ± 22.0 pg/ml by
MR2266.Statistica1 comparisons using a paired t-test
show that oxytocin concentration in plasma samples 5,6
and 7 Ct=6,t=16 and t~26 minutes post antagonist) to
be significantly elevated from pre-antagonist values,
(p >0.005 <0.05 for naloxone and p < 0.05,for
MR2266>.Once again there was no significant difference
between the magnitude of response to naloxone or
MR2266 using an un-paired t-test.
3.1.3 DISCUSSION
In these experiments,i.v. morphine significantly
decreased basal plasma oxytocin in urethane
anaesthetized rats with respect to saline treated
control animals.Since there are no p-receptors present
in the posterior pituitary ( or possibly a very low
distribution) this action is likely to be centrally
mediated at oxytocin neurone cell bodies.Acute
morphine may have an inhibitory effect on the
electrical activity of oxytocin neurones such as that
observed in hypothalamic slice preparations (Waherley
et a 1 , 1983; Pumford, Huun ter & Russel 1, 1987 ) .
Acute dependence to morphine does not develop since
there is no significant difference between elevated
plasma oxytocin value's in the control or morphine
treated rats following naloxone injection.
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In both the morphine and saline treated rats there was
no significant difference between the effects of
MR2266 or naloxone to elevate oxytocin secretion.The
predominant effect seen therefore,is probably due to
reversal of endogenous opioid tone at the posterior
pituitary and not due to reversal of centrally
mediated morphine actions.It is not possible to
discriminate their effects with respect to the opioid
receptor subtpes involved or their site of action.
Although naloxone is regarded primarily as a p-opioid
receptor agonist,it has been shown to effectively
reverse opioid-mediated inhibition of oxytocin
secretion known to be mediated by x-receptors in the
neural lobe (Coombes and Russel1,1988,chapter 2 this
thesis).
In the morphine treated group,fo11owing injection of
naloxone,plasma oxytocin is elevated in plasma sample
5 and continues to rise in sample 6 (t= 6 and 16
minutes post-na1oxone respectively).In control
animals,plasma oxytocin content is elevated in sample
5 but is starting to decline in sample 6 (although
there is no significant difference between plasma
oxytocin in the two groups fromsample 6).
The initial elevation of plasma oxytocin may be due to
reversal of endogenous opioids acting at the posterior
pituitary and the subsequent continued elevation of
plasma oxytocin in the morphine treated group from
reversal of centrally acting morphine.Although the
values of plasma oxytocin are not different between
the groups, the timed secretion profile of oxytocin may
be, an effect which could arise due to the time taken
for diffusion access of the opioid antagonist,from the
periphery, to central p—receptors where morphine is
acting.
In-vitro experiments using the isolated neural lobe
preparation have shown that both naloxone and MR2266
elevate stimulus evoked oxytocin presumably by actions
against x-receptor mediated endogenous opioid tone
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(Bicknel1,Chapman & Leng,1985).Detailed dose-response
analysis showed that MR2266 displayed a biphasic dose
response relationship with oxytocin
seeretion,disp1 aying inhibitory actions at high doses
in the perifusion medium ( 10'~"M) . MR2266 was regarded
as unsuitable for use to determine x-receptor
involvement in the regulation of oxytocin secretion in
this system due to its partial agonist activity.
Other in—vitro experiments (Kosterlitz &
Paterson,1985) determined that MR2266 could not be
used as a selective x-opioid receptor antagonist
except in isolated tissues where there are no p. or 5
receptors - such as the rabbit vas deferens.
In an experiment where MR2266 was used to investigate
the role of opioids in water and isotonic saline
intake in mice (Ukai, Nakayama and Kaineyama, 1988)
MR2266 was found to reduce water intake (believed to
be a x-mediated effect) with an accompanying motor
dysfunction.These locomotory effects were similar to
those induced in mice by p.—opioid receptor antagonists
naloxone and naltrexone (Ukai & Kamayama,1985).However
MR2266 did not produce opposing effects to those
induced by specific p (morphine) and x (dynorphin 1-7
and ethlyketocyclazocine) agonists implying the
effects may be due to non-specific opioid receptor
blockade rather than selective p and x actions.
Acute naloxone excites oxytocin neurones in
anaesthetized,morphine dependent rats,which at the
lowest dose used (10"®M) was considered to be a p—
opioid effect (Leng,Russel1 & Grossman,1989).
MR2266 was - 100 times less potent than naloxone in
exciting oxytocin neurones in morphine dependent rats
(as estimated from the lowest doses needed to produce
significant excitation).
The withdrawal excitation is mediated via receptors
with different properties from the x—receptor in the
posterior pituitary, since MR2266 is equipotent, or more
potent than naloxone in enhancing stimulated oxytocin
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secretion from the neural lobe (Carter &
LIghtman,1987).
These observations indicate that p-receptors are
involved in the central actions of morphine on
oxytocin neurones, inc1uding the development of
dpendence but they do not exlude the involvement of x-
receptors in centrally-mediated opioid modification of
oxytocin secretion (since k—receptors are also found
in the SON).
These experiments confirm the results obtained in this
Chapter.MR2266 is an effective non-specific opioid-
antagonist,its partial agonist activity and non-
selectivity with regard to x-opioid-receptors,however
make it unsuitable (at the doses used) to discriminate
between p and x-receptor mediated control of oxytocin
when coupled with naloxone.
This experiment could not isolate the site or the
receptor subtype for morphine action on oxytocin
secretion using these opioid antagonists.
3.2 Investigation of actions on oxytocin secretion
from the neural lobe of the rat of RX8008M (16—Me
cyprenorphine, a relatively selective 5 and p.—opioid
receptor antagonist
INTRODUCTION
Research into the function of p, 8 and x-opioid
receptors subtypes is f rustrated by the lack of
selective antagonists for these receptors.This is
effectively demonstrated by the experiment described
in 3.1.
RX8008M (16-Me cyprenorphine) is reported to be a
se1ec tive,non-peptide, 5-receptor ant agon1st. Its
structure is shown in Fig 3.1(a).
Cyprenorphine,an oripavine,has a virtually identical
tagonist profile to naloxone and naltrexone but RX8008M
with its 16-methyl substituent group has very
different properties.
<i> It has no partial agonist activity demonstrated by
cyprenorphine in the mouse vas deferens (MVD) and
guinea pig ileum <GPI> preparation.
(ii) It has decreased affinity for the x and p-opioid
receptors compared to cyprenorphine.
Ciii) The affinity for the 5-opioid receptor is
unchanged <Smith, 1987).
The Ke values for naloxone and RX8008M are as follows
(data obtained from the MVD preparation)
pKe(nM) xKe(nM) 5Ke(nM)
Naloxone 1.4 ± 0.1 15 . 9 ± 6 , 7 9.6±2,3
RX8008M 1.7 ± 0.2 59.6 ± 9.8 0.73 ± 0.15
As well as being a selective 5—antagonist,RX8008M
shows selectivity for ji-receptors over x —
receptors,which makes it a possible tool for
discriminating between p. and x—opioid receptor
mediated events.
In-vivo studies using RX8008M (Birch,Hayes et al,1988)
tested its effects on the antinociceptive action of p
(morphine) and x (U50.488H) selective agonists in the
mouse abdominal constriction test.
RX8008M was co-administered subcutaneously with the
agonist,preceded the agonist by 30 or 60 minutes,or
was given 15 minutes after administration of the
agonis t.
RX8008M (0.33,1 and 3mg/kg) was found to cause a dose
dependent antagonism of the antinociceptive action of
p-selective agonist morphine but had no effect on
antinociceptive effects mediated by the x-selective
agonist U50, 488H. Pretreatment with RX8008M 30 and 60
minutes prior to agonist injection only produced a
small shift. in the dose-response curve of morphine
indicating its actions to be short lived.
The advantages of this compound as a tool for
differentiating between p and x opioid receptor
mediated actions are twofo1d.First1y,it is a
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competitive antagonist unlike (3-fulnal trexamine < a
non-competitive antagonist with relative selectivity
for p over k-opioid receptors) which has also been
tested for its ability to distinguish between p and x
opioid receptors (Hayes,Skingle & Tyers,1987).
Secondly it is effective by the subcutaneous route of
administration unlike the selective p-opioid
antagonist CTP (D-Phe-Cys—Tyr-D-Try—Lys-Thr-Pen-Thr—
NH2, a cyclic somatostatin octapeptide) which is only
effective in vivo,by intrathecal or
intracerebroventricular administration (Shook,Pel ton
et al,1987).
A species difference in antagonist activity of RX8008M
has been found (Hayes & Birch, 1988) . A shift to the
right of dose-response curves for antinociceptive
activity of p-agonists morphine and f entanyl by
RX8008M, were similar in the mouse and guinea pig but
only the guinea pig showed a significant shift in its
dose-response curve to x-agonists U50,488H,U69,593 and
tif luadom. However, this effect was found not to be
dose dependent indicating RX8008M to be acting in a
non-specific manner or U50,488H,U69,593 and
trifluadom to exert some p or 5 receptor mediated
antinociceptive effects in the guinea pig- In the rat
RX8008M was unable to antagonize U50,488H induced
diuresis at doses of up to 16mg/kg administered
subcutaneously.
The following study set out to test the ability of
naloxone and RX8008M, to antagonize endogenous and
exogenous opiates acting at the neural lobe of the rat
in-vitro and in—vivo. If successful,this would allow
opioid effects on oxytocin secretion from nerve
terminals in the neural lobe to be dist i ngu i shed on
the basis of whether they were mediated through p or
x—opioid receptors.
3.2.1. IN VITRO METHODOLOGY.
These experiments were performed at the AFRC Institute
-81-
for Animal Physiology and Genetics
Research,Babraham,Cambridge with the help of
Dr.R.J.Bicknell.
3.2.1. < i > ANIMALS
Neural lobes were obtained from adult,virgin female
Sprague-Dawley rats (250-300g bodyweight.) which were
housed under controlled photoperiod (14hrs light/lOhrs
dark > and temperature <22-23 °C) . Standard rat diet
and tap water were freely available.
3.2.1.<ii> TISSUE PREPARATION
On the morning of the experiment the animals were
stunned and killed by cervical dis1ocation.A dorsal
midline skin incision exposed the skull vault and the
parietal bones were quickly removed with bone nibblers
and scissors.A transverse cut across the brainstem
just anterior to the cerebellum allowed the brain to
be tilted forward in the cranial cavity.This enabled
severance with scissors of the exposed optic nerves
and facilitated removal of the whole brain leaving the
pituitary gland and part of the neural stalk in—
situ. The dural membrane covering the pituitary was
removed using watchmakers forceps and the pituitary
gently lifted out into a petri dish of pre-warmed
rned i urn at 37 ° C (see 3.2.1.<iv>>. The t i ssue rema ined in
medium from this point onwards throughout the
experiment.
The neurointermediate lobe was separated from the
anterior lobe of the pituitary under a dissecting
microscope by careful handling with watchmakers
forceps.
In a fresh dish of medium the neurohypophysis was
secured by remnants of the neural stalk and lobules
of the intermediate lobe were carefully cleared away
until they could be freed at the edges using a
microscalpel with minimal disruption to the neural
1obe tissue.
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The neural lobe was Impaled on one of a pair of
platinum electrodes protruding from the upper part of
the superfusion chamber <Fig 3.2. (a)).The electrode
assembly was immersed in fresh medium forming a bubble
of solution and was lowered into the perspex
chamber,which was screwed onto the electrode assembly
to seal the chamber.
The per ifus ion medium was pumped through the chamber
at 150p.l/min by a peristaltic pump CGilson minipuls 2)
and the perifusate collected from an outlet into an
automatic fraction collector preset to collect
fractions over time intervals of 5 minutes.The entire
assembly was housed in a thermostatically controlled
cabinet at 37°C.
3.2.1. <iii> TIMING SCHEDULE
The neural lobes were left for 45 minutes in the
chamber filled with medium without collecting any
fractions,to allow hypersecretion of hormones
resulting from tissue trauma to subside.After this
period the tissue was perifused for 5 minutes to "wash
out" secretions of the gland during equl1ibrat ion, the
resulting perifusate being d i scarded.Subsequent 1y, 15
fractions each accumulated over 5 minutes were
collected from the perifused tissues.
The first stimulus train St was delivered at the start
of fraction 2.At the end of fraction 6 the tissues
were perifused with medium containing RX8008M or
naloxone (10 _ f3M; 10~"f5M; 3 . 3x lO ' ^M} or with medium
containing no drug as time controls.
The second stimulus S:S: was delivered at the
commencement of fraction 11 . At the end of the
experiment fractions 6—9 were discarded as these
represented fractions collected during the changeover
period of media and the amount of oxytocin secreted
during this time was not required. Fractions 1-5 and
10-15 were frozen at -20 °C until assayed for oxytocin


























Chamber used for stimulation and perifusion of isolated
neural lobe preparations
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Previous studies have shown that secret i on ofAVP can be
inhibited by the action of opioids at nerve terminals
in the neural lobe (Iversen,Iversen &
Bloom, 1980;Lightman, Iversen & Forsling,1982).Na1oxone
however,has no potentiating effect on vasopressin
release (Bicknel1 & Leng,1982) which implies that the
interaction of opioids with the vasopressin system may
not involve na1oxone—sensitive opioid receptors or
that there is differential opioid innervation within
the neural lobe to vasopressin neurones
(Bicknel1,Chapman & Leng,1985).
3.2. 1. <iv) MEDIA AND DRUGS
The buffered isotonic stock medium was made up as
f o 1 1 ows:-MgC l:->. 6H:;.0 <0 . 02mM/ 1 ) ; Hepes pH 4.3
<0. lmM/l> ; KC1 (0. 05mM/ 1 ) ; CaC 1 a. 2Ha.O (0 . 02mM/ 1 ) ; NaC 1
<1.45mM/l);NaHC03 <0.05mM/1).
On the day of use, glucose (lg/1) and bovine serum
albumin (0.5g/l) were added to the medium at 37°C with
stirring.The pH was buffered to 7.3—7.4 by adding 1.OM
NaOH dropwise.All drug solutions were made up in the
medium.
RX8008M,kind1y provided by Dr. C.Smith (Reckltt &
Colman),was initially dissolved in 0.1M HC1 <^30pl/mg)
and made up to volume with distilled water,gently
warmed,to give a stock solution of 2.45mM.A1iquots of
lOOpl were diluted in an appropriate volume of stock
medium to give solutions of 1 x 10""SM, 1 x 10""eM and
3. 3x 10'"'?\M.
Naloxone was dissolved in distilled water to give a
5mM stock solution which was frozen as lOOpl aliquots
until ready for use. These were also diluted in an
appropriate volume of stock solution to give doses of
1 x 10""'SM, 1 x 10-«M and 3 . 3 x lO'-^M.
3.2. 1. <v> ELECTRICAL STIMULUS
The stimulus parameters used to elicit oxytocin
secretion from the isolated neural lobe were similar
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to those associated with the firing of oxytocin
neurones during milk-ejecting activity and could
therefore be used in the parallel in-vivo study where
intramammary pressure changes recorded in lactating
rats were used as an index of oxytocin secret i on. The
stimulus consisted of matched 0.5mA biphasic pulses of
lms pulse width administered as a train of 150 pulses
at 50Hz.
3.2.2. IN VIVO METHODOLGY
3.2.2. < i > ANIMALS
The animals used were female Sprague-Dawley rats
between day 7—14 of their first lactation of
bodyweight 340-400g (as described in 1. 1>
3.2.2. (i i ) SURGERY
On the morning of the experiment the rat which had
been separated from all but one of its litter
overnight (Lincoln,Hi11 & Wakerley, 1973),was
anaesthetized by intraperitoneal injection of urethane
( 1 .25g/kg>.
The trachea,jugu1ar vein,femoral vein and three
abdominal mammary glands were cannulated (see 1.2).
Drugs were administered via the jugular vein and
oxytocin in bolus doses,through the femoral vein.The
mammary gland cannulae were connected to pressure
transducers which recorded changes in intra-marnmary
pressure for the bioassay ( see 1.6).
The neural stalk was exposed by the ventral approach
using the surgical method described in 1.5. (i).
A concentric bipolar stimulating electrode lowered
into the stalk enabled stimulation of descending
magnocellular oxytocin neurone axons from the
hypothalamus resulting in the release of oxytocin from
the nerve terminals in the neural lobe.
3.2.2.(iii) STIMULUS
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Trains of matched biphasic pulses CO.5mA peak to
peak, 1ms duration at 50Hz were used. Individual
stimulus trains consisted of between 60 and 240
pu 1 ses , des i gned to release approximately 0.75m(J
oxytocin (see 1.5. <11)>
3.2.2.(iv) OXYTOCIN BXOASSAY
Oxytocin released as a result of neural stalk
stimulation resulted in an increase in i ntrainammary
pressure.By administering bolus doses of oxytocin
0.25,0.5,0.75. and lmU,a pressure/response
relationship was determined from which the amount of
stimulus evoked oxytocin could be ca1culated.This is
described in more detail in 1.6.
3.2.2. Cv) DRUG PROTOCOL
In the in-vitro experiment the concentrations of
RX8008M and naloxone used in the peri fusion medium
were 10""GM and 3 . 3x 10 ""7M. In—vivo, it is more
difficult to expose the neural lobe to such a precise
drug dose due to the uncertain time course of tissue
distribution.
An intravenous route of administration was chosen to
permit rapid exposure to the antagonists but a
decrease in initial effect was expected as the drugs
distributed into various body compartments.For this
reason the antagonists effect on stimulus evoked
oxytocin was tested approximately 2 minutes after
injection.
In order to obtain drug doses as similar as possible
to those used on the isolated neural lobe in-vitro,the
following procedure was carried out.The blood volume
of each individual rat was estimated by assuming the
total blood volume to be equivalent to 50ml/kg.The
drug solutions were then made up so that intravenous
injection of 0. 1ml of solution would result in the
required concentration of drug being
present, initially, in the bloodstream of the rat.The
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oxytocin terminals in the highly vascular posterior
pituitary would be exposed to slightly 1 ess,a 11 owing
for tissue distribution.
Two lower doses of RX8008M and naloxone were
used, 3. 3xl0"e and 3. 3xlO~'9M, after preliminary
experiments indicated RX8008M and naloxone to be
equipotent at the higher doses used in the in—vitro
study.
In the in—vitro experiment the drugs were compared by
their ability to antagonize endogenous opioids acting
at the neural lobe.In-vivo the animals were given a
dose of the kappa opioid receptor antagonist
U50,488H,sufficient to cause - 50% inhibition of
stimulus evoked oxytocin release <500p.g/kg> and the
effectiveness of RX8008M and naloxone at wholly or
partly reversing this inhibition compared.This
approach was chosen as subtle changes in endogenous
opioid tone acting on oxytocin neurones would be
difficult to detect in an autobioassay and naloxone
has variable effects on electrically-evoked oxytocin
secretion in—vivo.
The strategy of drug administration was as follows:—
(i) doses of exogenous oxytocin were given to
construct a dose response curve followed by electrical
stimulation of the neural stalk to elicit oxytocin
release from the neural stalk as described in
1.5. <i i ) .
<ii> 500 or 1000pg/kg U50.488H was injected
intravenously and 216-3 minutes later the stimulus
repeated to check that oxytocin secretion in response
to stimulation had been inhibited by =« 50%.
<iii> Immediately after this the lowest dose of
RX8008M was administered intraveously and 116—2 minutes
post injection another stimulus applied to see if the
inhibition had been reversed.
Civ) The lowest dose of naloxone was then administered
intravenously and 116—2 minutes after this the stimulus
was repeated so that any effects of naloxone on
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U50.488H mediated inhibition of oxytocin release could
be determined.
<v> Another dose response curve to exogenous oxytocin
finished the sequence so that the drug effects could
be calculated and changes in mammary gland sensitivity
to oxytocin taken into account.
(vi) The neural lobe was allowed to recover, a i ded by
further dilution of the antagonist in the
extracellular volume and its metabolism, until its
response to stimulation of the neural stalk resulted
in approximately the same release of oxytocin as
before any drug treatment.The regime <i)-<v) was
repeated with the same dose of U50.488H and the next
doses of RX8008M and naloxone.
To eliminate any influence that the order of drug
addition may have had on the results, in a further 5
animals naloxone was given prior to RX8008M but
otherwise the protocol <i>-<vi> was used.
To check that U50,488H mediated inhibition of stimulus
evoked oxytocin outlasted the time taken to give
RX8008M and naloxone in any cycle,some animals were
given 500 or 1000pg/kg of U50.488H and the time course
of its action monitored without giving the
an tagonists.
3.2.3. ANALYSIS OF RESULTS
Statistical comparisons were
groups using a paired t-test
an unpaired t-test.
3.2.3. <i> IN_VITRO EXPERIMENT
For the 15 perifusate fractions collected from each
isolated neural lobe chamber, fraction 1 represented
the basal secretion of oxytocin from the gland prior
to the first stimulus train and was subtracted from
each of the values of oxytocin obtained in fractions
2-5.The excess oxytocin secreted above this basal
value from fractions 2-5 were combined and this taken
made within experimental
and between groups using
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as the increase in oxytocin released in response to
stimulus train S,.
The same procedure was carried out for fractions 10—15
where fraction 10 represented the basal secretion of
oxytocin prior to stimulus Ss and the excess oxytocin
release above this from each of samples 11-15 were
combined and taken as the stimulated release due to
the stimulus train Ss:.
To overcome variability between glands,absolute
amounts of oxytocin or vasopressin (detected by
radioimmunoassay as described in 1.7>, released by the
neural lobe In vitro were combined as described above
and the S2:S, ratio for each hormone calculated for
each neural lobe.
Mean S:2:S, ratios were then calculated for each
experimental group of isolated tissue
preparations.C1ear 1y a value greater than 1.0 would
indicate a facilitatory effect on hormone release from
the nerve terminals and a value less than 1.0 would
indicate inhibition of hormone release.
S2:S, ratios for oxytocin and vasopressin obtained for
each dose of naloxone and RX8008M are shown in the
histogram 3.2<b> .
3.2.3.<ii> IN VIVO EXPERIMENT
The depression of electrically evoked oxytocin
following administration of the x-opioid receptor
agonist U50.488H and any subsequent change following
RX8008M and naloxone injection were expressed as
percentages of the initial amount of oxytocin released
on stimulation of the neural stalk before U50,488H or
the antagonists were given.
The values were obtained from the dose-response curves
constructed from the mammary gland autobioassay.The
results from animals which received RX8008M before
naloxone were combined wi th the animals that received
naloxone before RX8008M as there was no difference in




In vitro S2 : SI ratios obtained from RIA values of oxytocin




p < 0.05,** p < 0.005,# p< 0.05 (inhibition)with respect to
control S2 :S1 oxytocin ratio (un-paired t-test).
t p < 0.005 with respect to S2 : SI oxytocin ratio from 3.3 x 10 -7M
RX8008M (un-paired t-test).
A p = 0.05 with respect to control vasopressin SI : S2 ratio
(un-paired t-test).




Intramammary pressure recording traces from animals
that were treated with the opioid antagonists RX800M
or naloxone.
The top trace shows how U50,488H (500pg/kg i.v.)
profoundly inhibits electrically-evoked oxytocin
release,from stimulation of the neural stalk (see 1.5)
whilst sensitivity of the mammary gland to oxytocin is
unaltered (see response to 0.75 mU exogenous
oxytoe in >.
The centre trace shows how RX800M and naloxone (3.3 x
10~'7M i.v.) reverse U50.488H mediated inhibition of
oxytocin re 1 ease,na1oxone reversing the inhibition to
the greatest extent.
.'/The bottom trace show the effect of giving the same
dose of opioid antagonists in reverse order,with
naloxone still showing the greater anatagonism to
U50,488H,indicating that the order than the drugs are
given does not significantly affect the subsequent
response (i.e.there is no appreciable summation
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they were given as shown in the traces in Fig 3.2(c).
The results have also been expressed in an alternative
way.The difference was calculated between oxytocin
release (expressed as a % initial amount of oxytocin
released on neural stalk stimulation) after U50,48QH
but before RX8008M and naloxone (Bd) to that after-
antagonist administration (Ad) i.e by relating the
effect of antagonist to oxytocin secretion during
U50.488H mediated inhibition (Ad-Bd).This was to try
and isolate effects of the antagonists and clarify the
extent of their ability to antagonize U50,488H
mediated inhibition of stimulus evoked oxytocin
release from the neural lobe. It must be remembered
that the doses of RX8008M and naloxone are those
initially in the bloodstream of the rat and may change
on tissue distribution.The doses injected are
approximately equivalent to
30ng/kg, 0 . 3p.g/kg, 3pg/kg, 10p.g/kg and O.lmg/kg naloxone
and 40ng/kg, 0. 4jj.g/kg, 4pg/kg, 1 2p.g/kg and 0.12j.ig/kg
RX8008M (corresponding to 3 . 3>< 10'"'aM, 3 . 3x 10"",:3M, 3 . 3x 10"
'7M, lxlO""r"M and lxlO~"BM respectively) for the
bodyweight of each rat.
3.2.4. RESULTS
IN VITRO RESULTS
Mean S^uS, values obtained for each experimental group
of in vitro neural lobe preparations,illustrated in
Fig 3.2(b) show that naloxone enhanced oxytocin
secretion above control values when included in the
perifusion medium at all the concentrations tested (p
<0.005,unpaired t-test).RX8008M showed a dose-related
effect on oxytocin seeretion,significant 1y elevating
it at 10—-'M (p <0.05) but just causing an inhibition
at 3.3xl0"';"M (p =0 . 05 , unpa i r ed t — t es t. ) Na 1 oxone was
only more effective than RX8008M in its elevation of
oxytocin secretion at a dose of 3.3x10 '"M (p
<0.005,unpaired t-test).Vasopressin secretion from
these isolated neural lobe preparations was unaffected
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with respect to the control values in the presence of
RX8008M and naloxone with the exception of naloxone at
a concentration of lxlO~sM which caused a just
significant depression in vasopressin secretion (p
=0.05).In vitro it would appear that action of RX8008M
against endogenous opioids acting at receptors on the
neural lobe to modify oxytocin secretion is dose
dependent,on 1y having a significant effect at the
highest dose tested.
IN VIVO RESULTS
U50.488H (500pg/kg> was an effective dose at achieving
a 50% inhibition of oxytocin secretion elicited by
electrical stimulation of the exposed neural stalk in
the rat (p <0.0005,paired t-test>.This dose was chosen
on the basis of the results obtained in Chapter
2, where the ID,=;o of U50,488H against oxytocin
secretion was found to be =500pg/kg (Coombes &
Russel1,1988.)
The duration of U50,488H mediated inhibition outlasted
the time course of the protocol for intravenous
injection of RX8008M and naloxone.
Intramammary pressure recording traces showed naloxone
to be more effective at antagonizing x-opioid receptor
mediated inhibition of oxytocin secretion in the
anaesthetized rat.The order of injection of the
antagonists proved to be unimportant responses to
intravenous RX8008M being smaller than to naloxone
even when it was administered after
naloxone., demonstrating that summation of the
antagonist effects was not occurring (see Fig.3.2<c>).
Both RX8008M and naloxone in increasing doses were
able to wholly or partly reverse U50,4S8H effects at
the neural lobe,in what appeared to be a dose-
dependent manner.The results ,expressed as a % initial
amount of electrically evoked oxytocin release before
administration of either agonist or antagonists,are

















Molar dose of antagonist
Fig 3.2 (d)
Effect ofRX8008M (open bars) and naloxone (striped bars) on
stimulated oxytocin secretion inhibited to < 50% by U50,488H
( 500pg/kg i.v.,solid bars) in urethane anaesthetized lactating rats.
Statistical comparisons :
*
p < 0.05, **p < 0.005, *** p < 0.0005, for both RX8008M and
naloxone with respect to U50,488H inhibited oxytocin response
to neural stalk stimulation.
t p < 0.05 naloxone stimulatory effect on electrically-evoked
oxytocin secretion with respect to the effect by RX8008M
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3.3 x 10-9M 3.3 x 10-8M 3.3xlO-7M 10-6M 10-5M
(n=10) (n=10) (n=15) (n=10) (n=14)
Molar dose of antagonist
Fig.3.2 (e)
Elevation of electrically-evoked oxytocin secretion in urethane
anaesthetized rats by increasing i.v. doses of RX8008M (open-
bars and naloxone (striped bars).The initial oxytocin response
to stimulation of the neural stalk had been inhibited by 500|ig/kg
U50,488H i.v. Values represent increases relative to oxytocin
released during U50,488H mediated inhibition.. (For full
description of Ad-Bd calculation see page 94).
Statistical comparisons :
* p < 0.05 with respect to initial effect of RX8008M or naloxone
(paired t-test)
t p < 0.05 with respect to effect of RX8008M at these doses (un¬
paired t-test).
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oxytocin secretion at 3.3x10"9M, 3.3x10—®M <p
<0.05> , 3. 3x10"'^, 10-®M <p«0.00005) and 10"eM
<pS0.0005) using a paired t-test for statistical
comparisons. Naloxone elevated oxytocin secretion at
all doses,3.3x10"~®M <p<0.005),3.3x10~eM
Cp<0.05),3.3xl0~VM and 10~®M <p<0.00005) and 10~eM
<p(0.0005) using paired t-tests.Naloxone was
significantly more effective at antagonizing x-opioid
mediated effects at doses of 3. 3x10""7M and higher
<p<0.05,unpaired t-tests).
When the results were expressed as Ad-Bd values,as
shown in Fig 3.2(e),which reflected the increment in
faci1itataion of oxytocin secretion during inhibition
by U50.488H effected by the agonists,RX8008M does not
appear to facilitate oxytocin secretion in a dose
dependent manner.Statistical ana 1ysis,using a paired
t-test shows that there is no significant difference
between the increments of facilitation of oxytocin
secretion at any of the doses tested. In
contrast,naloxone is significantly more potent at
doses above 3.3xlO~7"M (p<0 . 05 , pa i r ed t-test) although
it is a large jump in response rather than a stepwise
change.At doses above 3.3xlO~7M,naloxone is more
effective than RX8008M at antagonizing the U50,488H
modulation of oxytocin secretion <p<0.05,unpaired t—
test).
3.2.5 DISCUSSION
Naloxone stimulated electrically-evoked oxytocin
secretion from the isolated neural lobe preparations
at all doses tested.This was probably due to its
antagonism of endogenous opioid peptides acting via x—
opioid receptors to inhibit oxytocin secretion from
nerve terminals in the neural 1obe.Vasopressin
secretion was not affected by naloxone at doses of
3. 3 x 10~VM and 1 >: 10 "r;M but was inhibited by a dose of
lxl0""sM na 1 oxone. Th i s indicates that. vasopressin
secretion is not modified by endogenous opioids (or at
-98-
least not via na1oxone-sensitive receptors) although
the reason for the inhibitory response seen is
unc1 ear.
RX8008M showed a biphasic effect on oxytocin release-
it was stimulatory at a dose of lxlO""'GM, had no effect
at 1x10""M and was inhibitory at 3. 3><10""7M.
At the high dose, the faci1itatory effect may have been
due to non-selective binding at x—receptors,sinee the
antagonist was at a high concentration and reversal of
x-mediated opioid tone acting at the oxytocin nerve
terminals in the posterior pituitary.
The reason for the inhibitory effect of RX8008M at
3. 3x lO'-'^M is not clear. It could be that at this low
concentrat ion, in addition to its high p/5 selectivity
over x-recptors,that it shows partial x-agonist
act i vity.Previous in-vivo studies did not reveal any
partial agonist activity in the mouse vas deferens or
guinea pig ileum preparation <Smith,1987).
There is now evidence for a multiplicity of x—
receptors which have been identified in guinea pig and
rat brain.
There is a population of high affinity x-sites found
in guinea pig brain that is only found in low density
in rat brain (x,) and a low affinity x-site found in
high density in rat brain but at very low density (or
maybe absent) in guinea pig brain (xs).
The two sites display different ligand
se1ectivity,U50,488H and U69,593 being more potent at
the x -i site, the latter inactive at the x::;. site
CZukin,Eghbali et al,1988>.
There is now evidence for a x,, and x , t:j site following
binding studies in which classical x-opiates and
dynorphin A have a high affinity for the two types of
receptor located in guinea pig cerebellum whereas
dynorphin B and a-neoendorphin bind to x , fifty times
more potently than x, (Clark, Liu et al,1989).
A third type of x-opioid receptor subtype has now been
i den t i f i ed . Th i s receptor (x:.;;,) is U50,488H insensitive
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(as demonstrated by its inabilty to displace naloxone
benzoylhydrazone from its x3 site.
In the rat brain there is predominant 1ey a
distribution of x:;;. receptors. It may be that RX8008M
has some partial agonist activity at this receptor
site but that this type of x-receptor was not
presentin the tissues in which the properties of
RX8008M were characterized <Smith,1987).
In—vivo,RX8008M elevated U50,488H inhibited oxytocin
secretion in all doses tested but to a greater extent
at higher doses. Once again this may be due to non¬
selective effects at x-receptors at high
concentrations or due to RX8008M being able to
antagonize the x-opioid receptor subtype involved
despite having far higher affinity for the pand 5-
opioid receptors.The effect is not strictly dose
dependent indicating non-selective actions of RX8008M.
Naloxone was effective at reversing the U50,488H-
mediated inhibition and was more effective than
RX8008M at doses of 3.3x10 "^M and h igher. Chapter 2 has
already shown that naloxone effectively reverses
U50,488H mediated inhibition of electrically-evoked
oxytocin secretion but without apparently having an
effect on endogenous opioid tone, presumably due to the
different types of receptors involved.
Once again,these experiments show that RX8008M is not
a suitably selective opioid-receptor antagonist to
discriminate between p and x-opioid receptor mediated
action on oxytocin secretion.
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CHAPTER FOUR
STUDY OF WHETHER CENTRALLY-PROJECTING OXYTOCIN
NEURONES ARE SUBJECT TO OPIOID-MEDIATED MODULATION
OF HORMONE SECRETION AND WHETHER THEY CAN BE MADE
MORPHINE DEPENDENT FOLLOWING CHRONIC MORPHINE
INFUSION.
CHAPTER 4 : Study of central 1y—projecting oxytocin
neurones — are they subject to opiold-mediated
modulation of hormone secretion and can they be made
morphine dependent following chronic morphine
infusion.
INTRODUCTION
The distribution and projections of oxytocin and
vasopressin—containing neurones has been described in
the general introduction,
A measurable amount of oxytocin (and vasopressin) is
found in cerebrospina 1 fluid <CSF> which, it was
assumed,was secreted from the hypothalamo-
neurohypophysial system perhaps by transport across
the ependymal lining of the third ventricle
(Vorherr,Bradbury et a 1,1968).
Large amounts of exogenously administered peptides
only poorly cross the blood-brain barrier (Zaidu &
He11er,1974) so it was later believed that oxytocin
secreted into CSF came from centrally-projecting
oxytocin neurones.
In the guinea pig,oxytocin release into peripheral
plasma during suckling occurs without a similar
elevation in central oxytocin,indicating that CSF
oxytocin does not just reflect plasma oxytocin content
(Robinson & Jones, 1982). It also demonstrated that the.
magnoce11u1ar oxytocin neurones which project to the
posterior pituitary are not the primary source of CSF
oxytoe in.
Discrete brain areas which have been shown to contain
parvoce11u1ar oxytoeinergic projections (demonstrated
immunohistochemica11y) , show a local release of
oxytocin during suckling,following hyperosmotic
stimulation and after stimulation of the PVN
(Landgraf,Neumann 8t Schwarzberg,1988;Neumann &
Landgraf,1989;Neumann,Schwarzberg & Landgraf,1988)
Oxytocin released into the extracellular fluid of
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these brain areas can probably diffuse into CSF
(Robinson,1983).
Although stimulation of the PVN increases CSF oxytocin
content,stimulation of the neurohypophysis does
not,confirming that magnocellular neurones projecting
to the posterior pituitary are not the main source of
this peptide.However,oxytoein release from the
dendrites or axons of these neurones cannot be ruled
out.
The anterior commissural nuclei contain many
magnocellular cell bodies (Armstrong,Warach et
al, 1980 ) which project to the neural lobe but not to
the brainstem or spinal cord,contain neurophysin and
have one or two dendrites which project to the third
ventricle.These cells are separated from the PVN by
300-400pim. Ce 1 1 s from the PVN (medial and lateral
regions) are also seen to have dendrites projecting
medially toward the ventricular wall.Due to presence
of cilia extending from these processes , it has been
proposed that these projections to the ventricular
system are receptive in function. (Vigh—Teichman, Vigh
& Aros,1976)
Detailed ultrastructural studies have not been carried
out but it is known that cilia have been observed from
neurosecretory perikarya (Gregory & Hatton,1979).As
well as having a receptive function, these sub- and
intra- ventricular peptidergic projections may be
secretory in function. It has been observed that there
is a large rise of vasopressin in CSF following
hypophysectomy without a concomitant rise in plasma
vasopressin indicating that AVP processes may secrete
directly into the CSF (Dogterom,Van Wimersma Greidanus
& Swaab,1977)
Oxytocin and vasopressin secretion from nerve
terminals in the neural lobe is regulated by
endogenous opioid peptides co—secreted and co-released
with oxytocin and vasopressin.Oxytocin is principally
regulated by dynorphin acting at kappa opioid
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receptors located on or near to the oxytocin nerve
terminals. (Clarke,Wood et al, 1979;Coombes &
Russel1,1988).
Magnoce11u1ar oxytocin neurones display both tolerance
to and dependence on morphine when exposed to a
chronic i.e.v. infusion over several
days. (Bicknel1,Leng et a 1, 1988).Withdrawa1 by an
opioid antagonist such as naloxone administered i.v.
results in a hypersecretion of oxytocin.This type of
control over oxytocin secretion is thought to be
mediated via p-opioid receptors located centrally in
the hypothalamus.
Mechanisms controlling oxytocin secretion from
centrally projecting oxytocin neurones into the CSF
are not known.To investigate whether opioids are
involved in modification of centrally secreted
oxytocin,both plasma and CSF oxytocin concentration
was measured in morphine dependent and morphine naive
rats before and after a withdrawal challenge with
naloxone. In order to determine whether any oxytocin
detected in the CSF came from oxytocin neurone
projections originating from the PVN,in a separate
group of animals this nucleus was ablated bilaterally
prior to infusing the animals with morphine or
vehic1e.
Morphine is known to influence the secretion of
vasopressin in an inhibitory fashion (Aziz,Forsling &
Woolf,1981> whereas growth hormone and ACTH are known
to be increased by morphine (Buckingham &
Cooper, 1984; Wehrenberg,Bloch & Ling, 1985).Withdrawa1
from morphine with naloxone also leads to an increase
in plasma ACTH but this is probably due to the
stressful nature of the withdrawal
stimulus,Concentrations of these hormones were also
measured in the plasma samples since their secretion




The animals used in the following experiments were
virgin female Sprague-Dawley rats (250-300g average
bodyweight) housed under conditions described in 1.1.
4.1.1 INTACT RATS
Five days prior to the exper i. ment, under ether
anaesthes i a, one. group of animals (n=7) was implanted
with an intracerebroventricu1ar <i.c.v.) infusion
device connected to a subcutaneous osmotic minipump in
order to continuously deliver graded doses of morphine
sulphate into the left lateral cerebral
ventric1e.Contro1 animals (n=6> were fitted with the
same infusion system to deliver vehicle (sterile
pyrogen free water) in the ventricle.Surgical details
are described fully in 1.3.
After five days the animals were anaesthetized with
urethane <1.25g/kg i.p.) and were fitted with a
tracheal cannula and femoral venous and arterial
cannulae for terminal blood sampling.
The animals' heads were immobilized in a simple head
frame with the neck flexed to facilitate exposure and
cannulation of the at 1anto-occipita1 membrane so that
cerebrospinal fluid (CSF) from the cisterna magna
could be collected.DetaiIs of this cannulation
technique are fully described in 1.4.
Terminal blood and CSF sampling were carried out
according t.o the protocol described in Fig. 4.1(a).
Seventy minutes was left after the completion of
surgery to the collection of the first blood and CSF
samples in order that any increase in basal oxytocin
arising from surgical 'stress' would have subsided.
Blood samples (1ml) were withdrawn from the femoral
ar tery , i mrned i a t e 1 y cooled over ice, centrifuged at O'C
and plasma aliquots frozen at -20'C until assayed for
oxytocin (OT),vasopressin (AVP),growth hormone <GH)
and adrenocorticotrophic hormone (ACTH).The first
sample was replaced with sterile isotonic saline (1ml)
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Surgery completed t= —70 mins
Plasma sample 1 t= O mins
CSF sample 1 t= 5 mins
5mg/kg naloxone or t= 30 mins
O. 97, sal ine
Plasma sample 2 t= 35 mins
CSF sample 2 t= 40 mins
Plasma sample 3 t= 60 mins
CSF sample 3 t= 70 mins
Plasma sample 4 t— 120 mins
CSF sample 4
Fig 4.1 <a>
Terminal blood and CSF (from the cisterna magna)
sampling protocol applied to all groups of rats used
in the experiment.
-105-
via the femoral vein,subsequent samples were replaced
with red cells resuspended in isotonic sterile saline
to a volume of 1ml.
CSF samples were collected under gravity into
preweighed polystyrene tubes so that over each
collection period * 50pl was collected (assumption
that lpl CSF = 1 pg CSF) . The CSF samples were cooled
over ice and frozen at -20°C until assayed for
oxytoe in.
Naloxone <5mg/kg> was administered intravenously to
all the animals via the femoral vein at t=30 rains.
4.1.2 TIME CONTROLS
Morphine infused <n-7> and vehicle infused (n=8) rats
were set up as described in 4.1.1. After five
days, termina 1 blood and CSF samples were taken
according to the schedule in Fig. 4.1(a).In this group
of rats (n=15 total) an intravenous injection of
sterile isotonic saline was administered at t= 30 mins
instead of naloxone to investigate whether changes
take place in oxytocin content of CSF and plasma with
repeated sampling.Plasma ACTH was also measured.
4.1.3 PVN LESIONED ANIMALS
4.1.3 <i) SURGERY
Nine days prior to starting an i.e.v. morphine or
vehicle infusion,this group of experimental animals
<n=27> underwent a bilateral knifecut lesion of the
paraventricu1ar nucleus under barbiturate anaesthesia
(lesions performed by Dr. F.Antoni,Dept.of
Anatomy,Oxford.) so that the contribution of
magnoce11u1ar and parvoce11u1ar PVN oxytocin neurones
to changes in oxytocin in both CSF and plasma could be
rneasured.
After the experiment,histological preparation and
examination of the brains confirmed the extent of the
lesion in each animal.
The PVN lesioned experimental group underwent the same
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regimen of i.e.v. morphine and vehicle infusion and
terminal sampling protocol as described in 4.1.1.
4.1.3 <ii) HISTOLOGY
<a> TISSUE FIXATION AND CUTTING
At the end of the exper i ment, br a ins from the PVN
lesioned animals were removed and immediately placed
in Bouins fixative.After 48hrs the brains were
transferred to 70% alcohol and left overnight.The 70%
alcohol was then replaced with two changes of 90%
alcohol over two hours then three changes of 95%
alcohol and finally three changes of absolute alcohol
over lk> hours.The fixed brains were left in cedarwood
oil for two days.Following this,the brains were
immersed in three changes of molten paraffin wax in an
embedding oven over three hours and finally set in
paraffin wax in a cubic mould.
The resulting wax block was trimmed to a parallel
sided block prior to sectioning on a microtome
(Reichert—Jung,model 1130/Biocut). 15pm frontal
sections were cut through the hypothalamus and floated
out in water at = 40'C onto prewashed chrome-alum
gelatine dip coated slides.The slides were dried in a
37°C oven.
<b> STAINING
The following protocol was used to stain the sections
with cresyl fast violet (CFV).
The slides in slide racks were placed in xylene for .15
minutes to remove wax around the tissue sections.The
sections were then hydrated through absolute alcohol
(5 mins),90% alcohol (3 mins) and 70% alcohol <3
mins) .
The slides were immersed in 70% alcohol with LiCCU,
until the Bouins colouration had disappeared from the
sections.The sections were then stained in cresyl fast
violet for 3-5 mins and washed under running water
for 10 mins to remove any excess stain.
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The stained sections were dehydrated in successive
alcohol baths:70% alcohol <3 mins),90% alcohol <3
mins) and absolute alcohol <5 mins>.Fina11y, the
slides were immersed in xylene until the sections
cleared. The sections were mounted in DPX and cover
s1ipped.
Examination under a low power microscope revealed the
extent of the lesions which were visualised on
diagrams of serial frontal sections taken from a
stereotactic atlas (Kttnig & Klippel).
4.1.4 RADIOIMMUNOASSAY
Oxytocin was measured in unextracted plasma and CSF
samples by a specific radioimmunoassay previously
described by I.C.A.F.Robinson <1980).P1asma samples
were assayed twice on 10 and 50pl volumes,CSF samples
were assayed once in 50pl samples. The sensitivity of
the assay was 0.25-0.5 pg/tube.(Details of assay in
1 . 7)
Vasopressin was measured in unextracted plasma volumes
of lOpl according to the method described by
Horn,Robinson & Fink <1985).The sensitivity of the
assay was 0.5-1.Opg/tube.
Growth hormone was also measured in unextracted plasma
samples of lOpl according to the method of Clark &
Robinson <1985).The sensitivity of the assay was 20-
5Opg/tube.
ACTH was measured in unextracted plasma volumes of
20pl by a specific second antibody
radioimmunoassay. The sensitivity of the assay was
0.2fmo 1/tube. The primary rabbit antibody
<AS8514),which was provided by
Dr.G. Makara,Budapest, was raised against 1-32 ACTH
coupled with carbodiimide to bovine serum albumin.This
antibody specifically recognizes the mid portion of
ACTH but will only react weakly with 1-24 ACTH and not
at all with ot-MSH or g-endorph in. Ful 1 details of this
procedure are described by Kovacs & Makara <1988).
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All assays for oxytocin, AVP and GH were carried out
with the help of Dr.Iain Robinson at NIMR.Mill
Hi11,London.ACTH assays were carried out by
Dr.F.Antoni,Dept. of Anatomy,Oxf ord,
4.1.5 STATISTICS
Data points are represented by the group mean value ±
s.e.m.Statistical comparisons were made within animals





The results of changes in oxytocin secretion into
peripheral plasma are shown in Fig 4.2 (a).Basal
plasma oxytocin content in sample 1 (t=5 mins) was
51.8 ± 20.8 pg/ml in vehicle infused rats <n-6) and
28.6 ± 15.2 pg/ml in morphine infused rats (n=7).There
was no significant difference between these values.
Following i.v. injection of naloxone at t=3Q mins,the
vehicle group showed an approximate ten-fold increase
in plasma oxytocin to 574.8 ± 135. 1 pg/ml whereas the
morphine treated animals showed oxytocin levels
elevated approximately one hundred—fold to 2285.3 ±
264.5 pg/ml.Statistica1 comparison by a paired t—test
showed these values to be significantly increased with
respect to pre-naloxone values <p = 0.01 vehicle
group,p < 0.001 morphine group).Oxytoe in levels in the
morphine treated animals were also significantly
elevated with respect to the vehicle group,after
naloxone <p - 0.002 Wilcoxon).
In the following two plasma samples oxytocin levels in
the morphine treated animals fell to 785.4 ± 113.8
pg/ml and 322.4 ± 52.0 pg/ml but were still
significantly elevated with respect to pre-naloxone
values <p < 0.001,paired t-test) and also at t-60mins
with respect to oxytocin levels in plasma samples from
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Fig 4.2(a)
Oxytocin in peripheral blood plasma of rats under urethane
anaesthesia that received naloxone (5mg/kg,filled symbols) or
0.9% saline (open symbols) i.v. at t=30 minutes.Square symbols:
1.c.v. morphine infusion (n=7 both groups);circular symbols:
i.c.v. vehicle infusion (n=6,n=8 time controls)
* p=0.01,** p=0.002,***p<0.001 with respect to pre naloxone
values (paired t-test).
t p<0.05,tt p=0.002 vehicle treated v. i.c.v. morphine infused rats
at the same time points post-naloxone (Wilcoxon).
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Fig 4.2(b)
Oxytocin in CSF of rats under urethane anaesthesia which received
naloxone (5mg/kg ,filled symbols) or 0.9% saline (open symbols)
i.v. at t=30 minutes.Square symbolsii.c.v. morphine infusion
(n=7 both groups).Circular symbols:i.c.v. vehicle infusion (n=6,
n=8 time controls).
* p=0.05,** p<0.05,*** p<0.02 with respect to pre-naloxone values
(paired t-test)
t p<0.05,tt p<0.02 morphine infused v. vehicle infused animals at
the same time points post-naloxone (Wilcoxon).
-111-
the vehicle treated animals <p <0 . 05 , Wi1coxon).
Oxytocin in the vehicle infused group of rats also
remained elevated with respect to pre—naloxone values
in the following two samples at 490.3 ± 82.2 pg/ml and
264.8 ± 39.3 pg/ml (p = 0.002 and p = 0.01
respective1y,paired t—test).
Oxytocin content in CSF samples from the two groups of
experimental animals is shown in Fig 4.2 <b)
Initial basal oxytocin levels were 56.4 ± 6.4 pg/ml in
vehicle treated animals and 53.7 ± 10.6 pg/ml in
morphine treated anima1s.there was no significant
difference between these values.
Following i.v. naloxone injection at t=30
mins,oxytocin levels in the CSF samples from morphine
treated rats were elevated to 196.0 ± 71.0 pg/ml
rising to 275.6 ± 65.1 pg/ml at t = 60 mins and then
falling to 178.3 ± 35.3 pg/ral . At t=60 and t=120 rnins
these values were significantly higher than pre-
naloxone values <p < 0.02,paired t-test) and at t=35
and t =60 mins the values were significantly greater
than those found in the morphine-naive animals (p <
0.05 and p < 0.02 respective1y,Wi1coxon).
The veh i c 1 e-tr ea t ed group of rats did not show an
increased level of oxytocin in their CSF samples until
t = 60 mins when it rose to 92.2 ± 12.3 pg/ml (p =
0.05,paired t-test,with respect to pre-naloxone
values).This elevation in oxytocin continued and at
t=120 mins was 123.3 ± 25.1 pg/ml <p < 0.05,paired t—
test with respect to pre-naloxone values.
4.2.1 <ii) VASOPRESSIN <AVP>
The results of vasopressin content measurement in
plasma samples from the two groups of rats are shown
in Fig. 4.2 (c).Basal vasopressin content in the
vehicle infused experimental group) of rats was 72.6 ±
6.7 pg/ml and in the morphine treated group 87.0 ± 5.3




Vasopressin (AVP) in peripheral blood plasma from two groups
of experimental animals under urethane anaesthesia.Filled circles:
i.c.v. morphine infused rats (n=7),filled squares:i.c.v vehicle
infused (n=6).All animals received naloxone (5mg/kg i.v.) at
t=30 minutes.
* p<0.01 with respect to pre-naloxone value (paired t-test)..
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Following naloxone injection there appeared to be an
increase in plasma vasopressin in the morphine treated
animals but this is because the sample taken at t-35
mins had a lower AVP content than the basal sample
<75.4 ± 12.3 pg/ml >. A1 though this decrease was not
statistically significant,it gave the impression that
subsequent samples at t =60 and t-120 mins were
e1evated.
Vasopressin in plasma samples from vehicle treated
animals showed a gradual elevation which was
significantly above pre-naloxone values at t=120 mins
<94.3 ± 5.3 pg/ml,p < 0.01,paired t-test>.
4.2.1 <i i i > GROWTH HORMONE <GH>
The results of GH measurements in plasma samples from
the two groups of rats are shown in Fig. 4.2 (d).Basal
values of GH were 34.6 ± 4.0 pg/ml in the vehicle
treated group and 36.2 ± 6.7 pg/ml in the morphine
infused group.There was no significant difference
between these.
Following naloxone injection neither group of animals
showed any significant change from pre- naloxone
values or from each other.
4.2.1 <iv) ADRENOCORTICOTROPHIC HORMONE <ACTH>
Basal plasma ACTH in the morphine treated group of
rats was significantly higher than that in the
morphine naive animals (p<0.05,Wilcoxon) , as shown in
Fig 4.2e <i>. It was also significantly higher at t-35
mins <p<0.01,Wilcoxon).
Neither group of animals showed a significant increase
in ACTH immediately following naloxone administration
at t=30 mins.During the course of the experiment ACTH
in the morphine dependent group decreased until it was
of the same magnitude as the morphine naive group.This
decrease was significant with respect to basal values





Growth hormone (GH) in peripheral blood plasma from two
groups of experimental animals under urethane anaesthesia.
Filled circlesri.c.v. morphine infused rats (n=7),filled squares:
i.c.v. vehicle infused rats (n=6).All animals received 5mg/kg
naloxone i.v.
There was no significant difference in plasma GH values within
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Concentrations of ACTH in peripheral blood plasma in two groups
of urethane anaesthetized rats which had been treated with either
i.c.v. morphine (filled symbols) or i.c.v. vehicle (open symbols) for
5 days..
(i) Received 5mg/kg naloxone i.v. at t=30 mins (n=13,square
symbols.)
(ii) Received isotonic saline (0.5mls/kg) i.v. at t=30 mins (time -
controls (n=16,circular symbols)
Statistical comparisons:
t p > 0.05,ft P > 0.02 with respect to i.c.v. vehicle group
(Wilcoxon).





Oxytocin in peripheral blood plasma samples of the
animals which received 0.9% saline at t=30 mins
remained at basal values throughout the experiment,as
shown in Fig 4.2<a> .Neither the morphine infused
group <n=7> nor those receiving; i.e. v. vehicle showed
any significant change in oxytocin levels.There was no
significant difference in oxytocin content of the
plasma samples between the two experimental groups.
Oxytocin in CSF samples of these animals showed a
similar result to that seen in p1asma.Neither the
morphine infused or vehicle control animals showed any
significant change in oxytocin in their CSF following
intravenous injection of 0.9% saline,as shown in Fig
4.2 Cb>.There was no statistical difference in
response between the two groups of animals.
4.2.2 <ii> ADRENOCORTICOTROPHIC HORMONE <ACTH>
Basal plasma ACTH in the morphine dependent group of
rats was significantly lower than that in the morphine
naive group <p<0.05,Wi1coxon) , the opposite of the
finding in the above experiment,as shown in Fig 4.2e
(i i> .
This difference was still apparent at t = 35
mins,fo11 owing i.v. 0.9% saline i.v. (p<0.05
Wi lcoxon).After 120 minutes plasma ACTH levels were
significantly decreased with respect to basal values
in both the morphine and vehicle infused groups
<p<0.01,paired t-test).
4.2.3 PVN LESIONED RATS
4.2.3 <i> OXYTOCIN
Oxytocin levels in peripheral blood plasma samples
from rats with a bilateral ablation of the
paraventricular nucleus are shown in Fig 4.2<f>.
Following naloxone injection <5mg/kg i.v.) at t=30mins
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Fig 4.2(f)
Oxytocin in peripheral blood plasma of rats which had
undergone a bilateral ablation of the PVN 14 days
previously .Filled squares : i.c.v. morphine infused (n=9),
filled circles : i.c.v. vehicle infused (n=ll).
* p<0.05,** p<0.02,*** p<0.001 with respect to pre-naloxone
values
f p<0.05,ft p<0.001, i.c.v. morphine treated rats v. i.c.v.
vehicle treated rats at the same time points post-naloxone.
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morphine for 5 days showed an approximate 120-fold
increase in plasma oxytocin Cp < 0.001,paired t-test
with respect to pre-naloxone values).The peak
concentration of plasma oxytocin from these animals
<624.20 ± 114.54 pg/ml) was considerably less than
that from the intact rats which had been made morphine
dependent (2285.3 ± 264.5 pg/ml),a 1 though the
magnitude of the increase was of the same order (^
100-fo1d>.This was likely to be because basal plasma
oxytocin levels in the PVN lesioned rats receiving an
i.c.v. morphine infusion was considerably lower than
that found in the intact rats; 5.0 pg/ml compared to
28.6 pg/ml. In the following two samples the level of
oxytocin fell but was still significantly higher than
pre-naloxone levels <p < 0.001 and p < 0.02
respectively,paired t-test).
In the control,vehicle-infused animals there was a
more gradual increase in plasma oxytocin following
naloxone injection.The peak level recorded at t = 60
minutes <52.82 ± 20.24 pg/rnl > showed an approximate
ten-fold increase from basal values.This rise was of
the same magnitude as seen in the intact control
animals following naloxone but basal levels in the PVN
lesioned rats were considerably lower (5 pg/ml
compared to 51.8 pg/ml in intact rats).
After naloxone injection the oxytocin response in
plasma samples from morphine treated rats was
significantly higher than that in samples from control
rats at t= 35,60 and 120 minutes (p < 0.001,p < 0.001
and p < 0.05 respectively).
Oxytocin levels in CSF from animals with a bilateral
lesion of the PVN are shown in Fig 4.2 (g).In contrast
to basal oxytocin levels found in plasma samples from
PVN lesioned rats,basal oxytocin levels in CSF from
these rats was much higher than those measured in the
CSF from intact rats.Following naloxone injection,the
morphine treated animals showed a rapid elevation in
oxytocin from 377.68 ± 65.40 pg/ml to 945.31 ± 426.67
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Fig 4.2(g)
Oxytocin in CSF of rats under urethane anaesthesia which
had undergone a bilateral ablation of the PVN 14 days
previously.Filled squares ri.c.v. morphine infused rats
(n=6),filled circles : i.c.v. vehicle infused rats (n=9)
* p<0.05,with respect to pre-naloxone values
(paired t-test)
t p<0.02, i.c.v. morphine treated rats with respect to i.c.v
vehicle treated rats at the same time point post-naloxone
(Wilcoxon)
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pg/ml at t =40 minutes and 1876.41 ± 710.89 pg/ml at
t=70 minutes.In the control group of animals basal
oxytocin was measured as 435.94 ± 53.25 pg/ml and was
not significantly changed following naloxone
injection.Levels remained close to basal oxytocin at
471.27 ± 48.04,436.11 ± 27.90 and 456.62 ± 39.18 pg/ml
at t= 40,70 and 120 minutes respec t i ve 1 y. Due to the
rather large errors in the morphine-infused group
following naloxone it was only at t=70 mins that
oxytocin in the morphine— treated group was greater
than pre-naloxone values and also greater than levels
in CSF sample from control animals.The magnitude of
increase in oxytocin secretion from the morphine-
treated PVN lesioned animals following naloxone
treatment was the same as that in morphine treated PVN
intact animals four-fold).
4.2.3 < i i) ADRENOCORTICOTROPIC HORMONE <ACTH>
The ACTH concentrations measured in plasma samples
from the two groups of PVN lesioned rats are shown in
Fig. 4.2 (h).Morphine-infused rats showed a
significantly higher level of basal plasma ACTH at
595.4 ± 67.2 pg/ml compared to control animals which
showed a basal ACTH content of 418.3 ± 89.1 pg/ml <p <
0.05,paired t-test).
Following naloxone,the morphine treated animals
appeared to show an elevation in plasma ACTH but this
was not significant,due to the large error arising
from individual variation.The morphine animals then
showed a steady decrease in ACTH In plasma until in
the last sample at t-120 at 377.4 ± 50.8 pg/ml the
level was significantly lower than the basal
concentration measured (p < 0.01,paired t-test).
In the vehicle-treated group there was a steady
decrease in measured ACTH in the plasma samples until
in the last sample , when, at 299.3 ± 51.3 it was
significantly decreased from the basal measured level
Cp <0.05,paired t-test).The morphine-treated animals
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Fig 4.2 (h)
Adrenocorticotrophic hormone (ACTH) in peripheral blood
plasma of rats under urethane anaesthesia which had under¬
gone a bilateral ablation of the PVN 14 days previously.
Filled squares : i.e.v. morphine infused rats (n=8);filled circles
i.c.v. vehicle infused rats (n=l 1)
* p<0.05,** p<0.01,with respect to pre-naloxone values
(paired t-test).
t p <0.05,tt P<0.02,i.c.v. morphine v. i.c.v. vehicle treated rats
at the same time points (Wilcoxon).
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showed a much higher concentration of ACTH in
peripheral plasma at t = 60 mins,30 minutes post-
naloxone injection <p < 0.02,Wilcoxon).
4.2.3 <iii) HISTOLOGICAL CONFORMATION OF LESIONS
Following histological examination of the frontal
sections through the hypothalamus of the PVN— lesioned
rats only the animals satisfying the following
criteria were included in the data ana 1ysis.Bi1atera1
ablation of the medial,lateral and posterior portions
of the PVN had to be complete. The supraoptic nuclei
were intact as were the fornical nuclei and the
circularis nuclei.The anterior commissural nuclei were
not routinely damaged in PVN ablation but were fully
ablated in 3/5 i.e.v. morphine infused rats and 3/7
i.c.v. vehicle infused rats from which a full
complement of CSF and plasma samples were obtained.
Illustrations of typical lesions are shown in Fig. 4.2
<i-k>.A lesion from a vehicle i.c.v. infused animal is
p i c t ur ed in Fig 4.2. (i), from an i.c.v. mor ph i ne
infused animal in Fig. 4.2 <j> and a lesion that was
deemed to be incomplete and hence rejected from the




In control rats,injection of 5mg/kg naloxone elicited
an increase in plasma oxytocin consistent with
antagonism of endogenous opioids which exert an
inhibitory action on oxytocin secretion from the
neural lobe.
Experiments described in Chapter 2 demonstrated that
electrical stimulation of the neural stalk (and hence
descending oxytocin axons from the hypothalamic
nuclei) elicited oxytocin secretion into plasma,an
effect which could be inhibited by the systemic
introduction of a x-opioid receptor agonist
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Legend for 4.2 Ci-k)
Illustrations of bilateral knife—cut ablation of the
paraventricular nucleus.The outlines of three lesions
identified in cresyl violet-stained frontal sections
are shown superimposed as hatched areas onto drawings
of serial forebrain sections (from K6nig,J.F.R. &
K1ippel,R.A.,1963) .The coordinate at the bottom left
of each section gives the distance in pm anterior to
the inter-aural line.
ACN : anterior commissural nucleus
F: f ornix
NC : nucleus circularis
PVN : paraventricular nucleus
V3 : third ventricle
<i) shows a lesion from the brain of a vehicle infused
rat
< j ) shows a lesion from the brain of a morphine
inf used ra t.
The plasma concentrations of oxytocin in the two rats
illustrated were,before and 5,30 and 90 minutes after
naloxone, for (i> <5,91,100 and 41 pg/ml and for (j )
<5,448,337 and 173 pg/ml.The values for CSF oxytocin
before,and 10 and 40 minutes after naloxone were (i)
401,358, and 451 pg/ml and for < j > 524,2634 and 1493
pg/ml
<k> shows a lesion that was deemed to be incomplete
with magnoce11ular neurone cell bodies clearly visible
where marked by open arrows <A5660,A5430>.
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U50, 488H.This inhibition could be fully reversed by
1.v. naloxone (Coombes & Russel1,1988).Thus,na1oxone
probably acts to antagonize endogenous opioid peptides
acting at x-receptors in the neural lobe.
In the morphine-treated rats,basal plasma oxytocin was
not significantly different from control animals
indicating the animals to be tolerant to
morphine,sinee acute morphine inhibits oxytocin
secretion in urethane-anaesthetized rats (Chapter
2, thi s thesis) . To 1erance involves restoration of
electrical activity of oxytocin neurones to normal and
a down regulation of p-opioid receptors in the
hypothalamus (Rayner,Robinson &
Russe11,1988;Sumner,Coombes,Pumford & Russe11, 1990) .
After naloxone administration the large increase in
plasma oxytocin is the result of a withdrawal-
excitation response of oxytocin neurones.The resulting
hypersecretion of oxytocin stems from increased
electrical activity arising in the oxytocin neurone
cell bodies and is amplified by reversal of endogenous
opioid tone at the neural lobe.
Oxytocin release into the CSF of control rats given
naloxone showed a gradual increase with time,an effect
not seen in the CSF samples from the time control rats
which received 0.9% saline i.v. rather than
na1oxone.These results suggest that in urethane
anaesthetized rats .oxytocin released centrally
gradually reaches the cisterna magna,from neurones
under endogenous opioid control.
In the morphine-treated rats the basal secretion of
oxytocin into CSF was no different from rats in the
control group-indicating that the centrally projecting
oxytocin neurones are subject to tolerance to infused
morphine.
After systemic naloxone,CSF oxytocin content was
increased although the time course for this increase
was much greater than the rise in oxytocin secretion
seen in plasma.However, it is known that the appearance
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and clearance of oxytocin is approximately ten times
slower in CSF than in peripheral plasma (Mens, Witter &
Van Wimersma-Greidnaus, 1983).
These results imply that centrally projecting oxytocin
neurones undergo a withdrawal-excitation response and
hypersecretion of oxytocin i.e. that they can be made
dependent on morphine after a chronic i.e. v. morphine
infusion.
Unlike the oxytocin neurones projecting from the
hypothalamic nuclei to neural lobe there is no
information as to whether this hypersecretion is due
to increased electrical activity at the cell bodies or
due to a change in excitability at the
termina1s.However,sinee morphine is a p-opioid
receptor agonist and naloxone is most potent at the p-
receptor it would appear that this opioid modification
of oxytocin secretion from these central oxytocin
neurones is mediated by the p-opioid receptor subtype.
High levels of oxytocin in the circulation could cross
the blood-brain barrier,possib1y by influencing its
permeabi1ity.The morphine infusion cannu1 a,chronic
morphine treatment or the action of na1oxone-induced
withdrawal may all disturb the integrity of the blood-
brain barrier (Ermishe, Rllhle et al, 1.985) . Physiological
plasma concentrations of oxytocin do not transfer
appreciable amounts into the CSF (Mens, Witter & Van
Wlmersma Greidanus,1983).
Further experiments to investigate this possibility by
measuring the transfer of -'H-oxytoc in into CSF are now
being done in morphine naive animals with an
artificially elevated plasma oxytocin concentration
acheived by intravenous infusion and morphine
dependent animals treated with naloxone.
4.3.1 Cii) AVP,ACTH & GH
Urethane anaesthesia was applied to all groups of rats
in this experiment and can be considered to be a
stressful stimulus as determined from the resulting
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increase in basal circulating ACTH following its
administration (Hamstra,Doray & Dunn, 1987) .
Growth hormone in the rat is also affected by urethane
anaesthesia,which interrupts its pulsatile secretory
pattern (C1ark,Car1sson et al, 1988) and a decrease in
secretion occurs during stress which is believed to
arise as a result of an increase in circulating
somatostatin (Arimura,Smith & Schally,1976).
Taking into account these effects on the secretion of
ACTH and GH it was clear that the effect of naloxone
was specific to increase oxytocin in peripheral
p1asma.
Basal levels of vasopressin in morphine—dependent and
morphine-naive animals were not significantly
different implying the system to be unaffected by
morphine infusion or tolerant to its effects.Fo11 owing
i.v. naloxone there was no significant change in AVP
secretion in either group indicating the secretion of
this hormone is not under endogenous opioid control
and that dependence does not develop for morphine.
Plasma ACTH in control rats was not affected by i.v.
naloxone.This result was not unexpected since CRF
released into hypotha1 amic-hypophysia 1 portal blood in
morphine naive animals remains unaltered following
naloxone administration (Sheward,Coombes et
al,1990>. In the morphine dependent rats basal plasma
ACTH was much greater than in the morphine naive
group.
Following naloxone there was no increase in ACTH which
was once again consistent with results that show there
is no increase in CRF secretion into hypothalamo—
hypophysial portal blood after naloxone in urethane
anaesthetized morphine dependent rats
(Sheward,Coombes,Bickne11,Fink & Russel1,1990).ACTH
levels gradually decreased throughout the sampling
protocol until they were of the same magnitude as the
control group of rats.
The combination of urethane anaesthesia (Walker, Perrin
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et al,1986) and na1oxone-induced morphine withdrawal
could be regarded as a stressful stimulus which would
keep ACTH levels elevated in the morphine-dependent
group but in the time contro 1 s, both the morphine-
dependent and morphine-naive rats had basal levels of
the same magnitude as the naloxone treated control
rats. In this group it was the morphine- naive rats
that had the higher plasma ACTH concentration prior to
saline injection.Repeated administration of morphine
may lead to inhibition of the release of excitatory
neurotransmitters for ACTH release (Yaksh,Jessell et
al , 1980) . Na 1 oxone may then lead to an overshoot in
excitatory neurotransmitter re 1ease.Evidence suggests
that neurotransmitters from primary afferent C fibres
are involved in inducing ACTH release during naloxone
induced morphine—withdrawa1 (Donnerer & Lambeck,1988>.
Basal plasma growth hormone secretion in the morphine-
dependent and the morphine-naive groups of rats was
not significantly different. Fo11 owing na1oxone, there
was no change in secretion in either group-imp1ying
that there is no endogenous opioid influence on GH
secretion (Gabriel,Simpkins &
Mi 11ard, 1985;Russe11,Antoni et al,1988>.
From the measurements of AVP,ACTH and GH it can be
concluded that any increase in oxytocin secretion
after naloxone induced morphine withdrawal results
from the change in excitability of the oxytocin
neurones and not from a generalized stressful stimulus
arising from the withdrawal . Since the secretory
profiles of these hormones are also sensitive to
stressful stimuli,the lack of effect of morphine
withdrawal on these hormones in urethane anaesthetized
rats cannot be considered 'stressful'.
4.3.2 PVN LESIONED RATS
In rats with a bilateral ablation of the PVN, plasma
oxytocin in morphine-dependent and morphine-naive rats
follwed the same pattern as the intact rats.An
-131—
increase in oxytocin secretion reflecting removal of
endogenous opioid tone was seen in the controls and a
much larger increase indicating withdrawal from
morphine dependence in the morphine infused group.
The actual concentrations of oxytocin in the plasma
samples in both groups of PVN lesioned rats is much
lower than in intact rats although the magnitude of
the increase in secretion following naloxone remains
the same.
Plasma oxytocin secretion was expected to be decreased
by ablation of the PVN since the contribution of PVN
oxytocin neurones projecting to the neural lobe and
hence secreting into peripheral plasma had been
removed.Oxytoe in neurones in the neural lobe arising
from the SON were undisturbed and reduced oxytocin
levels seen reflected their secretion and withdrawal
response.The results however,suggest that PVN
magnoce11u1ar neurones contribute to the withdrawal
hypersecretion of oxytocin into plasma.
Conversely , basal oxytocin levels in CSF in both
morphine dependent, and morphine naive groups with a
bilateral ablation of the PVN, were higher than in
intact rats.The increase in CSF oxytocin in the
morphine dependent group was almost the same as that
seen in intact rats although no change in oxytocin
secretion was seen in the morphine naive rats unlike
the slow increase detected in the intact group.
These results indicate that in normal rats,na1oxone
acts on oxytocin secreting PVN neurones which project
centrally releasing oxytocin into CSF and that this
effect is abolished by ablation of the PVN,which
unlike the SON contains a significant proportion of
centrally-projecting oxytocin neurones (Swanson &
Kuypers, 1980; Vich & Vich-Teichmaii, 1983) .
Since oxytocin secretion into the CSF continues in the
morphine dependent PVN lesioned rats following
naloxone, it could be concluded that. centrally
projecting oxytocin neurones are not confined to the
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PVN.
However, in these PVN- lesioned rats there may be a new
source of oxytocln.Following a knifecut bilateral
ablation of the PVM,reorganization of oxytocin fibres
occurs within the median eminence.After 2 weeks there
is a large increase in the amount of oxytocin that can
be released following stimulation of an in-vitro
preparation,a 1 though there is a decrease in the amount
of oxytocin released 1 week after ablation
(Antoni,Kovacs & Mazurek,1988).Magnocellular neurones
release oxytocin from their dendrites/axons in the
median eminence and some of these neurones have
centrally projecting processes from which release
could also take p1ace.Fo11owing PVN lesion there could
be reorganization of these processes to somehow
facilitate the release of oxytocin as demonstrated
(Antoni , Kovacs & Mazurek, 1998).
Anterior commissural oxytocin neurones have been shown
to express centrally projecting dendrites
(Armstrong, Warach et al,1980~), however, this nucleus was
destroyed in some of the lesioned rats and intact in
others without reflecting any difference in CSF
oxytocin content implying that these projections could
not account for the high levels of oxytocin seen.
Chronic morphine infusion has not been demonstrated to
enhance oxytocin content of magnoce11u1ar neurones
(Rayner,Robinson & Russel1,1988) although its
influence on non magnoce11u1ar components has not been
reported.The reduced plasma oxytocin levels in PVN
lesioned animals demonstrates that bilateral
destruction of the PVN suggests that there is not a
compensatory increase in activity of oxytocin SON
neurones.
The results of this study show that centrally
projecting oxytocin neurones like those projecting to
the neural lobe are subject to control from endogenous
opioids as demonstrated from the response of CSF
oxytocin in control animals to i.v. na1oxone.These
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infusion for 5 days but that they do not become
dependent upon the opiate as they do with
rnorphine. A 1 thought there is no na 1 oxone-induced
withdrawal seen,na1oxone still leads to an increase in
plasma oxytocin (as seen in the vehicle treated
animals) indicating that there is no cross tolerance
from U50,488H to the endogenous K-ligand.
Tolerance to i.e. v. infused U50,488H was inferred from
the lack of change in the parameters measured in these
and control animals i.e. weight, body temperature, water
consumption, plasma osmolal ity, [ Na"'] , t K"1"] and basal
plasma and CSF oxytocin content.Another explanation
could be that the infused U50.488H was ineffective due
to
a) excessive dilution from the sterile water in the
minipump in the modified i.e.v. infusion protocol (see
1.3).
b) degradation of the U50.488H during the infusion
period.
The latter point could be resolved in future by testing
the activity of the U50,488H remaining in the infusion
device in another experimental system (e.g. stalk-
s timulation preparation, 2. 1 (v). )
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CHAPTER FIVE
INVESTIGATION OF WHETHER OXYTOCIN NEURONES DEVELOP
TOLERANCE TO AND DEPENDENCE UPON A SELECTIVE KAPPA-
OPIOID RECEPTOR AGONIST U50.488H.
CHAPTER 5 : Investigation of whether oxytocin neurones
develop tolerance to and dependence upon a selective
kappa—opioid receptor agonist, U50,488H.
INTRODUCTION
The principal opioid-receptor subtype located at the
neural lobe of the rat is the kappa receptor. Thi s has
been demonstrated by in—vitro (Zhao.Chapman &
c
Bicknell, 1988), in—vivo (Coombes 8t Russell, 1988 and
Chapter 2,this thesis) and autoradiographic studies
(Herkenham,Rice et al,1986).
Oxytocin secretion from magnocellular nerve terminals
in the neural lobe of the rat can be modified by
intravenous <i.v.) administration of the kappa opioid
receptor agonist U50.488H (Coombes &
Russel1,1988).Since in these experiments oxytocin
secretion arose from stimulating the neural stalk,the
neural lobe was, in effect, isolated from the
hypothalamus and we could conclude that the inhibition
of oxytocin secretion was due to the action of the
kappa agonist at the neural lobe.The effect was fully
reversible by i.v. naloxone,a relatively non-selective
opioid-receptor antagonist indicating it to be opioid—
receptor mediated.
In-vitro,it has been shown that kappa opioid agonists
U50.488H and dynorphin A,_,3 inhibit oxytocin (and
vasopressin) secretion evoked by K*' induced
depolarization of isolated neurosecretory
termina1s.U50,488H will also inhibit electrically-
evoked release of oxytocin and vasopressin in the
intact neural lobe preparation (Zhao,Chapman &
Bicknell , 1988°) .
Oxytocin neurones can be made tolerant to and dependent
upon morphine following i.e.v. infusion of graded doses
of morphine for five days (see 1.3).Na1oxone induced
morphine withdrawal is characterized in the rat by an
increase in cell body firing rate, hypersecretion of
oxytocin into plasma and CSF and a sustained elevation
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of intraraammary pressure in the lactating rat
(Bicknel1,Leng et al, 1988; Coombes,Robinson &
Russel1,1988;Rayner,Robinson & Russel1,1988).
Tolerance and dependence are believed to be mediated
via p-opioid receptors in the hypothalamus at the level
of the cell bodies.
There are x-opioid receptors located in the rat SON as
well as at the posterior pituitary
(Mansour,Khatchaturian et al, 1988;Tempel & Zukin,1987>.
Dependence studies upon x-opioid agonists have been
carried out in the rat (Cowan, Zhu et al,1988>.
Following a 70 hour infusion of U50,488H into the
Sylvian aqueduct,rats were given 3mg/kg naloxone s.c.
and naloxone withdrawal (abstinence) scored.The dose of
U50,488H infused was 2.9pmo1 (^ 1.2mg/ml) at
lp1/hr.Rats treated with U50,488H showed negligible
withdrawal syndrome scores like the animals treated
with distilled water, the only condition to score being
hypothermia ) . Rats infused with U50.488H for 2 weeks
showed no signs of withdrawal when challenged with
3rng/kg naloxone (Tang & Co 11 ins, 1985> .
Tolerance has been demonstrated to the antinociceptive
and hypothermic effects of U50,488H,fo1 1 owi ng twice
daily i.p. injections but not to its diuretic response
(Bhargarva,Hemendra et al,1989).
In studies which investigated the advantages of x over
p-receptor mediated analgesia,the rat has been shown to
be a far from ideal model due to its low density of
supraspinal x-receptors compared to the guinea—pig
(MI 1lan, 1990).However,oxytoe in neurones have been shown
to be potently inhibited by K-receptor agonists both at
the cell bodies and at the level of the posterior
p i tuit ary.
The aim of this experiment was to see whether oxytocin
neurones could be made tolerant to and dependent upon
the x-opioid receptor,U50,488H acting via kappa-
receptors in the neural lobe and hypothalamus.
The rats were infused i.e.v. with U50,488H in the same
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way morphine was infused to cause tolerance and
dependence (see 1.3).To 1erance to the x- agonist was
determined from the effect of U50.488H i.e. v. infusion
on weight change,water consumption,body temperature and
p 1 asma [ Na"*'] , t K_l~ 1 , osmo 1 a 1 i ty and initial
oxytocin content of plasma and CSF,
Dependence of oxytocin neurones upon U50,488H was
tested by giving the rats i.v. naloxone (5mg/kg> to try
and precipitate a withdrawal response.Oxytoe in was
assayed for in plasma and CSF to see if the oxytocin
neurones projecting to the neural lobe and central
brain regions would respond with a hypersecretion of
oxytoein.
Tolerance to and dependence upon a kappa—opioid
receptor agonist by oxytocin neurones would imply
that, in the rat, secret ion of oxytocin can be modified
by an endogenous kappa opioid agonist.
5.1 METHODS
5.1.1 ANIMALS.
The animals used were virgin female Sprague-Dawley rats
(mean weight 262.53 ± 5.98 g) which were housed in
individual cages under controlled light and temperature
conditions described in 1.1.
Following implantation of an intracerebroventricu1ar
(i.c.v.) infusion device (day 0> until terminal blood
and cerebrospinal fluid (CSF) sampling (day 5), the
animals were weighed daily,had their core body (rectal)
temperature monitored and their daily water consumption
determined gravimetrically.
These parameters were monitored due to the results
obtained from previous studies which showed chronic
U50,488H treatment to cause hypothermic effects
(Bhargarva,Hemendra et al,1989) and the diuretic effect
seen upon acute administration of U50, 48811
(Leander,1983(a) & (b)).Chronic U50,488H resulting in a
diuresis would lead to disturbances °f water and
electrolyte metabolism and ultimately a loss in weight.
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5.1.2 SURGERY.
Five days prior to the terminal blood and CSF sampling
experiment, the rats were anaesthetized with ether and
fitted with an intracerebroventricular infusion cannula
driven by a subcutaneous osmotic minipump designed to
continuously infuse sterile pyrogen free water
("vehicle" for the control animals) or graded doses of
U50,488H at lpl/hr for five days into a lateral
cerebral ventric1e.The surgery was carried out as
described in 1.3 with the following modifications.The
length of the polythene cannula was increased from 18cm
to 32cm which,in the U50,488H treated animals was
filled with 40jj.1 10pg/p1,40p1 20pg/pl and 80pl 50pg/pl
U50.488H solution,each separated by lpl air.The
minipump was filled with vehicle to drive the system
thus reducing the total amount of U50.488H needed for
the infusion. In the control animals, the whole system
was filled with vehicle.
Five days after implantation of the infusion device,the
animals were anaesthetised with urethane <1.25g/kg
i.p.) and fitted with a tracheal cannula,a femoral
venous cannula and a femoral arterial cannula.The
animals were then placed in a simple headframe to
immobilize the head with the neck flexed and the
at 1 anto—occipita 1 membrane cannulated to collect
cerebrospinal fluid from the cisterna magna.Detai1s of
the surgery are given in 1.4.
5.1.3 TERMINAL BLOOD AND CSF SAMPLING PROTOCOL.
The sampling protocol is shown in Fig 5.1(a) and is the
same as that used in Chapter 4. Blood samples of 1ml
were withdrawn from the femoral artery,coo 1ed over
ice,centrifuged at 0°C and the resulting plasma removed
and frozen at -20°C until assayed for oxytocin.
The first plasma sample was divided into two
a 1 i quots, 200p 1 for Na'h',K"~ and osmolality measurements
and the residue for oxytocin radioimmunoassay.
To maintain plasma volume,the first sample was replaced
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Time (mlns) Samp1e No.
t = —70 Surgery completed
t = 0 CSF sample 1 <~50pl>
t = 5 Plasma sample 1 <lml>
t = 30 Naloxone <5mg/kg i.v.>
t = 35 Plasma sample 2 <1ml)
t = 40 CSF sample 2 <~50pl>
t = 60 Plasma sample 3 <lml>
t = 70 CSF sample 3 <~50pl>
t = 120 Plasma sample 4 <lml>
CSF sample 4 <~50pl)
Figure 5. 1<a)
Protocol for plasma and cerebrospinal fluid (CSF)
sampling in urethane anaesthetised female Sprague-
Dawley rats.The rats had either received an
i ntracerebroventricu1ar (i.e. v.) infusion of U50,488H
(n = 8> or vehicle (n = 7) for the previous five days.Blood
samples were taken from a femoral artery;p1asma from
sample 1 was used for osmolality , C K""l and [ Na""l
analysis,as well as oxytocin determination.Oxytocin
content of plasma aliqots and CSF samples was
determined by radioimmunoassay.
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with lrnl isotonic sterile saline via the femoral
vein,subsequent samples were replaced with resuspended
red blood cells made up to a volume of 1ml in isotonic
sterile saline.
CSF samples of =* 50jj.1 were collected into preweighed
polystyrene tubes,immediately cooled over ice and then
frozen at -20°C until assayed for oxytocin.
[Oxytocin radioimmunoassay of plasma and CSF samples
was carried out at N.I.M.R.,The R1dgeway,Mi 11
Hill,London with the help of Dr. Iain Robinson.]
At the end of the experiment,the animals were killed by
an overdose of barbiturate <0.6ml Sagatal) and the
infusion devices removed and examined to check that the
system remained patent and did not leak or become
blocked.The parietal bones of the skull were removed to
expose the brain surface in order to check that the
cannula entry position into the brain was correct and
thick sections cut with a scalpel blade to track the
path of the cannula tip to the lateral ventricle .
5.2 RESULTS
Statistical comparisons were made within groups using a
paired t-test and between group using an unpaired t-
test.
5.2.1 WEIGHT CHANGE
The initial mean weight of the rats at the beginning of
the experiment (Day 0) was 255.5 ± 10.2g (n=8,U50,488H
infused group) and 254.5 ± 5. 6g (n=9,vehicle infused
group).There was no significant difference between
these starting weights. The rats were weighed daily,at
the same time each day (9-10 a.m.),for the duration of
the 5 day i.e. v. infusion.The results are shown in
Fig. 5. 2 (a) as mean change in weight (± s.e.rn. ) f roin
the mean initial weight (± s.e.m.) of each group of
rats taken on Day 0. On Day 1 both groups of rats
experienced a loss in weight although there was no







Daily weight change in rats during a five day infusion
of vehicle (n=9,solid bars) or U50,488H (n=8,striped
bars).
Statistical significance:
* p<0.05 with respect to U50,488H treated group
(unpaired t-test)
** p<0.01 with respect to U50,488H treated group
(unpaired t-test).
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the vehicle infused animals gained weight with respect
to their initial weight on Day 0,whereas the U50,488H
infused group of animals did not gain weight and still
remained below their initial starting weight (p < 0.05
with respect to vehicle infused group,unpaired t—
test).On the subsequent days both groups of animals
increased their weight above that recorded on Day 0 but
there was no significant difference in weight change
between the two groups of animals on these days.
5.2.2 CORE BODY TEMPERATURE
Core body temperature was monitored daily in the two
groups of rats,the results are shown in Fig 5.2b
(i>.There was no significant change in temperature
recorded in either group over the 5 day infusion period
and no difference between the U50,488H infused and
vehicle infused groups of rats on any day.
5.2.3 WATER CONSUMPTION
Daily water consumption was measured in the two groups
of experimental animals during the 5 day infusion
period.The results are shown in Fig 5.2b Cii).There was
no significant change in daily water consumption over
the 5 day infusion period in either the U50,488H
treated or vehicle treated groups.Daily water
consumption between the two groups of rats was not
significantly different.
5.2.4 PLASMA OSMOLALITY, 1 Na~3 and I K~3
Osmo 1 a 1 i ty , 1 Na"" 3 and [ K "! were measured in plasma
aliquots obtained from the first (basal) blood sample
of each rat after induction of anaesthesia with
urethane.The results are shown in Fig 5.2
(c) . Osir.olal ity values were 280.6 ± 2.2 mOsrn/kg in the
vehicle infused rats and 280.6 ± 1.2 mOsm/kg in the
U50,488H infused rats. Plasma C Na+'l values were 137.2 ±







Graphs showing (i) core body temperature (°C) and (ii)
daily water consuption in two groups of animals during a
five day infusion of vehicle (solid bars,n=6) or U50,488H
(striped bars,n=7).Values shown are mean ± sem.There
was no significant difference between the two groups of
rats in either temperature or water consumption on any












Osmolality, [Na+] and {K+] measurements taken from the first
blood sample withdrawn from two groups of rats under urethane
anaesthesia.The animals had received an i.c.v. infusion of vehicle
(solid bars,n=9) or U50,488H (striped bars,n=8) for the previous
five days.There was no significant difference in any of the
parameters measured between the two groups of animals.
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mm/L in the U50.488H infused group. Plasma [ K 'Tl values
were 5.0 ± 0.5 mm/L in the vehicle treated rats and 4.8
± 0.5 mm/L in the U50,488H treated rats. There was no
significant difference between these results in either
treatment group of rats.
5.2.5 PLASMA OXYTOCIN
Mean plasma oxytocin values in both groups of animals
during the blood sampling protocol are shown in Fig
5. 2 <d>.
Basaloxytoe in levels were 35.5 ± 26.3 pg/ml in vehicle
infused animals and 39.4 ± 18.7 pg/ml in U50.488H
infused animals <n=7 in each group).The standard errors
are large due to a few animals in each group showing
high levels of oxytocin throughout the experiment but
there is no significant difference in basal oxytocin
levels between the two treatment groups.
Following i.v. naloxone at t=30mins plasma oxytocin was
elevated in both groups of rats <382.0 ± 195.7 pg/ml in
vehicle infused rats and 357.9 ± 120.6 pg/ml in
U50.488H infused rats).This elevation in plasma
oxytocin was significant with respect to pre-naloxone
values in the vehicle infused group <p< 0.03,paired t—
test) but not in the U50,488H infused group (this is
due to the large variation in plasma oxytocin values
for this group of animals and the resulting large
errors).There was no difference in response to naloxone
between the two groups.
Plasma oxytocin remained elevated in the following two
plasma samples in both groups of rats (413.6 ± 152.5
and 323.4 ± 168.9 pg/ml in vehicle treated rats and
387.2 ± 105.6 and 330.7 ± 107.4 pg/ml in U50.488H
infused rats).These values are significantly elevated
from pre-naloxone plasma oxytocin levels,(p=
0.008,vehic1e infused group,p<0.04,U50,488H infused
group, paired t — test.). There was no significant




Oxytocin measured in plasma of urethane-anaesthetized
rats which had received an i.c.v. infusion of U50,488H
(filled circles,n=7) or vehicle (open circles,n=7) for the
previous 5 days.Naloxone was given at t=30 mins.
Statistical comparisons :
* p< 0.03,** p< 0.02,*** p< 0.008,t p<0.04 with respect to
pre-naloxone values (paired t-test).There was no significant




Oxytocin measured in CSF of urethane-anaesthetized rats
which had received an i.c.v. infusion of U50,488H (filled
circles,n=7) or vehicle (open circles,n=7) for the previous
5 days Naloxone was given at t=30 mins.
Statistical comparisons:
* p< 0.05 with respect to pre- naloxone value (paired t-test)
No significant differences in CSF oxytocin between the
groups.
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groups of rats at any time point during the blood
sampling protocol.
5.2.6 CSF OXYTOCIN
Mean CSF oxytocin levels in both groups of animals are
shown in Fig 5.2(e) . Basal CSF oxytocin concentration
was 365.7 ± 19.9 pg/ml in vehicle infused rats and
410.9 ± 35.5 pg/ml in U50,488H infused rats.There was
no significant difference between these values.
Following i.v.naloxone injection at t=30 minutes there
was no change in CSF oxytocin in the vehicle treated
rats <365.7 ± 34.8 pg/ml) and a decrease in CSF
oxytocin in the U50.488H treated rats (337.4 t 12.8
pg/ml,p<0.05 with respect to pre-naloxone values,paired
t-test).
At t=70 minutes CSF oxytocin in the vehicle treated
group had risen to 423.3 ± 22.4 pg/ml and to 391.6 ±
27.9 pg/ml in the U50.488H treated group.These changes
in oxytocin were not significant and CSF oxytocin did
not significantly differ between the two groups of
experimental animals at any time.
5.3 DISCUSSION
Measurements of weight change,water consumption,body
temperature,hydrominera 1 balance and plasma oxytocin
failed to reveal any significant differences between
the U50,488H infused rats compared to the vehicle
treated groups.This can be interpreted in two ways,(i)
U50,488H infused for 5 days does not affect these
parameters or, (ii) the animals have become tolerant to
the effects of U50.488H.
Previous experiments have shown that acute
administration of U50,488H has profound diuretic
effects in rats (Leander,1983 <a & b)).This is believed
to be opioid-mediated and is dependent upon an intact
and functional adrenal raedulla,iraplicating a blood-
borne diuretic factor of adreno—medul1ary origin
(Borkowski , 1989 >.Although the animals were not
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housed in metabolism cages and hence their urinary
output accurately determined,there was no obvious sign
of a diuretic response to the U50.488H infusion and
measurement of plasma osmolality and electrolyte
balance showed that there was no disturbance to
hydromineral balance on Day 5.
The U50.488H infused group of rats maintained a weight
loss following surgery until Day 3,when their weight
was not significantly lower than the vehicle infused
group.Animals treated with vehicle (and animals infused
with morphine observed in other studies) show a weight
loss on Day 1 after surgery but by Day 2 have gained
weight to above their initial recorded mass on Day
O.This would indicate that the maintained weight loss
was an effect of the U50,488H,possib1y as a result of a
diuresis but that the animals became tolerant to the
U50,488H and that there was not a continued diuresis or
weight loss.
Plasma and CSF oxytocin concentration in the first
samples taken showed that there was no significant
difference in these basal values between the U50.488H
treated or vehicle treated animals.Inhibition of
oxytocin release from the isolated neurohypophysis and
isolated neurosecretory terminals has been effected by
x—opioid receptor agonists (Bicknel1,Chapman &
Zhao, 1987 (a & b>) . Acute injection of the x—opioid
receptor agonist bremazocine (O.lmg/kg s.c.) decreases
plasma oxytocin as the initial effect in a biphasic
response to the opiate (Grel1,Fjalland &
Christensen,1989).However,it is not possible to say
whether the similar plasma oxytocin levels in the two
groups of rats is due to lack of effect of U50,488H or
tolerance to the opiate.
Administration of naloxone <5rng/kg i.v.) did not
produce the hypersecretion of oxytocin into plasma and
CSF associated with morphine withdrawal (Chapter 4,this
thesis;Coombes,Robinson & Russe11,1988).This implies
that the oxytocin system does not become dependent upon
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K-opioid agonists as It does upon the p-opioid agonist
morphine.There was a significant elevation In plasma
oxytocin in both groups of rats following naloxone
injection but this was probably due to antagonism of
endogenous opioid tone acting at oxytocin nerve
terminals in the neural lobe.
Dependence of oxytocin upon morphine and subsequent
na1oxone-induced withdrawal is believed to be mediated
via p-opioid receptors. In this experiment,dependence
upon U50.488H following continuous infusion for 5 days
would be via x—opioid receptors.There are several
reasons why dependence was not established or
withdrawal from the opiate not seen.
<i> Morphine crosses the blood brain barrier relatively
easily and therefore finds the p—receptors within the
SON easily accessible from its site of infusion in the
lateral ventricle.It is possible that U50.488H does not
cross the blood brain barrier so easily and therefore
is not so easily distributed to central x-opioid
receptors. Prev ious studies where (J50.488H has been
infused into the Sylvian aqueduct have shown that the
drug is distributed successfully (Cowan,Zhu et al,1988)
and therefore this cannot account for the lack of
dependence of oxytocin neurones on U50.488H.
<ii) There is now evidence for at least three kinds of
x—opiate receptors,x,,x2 and x3 (Zukin,Eghba1i et
al,1988;C1ark,Liu et al,1989).The density of these
receptors is species specific and they bind different
x-opiate receptor agonists with differing affinity. It
is possible that the subtype of x—receptor within the
SON is different to that found at the neural lobe where
U50.488H has profound inhibitory effects (Coombes &
Russel1, 1988 >.U50,488H is f ound to inhibit
magnoce11u1ar oxytocin cell body firing rate in the
anaesthetized rat, (Leng, Pumford & Russel 1 , 1990) and it
is theref ore unlikely that the predominant type of x —
receptor found in the rat hypothalamus only binds
U50,488H with low affinity.
-150-
It has been shown that there is down-regulation of x —
receptors in the neural lobe as a result of increased
endogenous opioid release (Brady,Rothman &
Herkenham,1988).It is possible that exposure of central
x-opioid receptors to U50.488H over 5 days would also
lead to down regulation of receptors, whi ch is what is
seen to happen to p.—receptors in the SON during the
development of morphine tolerance (Sumner,Coomhes et
al,1990).Tolerance to U50.488H may,therefore,have
occurred
(iii) If down regulation is a sign of the development
of tolerance then a withdrawal excitation such as that
seen upon withdrawal from morphine is difficult to
exp1 ain.There may be changes in post-receptor
mechanisms regulating ion fluxes that account for the
withdrawal excitation seen in morphine dependent
oxytocin neurones challenged with naloxone.
Mu opioid receptors are coupled to a G protein CG., )
which has been demonstrated in the anaesthetized rat
pretreated with pertussis toxin to inactivate the G
protein by ADP-ribosy1 ation. In these animals, the
inhibitory action of morphine on oxytocin cell body
firing is significantly reduced (Russe11,Pumford &
Leng,1991>.
U50,488H does not work via a G protein since it is
still effective at inhibiting oxytocin cell body
activity in pertussis toxin treated rats.U50,488H is
known to decrease [Ca:J"hJ by blocking the voltage-
sensitive N-type calcium channel through a x—opioid
receptor mediated mechanism.This inhibits oxytocin
seeretion,since intracellular calcium is decreased thus
preventing the release of oxytocin from its synaptic
vesic1es . Fo11owing infusion of U50,48SH and possible
development of tolerance it may be that the post-
receptor mechanism leading to the reduction of C Ca2"1', ]
cannot be modified by naloxone and hence a withdrawal
excitation of oxytocin neurones is not seen.
In conclusion,it would appear that oxytocin neurones
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centrally projecting neurones can also be made
morphine dependent by i.e.v. infusion of morphine and
undergo withdrawal excitation following naloxone
in jec t ion.
In control animals with a bilateral PVN lesion there
was not a rise in CSF oxytocin following naloxone
suggesting that endogenous opioids do act on centrally
projecting neurones in the PVN. In morphine-dependent
animals following naloxone administration,
hypersecretion of oxytocin into CSF is seen in animals
with a bilateral ablation of the PVN and it must
therefore be concluded that it is not only oxytocin
neurone projections from the PVN that are responsible
for oxytocin seen in CSF,at least after PVN lesion.
The source and nature of the endogenous opioids
concerned with regulation of centrally projecting
oxytocin neurones and whether they act at the cell
bodies or nerve terminals is not yet known.
The elevated basal CSF oxytocin content observed in
PVN lesioned animals <Fig 4.2g> is similar to that
seen in the i.e.v. vehicle- and i.e.v. U50,488H-
infused animals in Chapter 5 <Fig 5.2e).No calculation
errors can be detected from the assay results. It is.
possible that during storage of the samples some
breakdown product was formed that cross-reacted with
the assay but this is unlikely since the
storage,transit and assay procedure was the same for
all CSF samples generated.The similarity between the




AUTORADIOGRAPHIC RECEPTOR BINDING STUDY TO DETERMINE
CHANGES IN OPIOID RECEPTOR SUBTYPE POPULATIONS IN
THE NEURAL LOBE OF THE RAT DURING THE DEVELOPMENT OF
MORPHINE TOLERANCE.
CHAPTER 6 : Autoradiographic receptor binding study to
determine changes in opioid receptor subtype
populations in the neural lobe of the rat during the
development of morphine tolerance .
INTRODUCTION
In the rat,both endogenous and exogenous opiates are
known to inhibit oxytocin secretion from nerve
terminals in the posterior pituitary (Bicknell &
Leng, 1982;Russel1,Gosden et al, 1989;Russel1 &
Spears,1984).Opiates acting on oxytocin neurones exert
their influence at the perikarya (within the supraoptic
(SON) and paraventricu 1 ar nuclei (PVN) of the
hypothalamus) and at the nerve terminals in the
posterior pituitary.
There are three principle opioid receptor
subtypes, identified pharmacologically by their binding
selectivity for opiate agonists and antagonists (Glllan
& Kosterlitz,1982).In-vitro receptor autoradiography
has been used to investigate the distribution of p. 5
and x receptors in the rat brain (Mansour, Lewis et
al, 1986; Mansour,Khachaturian et al,1987 & 1988;Tempel &
Zukin,1987).
In the SON, x but no p or 5 opi oi d-receptors were
found.Both morphine,a p-opioid receptor agonist and
U50,488H,a x-opioid receptor agonist have been shown to
inhibit the electrical activity of oxytocin neurones in
the SON (Leng, Pumford and Russel 1 , 1990) , so It is
puzzling that no p—receptors were located at this site.
In the posterior pituitary,x-opioid receptors were
found to predominate with a few p but no 5-receptors
present (Bunn,Hanley & Wilkin, 1985) .This correlates
well with experiments previously described which
demonstrated that in the anaesthetized rat,the x—opioid
receptor agonist U50.488H will inhibit oxytocin
secretion evoked by electrical stimulation of the
neurohypophysial stalk whilst morphine,a p-opioid
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receptor agonist is ineffective at this site (Coombes &
Russel1,1988;Chapter 2 this thesis).
Infusion of morphine into a lateral cerebral ventricle
of the rat for a period of 5 days, (as described in
1.3),results in oxytocin neurones becoming first
tolerant and then dependent upon the opiate.To 1erance
is described as lack of opiate effect or the need for a
greater dose to acheive the initial effects seen on
oxytocin neurones.Dependence is revealed upon
administration of the opiate antagonist naloxone which
results in excitation of oxytocin cell body activity
and hypersecretion of oxytocin into plasma and CSF
(Bicknell.Leng et al,1988;Rayner,Robinson &
Russell, 1988;Coombes,Robinson & Russe11, 1988>.
Chronic infusion of the x—opioid agonist,U50,488H
appears to result in tolerance to the opiate (as
determined by its lack of effect on basal plasma and
CSF oxytoe in,with respect to control animals) but there
was no naloxone induced withdrawal response in terms of
oxytocin neurone electrical activity or secretion into
plasma or CSF (Chapter 5,this thesis).
Tolerance to opiates could be explained by a decrease
in opioid receptors that modify oxytocin secretion. In
the hypothalamus,including the SON,there are p-opioid
receptors (as judged by the actions of selective
opioid-agonists on oxytocin neuronal activity) and it
is thought that tolerance and dependence are mediated
through p-receptors at the cell bodies of oxytocin
neurones and not at their terminals in the posterior
pituitary (Bicknell.Leng et al, 1988) .However,cross
tolerance between receptor subtypes has been described
in some systems (Yamamoto,Ohno &
Ueki , 1988;Bhargarva,Hemendra et a1,1989) and this
experiment was designed to look for changes in
specific opioid-receptor populations in the




The animals used were female Sprague-Dawley rats which
were caged individually under conditions of controlled
photoperiod (12hrs light/12hrs dark,lights on 8am) and
temperature <23°C) . Food and water were freely
avai1ab1e.
There were 6 rats in each experimental group and the
mean weight <± sem> of the groups were 274.8 ± 5.lg in
the morphine infused group and 288.8 ± 8.7g in the
vehicle infused group.
6.1 < i i > SURGERY
The animals were implanted with a subcutaneous osmotic
minipump and intracerebroventricular infusion cannula,
under ether anaesthesia,five days prior to the terminal
experiment.Ful1 details of this procedure are described
in 1.3.
Six animals were infused with vehicle and six with
morphine in graded doses of 10,20 and 50pg/pl at a rate
of Ipl/hr.The rats were set up in pairs i.e. one
morphine treated and one vehicle treated were set up on
the same day so that one animal from each treatment
group would be processed together.
6.1 CI 11) TERMINAL EXPERIMENT : TISSUE COLLECTION
After 5 days of morphine infusion the rats were
decapitated and trunk blood collected into heparinized
tubes.The blood was centrifuged at 0°C and divided into
aliquots for : -
a> Oxytocin determination : to see if morphine
tolerance was reflected by basal plasma oxytocin levels
CRIA as described in 1.7.3.
b> Osmolality and Na* : to determine whether chronic
morphine treatment effected any change in hydromineral
balance.Changes in Ma" or osmolarity may stimulate the
oxytocin/vasopressin system leading to changes in
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opioid receptors in the posterior pituitary as
described by Brady & Herkenham,1987.
c> Glucose content : to see if chronic morphine
treatment leads to any change in plasma glucose
concentration,using a Boehringer kit: Glucos GOD-
Perid.(Acute morphine is reported to elevate plasma
glucose,Gross & Pierce,1935).
The skull was opened and the brain quickly
removed.Coronal frozen cryostat sections including the
supraoptic nuclei (SON) and medial preoptic nucleus
(MPN) were taken to determine changes in opioid
receptor density in these regions during development of
morphine tolerance and dependence (Sumner, Coombes et
al,1990).
The whole pituitary was removed from its protective
meninges (see 3.1) and oriented for coronal sectioning
on a layer of frozen Tissue-Tek II OCT compound (Miles
Laboratory) on a chuck pre-cooled in solid C02.The
gland was completely covered with more OCT compound and
returned to the solid CO;;;, until thoroughly frozen. 10pm
pituitary sections were cut with a cryostat and thaw
mounted on to pre-cleaned and pre—coated
slides.(Cleaned in chromic acid,washed in running water
followed by double distilled water and coated with
chrome alum gelatine).
Four sections were taken for each incubation category
per rat,each containing a coronal section of neural
lobe surrounded by intermediate lobe and anterior lobe
tissue. The slides with sections were kept in a slide
tray, sealed in polythene bags and stored in a deep
freeze at. ~20°C for up to three weeks before incubation
with the appropriate 3H-ligand.
6. 1 (iv) INCUBATION MEDIA
The frozen sections of neural lobe were incubated with
3-H 1igands and displacers in order to identify and
allow quantification of the opioid subtypes present.The
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incubation medium used for these sections contained 2nM
3H-<-> bremazocine.Bremazocine is a kappa opioid
receptor ligand although it is not highly selective for
kappa receptor binding (Morris & Herz .1986).This was
preferred to using 3H-etorphine (which was used to
determine total opioid receptor binding in sections
containing the SON and MPN taken from the same
animals).3H etorphine was found to show negligible
labelling of pituitary sections. [Pi lot studies carried
out by B.E.H.SI.
Etorphine is a p-opioid receptor ligand although it is
regarded as being non-selective and has been used in
autoradiographic studies to locate x-opioid receptors
(Bunn,Hanley & Wi1kin, 1985;Lightman,Ninkovic et
al,1983).Since the predominant receptor subtype at the
neural lobe is kappa,bremazocine would be expected to
show greater binding at this site than etorphine, as
f ound.
To expose the specific opioid receptor
subtypes,un1abe11ed,high1y selective agonists were used
as competitive displacers.
i) p.—receptor displacer: DAGO (Tyr-D-Al a-Gl y-MePhe-
NHCCH^aOH.
ii> 5—receptor displacer: DPDPE [D—Pen2,D~Pens3
enkepha1 in.
iii) x—receptor displacer: U50,488H (trans-(±)-3,4-
dich1oro—N-methy1—N-(2-[ 1-pyrro1diny1eye 1ohexy11 >
benzene methane sulfonate.
To detect individual receptor subtypes two unlabel led
displacers were included with the 3H—1igand in the
medium so that only the third type of receptor would be
selectively located by the 3H~ligand.
2pM displacer (1000-fold excess) was used with 2nM 3H-
ligand.Pilot experiments (B.E.H.Sumner) showed that
displacer .in concentrations of up to 50pM did not
further reduce 3H—ligand binding.Naloxone ( a non¬
selective opioid antagonist) was used in the medium on
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Summary table to show the specific labelled 1igand and
unlabel led displacers included in the incubation media
for each receptor subtype iso 1 ated.Four sections of
neural lobe were cut in each incubation category.
control for total opioid receptor-specific: binding of
the probe.
Other control sections were incubated without 3H—ligand
in the incubating medium to act as chernography controls
- i.e. to check that the unlabel led sections did not
produce images on the emulsion.
The combination of drugs in each incubation medium type
is summarized in Table 6.1 (I).All solutions were made
up in double distilled water.
6.1 <v> INCUBATION PROCEDURE
The frozen sections were allowed to come to room
temperature over one hour.They first underwent pre¬
incubation to detach and wash out endogenous opioid or
exogenous opiate (arising from the morphine infusion)
from the tissue.The pre-incubation medium (0.015M
potassium phosphate buffer containing 0.15m NaCl + 0.1%
BSA.pH 7.4) was applied to the sections with a Gilson
pipette as a 20jj.1 puddle. Pre-incubation was for 30
minutes at 0°C and took place in moist chambers,p1astic
boxes lined with filter paper saturated with ice cold
pre-incubation medium.
After this, the puddles were drained off the slides and
replaced with 20pl incubating medium containing 3H-
1igand and displacers as appropriate.The slides were
incubated for 3hrs at 0°C in moist chambers. After this
time, the medium was drained off the slides which were
then loaded into slide racks.They were then immersed in
successive baths of ice cold pre-incubation medium to
remove excess unbound ligand displacer from the
tissue,for one minute per bath.Fina11y, the slides were
immersed in ice cold double distilled water to remove
salts.The si ides were propped vertically in drying
racks and allowed to dry in air at room
temperature, protected from dust by a canopy of paper
towels.The dried slides were stored in sealed boxes
with a gauze bag containing silica gel as a dessicant
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for a maximum of 24hrs at 0*C before autoradiographic
processing.
6.1 <vi) AUTORADIOGRAPHIC EXPOSURE
The slides from a pair of rats (one vehicle infused and
one morphine infused) were allowed to come to room
temperature slowly before opening the boxes,to avoid
condensation forming. In a dark room under safe light
conditions,the slides were apposed to Hyperfilm—3H
(Amersham),keeping slides from the same incubation
category of the two rats together.A 5pM tritiated
standard (3H-microscales,Amersham) was also attached to
each sheet of film for norma 1ization purposes in grain
density analysis. The slides were secured to the sheets
of film with strips of adhesive masking tape.The sheets
of film were then sandwiched between two mirror tiles
held together with adhesive tape to maintain a good
even contact between slides and film,wrapped in brown
paper followed by aluminium foil and finally sealed in
opaque plastic bags.The films were exposed at 0-4°C in
a cold room for 16 weeks.
6.1 (vii) HYPERFILM PROCESSING
The following procedures were all carried out in the
dark under safe light conditions.The sealed packages
containing Hyperfilm and slides were allowed to come to
room temperature.the packages were then unsealed and
the slides removed from the Hyperfilm by slitting
through the adhesive tape.The slides were loaded into
labelled slide boxes for the sections to be stained
later and the film marked by cutting notches in the
corner to denote the orientation in which the slides
had been exposed and which pair of rats it corresponded
t o.
The film was immersed,emulsion side uppermost,in
developer (Kodak D.19 developer) for five minutes. The
film was then rinsed quickly in tap water and immersed
in a tray of fixer,emulsion side upwards for five
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minutes (Ilford Hypam rapid fixer,diluted 1:4 with tap
water). The film was transferred to a second tray of
fixer for five minutes and then washed in the sink
under running tap water for 30 minutes and finally hung
up to dry.When dry,the film was labelled with the slide
serial numbers so that the images could be
identified;fi1ms were stored in polythene bags to
prevent scratching.
6.1 Cviii) STAINING
The pituitary sections were fixed for 10 minutes in a
1:17:2 mixture by volume of acetic acid:absolute
alcohol: formalin.Following this they were
dehydrated,rehydrated,stained for 15 minutes in 1 %
cresyl fast violet,differentiated,dehydrated,c1 eared
and mounted in DPX for neuroanatomica1 analysis
<Pax1nos & Watson, 1982).
6.2 IMAGE ANALYSIS
The sheets of film were cut into microscope slide sized
strips and attached to microscope slides with adhesive
tape for analysis.The autoradiographic images were
assessed in two ways:-
6.2 <i> SUBJECTIVE QUALITATIVE ASSESSMENT
The autoradiographs were examined under a binocular
microscope (Wild M3),magnification x!6 and the grain
density assessed in the following way 0 (none),+
(weak),++ (moderate),+++ (moderately strong) and ++++
(strong).
6.2 <iI) QUANTITATIVE ASSESSMENT
The neurohypophysis boundary was scratched on the film
with a needle under the microscope so that the area was
clearly defined for analysis at high
magnification.Analysing apparatus consisted of a Joyce-
Loebi pMagiscan image analysing computer that received
its input from a Phillips black and white video 4QTV
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camera mounted on a Vickers M17 microscope
(Sumner.Kawata & Russel 1, 1989) . Magn i f i c a t. i on in the
microscope was xlO (objective) with a further xl.6
(intermediate lens),whilst on the TV monitor the scale
factor was 1.1878pm per pixel.
A counting frame equivalent to 201.63pm x 133.04pm was
placed over images on the TV monitor of both central
and peripheral regions of the neurohypophysis for grain
density measurements, since more opioid receptors have
been reported in the external rim of the
neurohypophysis (Herkenham,Rice et al,1986;Brady &
Herkenham, 1987).The "grey level" threshold which
defined silver grains could be altered for each
individual image so that only silver grains were
detected by the computer.The grain density was
calculated thus:
Total area of sliver deposit
Total area of counting frame
(Sumner et al,1989>.
6.3 RESULTS
6.3 <i) EXPRESSION OF RESULTS
For each grain density measurement (T) , a backgrounci
measurement <BT> was subtracted.The background
measurement was taken close to the tissue area counted
but in a tissue free area. For each tissue incubation
category,activity above background was determined by
<T—BT>.The mean (T—BT) value for each incubation
category was calculated - as tissue from morphine and
vehicle treated rats was processed in pairs,these
values were compared by the paired t-test.
For conversion to absolute values,grain densities were
measured in triplicate for each step of the standard
scale exposed on each sheet of film and the background
values subtracted -A mean standard curve of grain
density against radioactivity in terms of its brain-
gray matter-tissue equivalent (calibrated by Geary &
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Wooten for Amersham) was computed for the SON arid MPN
analysis <9 weeks exposure) and for analysis of the
posterior pituitary <16 weeks exposure).These were then
fitted to a power function -
y=0. 34x° ■ 1 "l and r=0.96 for posterior pituitary standard
c urve.
Tissue radioactivity values <nCi/mg of tissue) were
then calculated from the mean grain densities and were
converted to frnol of 3H—ligand bound per mg of tissue
by reference to the specific activity of the 3H-
1igand.Specific binding to opioid receptors was
obtained by subtracting binding in the presence of
na1oxone.Comparisons between morphine and vehicle
treated groups mean sH-ligand binding values were made
using the Student t-test.
6.3 <ii) QUALITATIVE RESULTS
Autoradiographic images were obtained from the
posterior pituitary but not from the anterior lobes.The
subjective assessment results are shown in Table 6.3
<I) .
6.3 <i i i> QUANTITATIVE RESULTS
There was no significant difference between the mean
grain density or mean binding of central or peripheral
regions of the posterior pituitary.Centra 1 and
peripheral data,therefore,have been combined and the
mean values used.The mean grain densities and mean
specific binding values for each incubation category
in both groups of rats are shown in Tables 6.3 < 11) anc!
6.3 <III> respectively.
The autoradiographic images obtained from the
B.fc, BM, B«and the B,M incubation categories along with the
corr espond i rig CFV stained tissue section are shown in
Plate 6.
6.3 < i i i > BLOOD PLASMA ANALYSIS
The blood plasma analysis results are shown in Table
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Incubation category and code Assessment
[ 3H1 (-)-Bremazocine alone (B> ++ +
I ^Hl(—>—Bremazocine + DAGO +++
+ DPDPE (B^ >
[ 3H1(-)-Bremazoclne + DPDPE ++
+ U50.488H <BM>
[3H3<->-Bremazocine + U50,488H O-+
+ DAGO <B5 >
I ^Hl <—)—Bremazoc ine + naloxone CB^,) O
Chemography controls No image
Table 6.3 <I>
Subjective assessment results for the posterior
pituitary for each incubation category.There was no
difference in autoradiographic image intensity between
morphine treated and control animals.
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Incubation Category Mean Binding
pnf2 silver deposi t/pm2 field
Vehicle Morphine
13H](-)-Bremazocine 0.18 ± 0.04 0.19 ± 0.05
I 3,H1 < —> —Brernazoc ine 0.13 ± 0.05 O. 15 ± 0.03
+ DAGO + DPDPE
[3H1(-)-Bremazocine 0.11 ± 0.05 O.10 ± 0.03
+ DPDPE + U50.488H
Table 6.3 (II)
Table of mean ( ± sern) binding results obtained for the
B,B„ and BM incubation categories in rat neural lobe
tissue. <Bft images were not significantly above
background>.The specificity control values have been
subtracted from these results.There were no significant
differences between morphine treated and control
animals (n = 6 animals per group).




f DAGO f DPDPE
[3}|] <—)-Bremazoc ine
+ DPDPE + U50, 48811





1 .07 ± O . 73
Table 6.3 (III)
Table of mean binding results obtained for the B,B« and
B,, incubation categories in rat neural lobe, expressed
as fmol/mg tissue.Bs images were not significantly
above background.There was no significant difference
in binding between morphine treated or morphine naive








(a> shows a 1 Op.m section of rat pituitary incubated
with [3H] (-)-bremazocine, apposed to Hyperfilm-SH for 16
weeks, then fixed in acetic ac i d-ethano 1 -forrna 1 in and
stained with Cresyl Fast Violet. Cb> is the
autoradiographic image of Ca) , showing total binding to
opioid receptors.On 1y the posterior pituitary produces
an image. <c> & (d) show autoradiographic images
selective for x. and p-receptors respectively Cby virtue
of the displacers in the incubating media), (e) shows
non-specific binding of probe in the posterior
p i tu i t ar y. Magn i f i cat i on ><8 throughout.
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Treatment Group
Vehicle Infused Morphine 1nfused
<n=6) Cn=6)
Plasma oxytocin 13.23 ± 5.06 8.67 ± 1.77
<pg/ml>
Plasma glucose 7.82 ± 0.43 7.31 ± O.24
CmM/1)
Plasma [ Na-3 138.29 ± 2.23 142.71 ± 1.41
CmM/1)
Osmolality 270.00 ± 5.63 268.29 ± 5.99
(mOsmo1/kg)
Table 6.3 CIV)
Table to show the mean (± s.e.m.) values of data
obtained from blood plasma ana 1ysis.There was no
significant difference in values between the morphine
naive and morphine tolerant rats.
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6.3 CIV).There were no significant differences between
morphine treated and control animals for any of the
parameters measured.
6.4 DISCUSSION
In the control group of rats,highest levels of binding
to opioid receptors was seen after incubating the
posterior pituitary sections with C 3H1 (-) bremazocine
alone,which was expected to bind to all types of opioid
receptor present in the tissue.Strong binding was also
seen in the tissue sections incubated with C'3H1 (-)
bremazocine with DAGO and DPDPE included in the
incubation medium which was intended to isolate kappa-
opioid receptor binding.(DAGO which has a relatively
high affinity for ^-receptors and DPDPE which has a
relatively high affinity for 5—receptors were in 1000-
fold excess-1eaving predominantly x-receptors available
for binding) (Brady & Herkenham,1987;Bunn,Haniey &
Wi lk in, .1985; Herkenham, Rice et a 1,1986).
Addition of U50,488H to the medium containing DAGO or
DPDPE significantly decreased grain density or specific
binding values indicating that the x-opioid receptor
predominates in rat neural lobe.This correlates well
with other autoradiographica1,in—vitro and previously
described in—vivo (see Chapter 2) studies,whose results
indicate that it is principally x-receptors that are
found in the neural lobe (Bunn, Hanley &
Wi lkin, 1985;Herkenham,Rice,Jacobson &
Rothman,1986;Zhao,Chapman & Bicknel1988;Coombes &
Russe11,1988).
The resolution of the autoradiographic method in this
study was not sufficient to determine whether the
receptors visualised were located on oxytocin nerve
terminals or on surrounding pi tuicytes,Other studies
have suggsted that x-opioid receptors in the
neurohyphophysis may be located on pituicytes
<L i gh tman, N i rikov i c et al,1983) or neurosecretosomes .
There appeared to be some significant binding of
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bremazocine when U50.488H and DPDPE were included in
the incubation medium.These conditions should have been
selective for p-opioid receptor binding. In pilot
studies (8.E.H.Sumner) on the posterior pituitary using
tritiated etorphine as a probe,much less binding under
conditions selective for isolating p—opioid receptors
was seen.These results are therefore ambiguous as to
the presence of p-receptors on the neural lobe.The
density of this p-type binding was not altered in
chronic morphine-treated rats.
Although x-opioid receptor binding was measured in
central and peripheral regions of the neural lobe for
each incubation category.no differences were found in
binding between these regions.
It has been reported that x-receptors are densest in
the external rim of the posterior pituitary where
oxytocin nerve terminals predominate
<Herkenham,Rice,Jacobson & Rothman,1986).No significant
difference in binding between morphine treated rats and
vehicle treated rats was detected in any incubation
category.
In—vitro experiments have shown that endogenous opioids
still inhibit oxytocin secretion from isolated neural
lobe preparations taken from i.e.v. morphine infused
rats (Bicknel1,Chapman, Leng &
Russel1,1985).Thus,chronic morphine treatment resulting
In tolerance to and dependence upon morphine neither
affects the number of available kappa receptors in the
posterior pituitary nor induces cross tolerance to the
endogeous ligand,which may be dynorphin,co-produced in
and co—secreted from vasopressin neurones.
In—vivo experiments described in Chapter 2 demonstrate
that chronic morphine treatment confers no cross-
tolerance to the inhibitory action of U50.4-88H on
electrically stimulated oxytocin secretion but instead
leads to increased sensitivity to the kappa-opioid
receptor agonist; the mechanism of this is not
c1 ear.Binding affinity was not measured in the present
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study.
The x-receptor population in the rat posterior
pituitary does display plasticity under certain
conditions,for example during dehydration,when the
osmotic stimulus leads to a decrease in x-receptor
numbers,a 1 though not' to a change in receptor affinity
(Brady & Herkenham, 1987).Therefore the system has the
capacity for receptor number plasticity during some
circumstances.
Measurements on plasma glucose, [Na""] and osmolality
showed that there was no significant difference in
these parameters between morphine naive and morphine
treated anima1s,demonstrating that there were no
osmoreceptor mechanisms acting to alter opioid receptor
density in the posterior pituitary.
So,morphine tolerance and dependence in the oxytocin
system are not associated with detectable changes in
opioid number in the posterior pi tui tary. The. situation
is different for the cell bodies of oxytocin
neurones.In a parallel study to the present one,brain
sections f rom the same rats were used to study opioid
receptor changes in the SON and median preoptic nucleus
(MPN),which is part of the region anterior and ventral
to the third ventricle CAV3V region) that projects t.o
the supraoptic nuclei and might contribute to tolerance
of the oxytocin system.These data have been published
(Sumner,Coombes et al,1990> and are discussed here.
For the SON,brain sections were incubated with 3H-
etorphine (for non-selective binding to all opioid-
receptor subtypes) and etorphine with displacers DPDPE
and U50.488H for (ji-receptor isolation. Kappa receptors
were detected using C r:H! (-) bremazoc ine as probe with
DAGO and DPDPE as displacers since pilot studies had
shown that this displayed stronger binding than did
etorphine. MPN sections were incubated with etorphine
alone for total opioid receptor binding.
In the control group of vehicle-infused rats, C 3H1 (-.)
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etorphine binding in the SON was found under conditions
selective for p—receptor binding i.e. when DPDPE and
U50.488H were added to the incubation medium.Patches of
intense binding under these conditions were also
located in the caudate putamen which has been
documented to contain p-opioid receptors (Tempel &
Zukin,1987).
During chronic morphine treatment,p-opioid receptor
binding in the SON was reduced by over 80%, a
significant change with respect to control
animals.Morphine is known to be a selective p—opioid
agonist which has been shown to have a profound
inhibitory effect on oxytocin neurone firing when
applied in the vicinity of the cell bodies
(Wakerley,Noble & Clarke,1983) and tolerance to this
action with respect to morphine but not U50.488H has
been shown in chronic morphine-treated rats
(Leng,Pumford & Russel1,1990).This decrease in receptor
number may,at least in part,explain morphine tolerance
of oxytocin neurones (Bicknel1,Leng et
a1, 1988;Rayner,Robinson & Russel1, 1988).
Binding to opioid receptors under conditions selective
for x-opioid receptor binding - <i.e. with C3H1 (-)
bremazocine as a probe and DPDPE and DAGO included in
the incubating medium to exclude pi and 5-receptor
binding) - was also detected in the SON and to a small
extent in the caudate putamen.This binding was
decreased to a very low level by addition of U50, 483H
to the incubating medium,indicating it to be mediated
via x-receptors.The presence of x-receptors in the SON
has been demonstrated by autoradiography and
electrophysiological studies (Mansour.Khachaturian et
al, 1987; Russel1,Pumford & Leng, 1989).Chronic morphine
exposure did not affect x—selective C3HI C — > bremazocine
binding in the SON,consistent with the sensitivity of
firing-rate of oxytocin neurones in such rats
(Leng,Pumford & Russel1, 1990) .
A significant reduction in C3H](-) etorphine binding
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was detected in the MPN following i.e.v. morphine
infusion although this is only an indication of change
in total number of receptors and not the opioid
receptor subtype responsible since only total opioid
receptor binding was measured.However, th i s could
represent a decrease in opioid receptor number in an
input pathway which contributes to oxytocin neurone
regulation (Russel1,Blackburn & Leng,1988).
It is possible that morphine from the i.e.v.
i nfusion,bound to p-opioid receptors in the
SON,competed with [3H 3 etorphine binding and hence
reduced the binding seen in this incubation category.
Another possibility is that morphine infusion alters
endogenous opioid peptide secretion in the SON,thus
preventing opioid receptor binding.
Hopefu11y,the preincubation procedure emp1oyed,with 5'
guany1y1imidodiphosphate included in the medium would
have encouraged dissociation of any receptor—bound
opiates and allowed binding of the labelled ligancl
(Bunn,Hanley & Wilkin, 1985> .
A reduction in ^-receptors may allow normal
functioning of SON oxytocin neurones (i.e.tolerance)
which is indicated by the similar values for plasma
oxytocin in both morphine naive and morphine treated
rats.Partial loss of ^-receptors from the available
pool will ultimately decrease the number of receptors
binding morphine at any given concentration and thus
decrease the efficacy of morphine.This partial loss of
p-oploid receptors may explain the phenomenon of
tolerance to morphine in the oxytocin system of the
fema1e rat.
Conversely , the lack of change in x—receptor numbers in
the SON or posterior pituitary is consistent with the
lack of tolerance to the x—opioid receptor
agonist,U50,488H in morphine tolerant rats,both with
respect to electrical activity of the ceil bodies
(Leng,Pumf ord & Russell, 1990) and to actions in the
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INVESTIGATION OF THE EFFECTS OF
INTRACEREBROVENTRICULAR PERTUSSIS TOXIN ON OPIATE
MEDIATED MODULATION OF OXYTOCIN SECRETION.
Chapter 7 : Investigation of the effects of
intracerebroventricular pertussis toxin on opiate
mediated modulation of oxytocin secretion.
INTRODUCTION
Experiments described in previous chapters have
identified that in the rat,opiate receptors are
involved in the regulation of oxytocin secretion from
neurosecretory terminals located in the neural
lobe.Manipulation of oxytocin release both in vivo
(Coombes & Russel1,1988) and in vitro
(Bicknel1,Chapman & Leng,1985) by the use of selective
opioid receptor subtype agonists and antagonists
implies that their binding to opiate receptors alters
the activity of oxytocin neurones by opening or
closing ionic membrane channels.The signal
transduction system from binding of an effector
molecule to opening an ion channel is not yet fully
described.
THE SECRETORY EVENT.
During a depolarizing action potentia 1,ca1ciurn enters
the oxytocin nerve terminals,leading to an increase
in [CaS:H".Ll and acting as a primary signal for
exocytosis of oxytocin from the terminals
(Bicknel1,1988).
Studies using a suspension of isolated
neurohypophyseal terminals (neurosecretosomes) loaded
with the fluorescent Ca2"'" indicator, fura-2, show that
the rise in terminal CCa2*t1 induced by electrical
stimulation is enhanced by a phasic pattern of
stimulation (Brethes,Dayanithi et a 1 , 1987).During
conditions of high oxytocin secretion,at parturition
and lactation oxytocin neurones are seen to fire in a
synchronized bursting pattern (Lincoln &
Wakerley, 1971;Lincoln & Wakerley, 1974; Summer lee, 1981).
-174-
Isolated oxytocin nerve terminals from the rat show an
increase in [Ca2+J during depolarization induced by
elevation of extrace 11u11ar potassium ion
concen tra tion.
Kappa opioid receptors which are found on oxytocin
nerve terminals inhibit
oxytocin secretion.Ac11 vation of these receptors
by 1igand binding does not affect basal intracellular
calcium ion concentration but reduces the peak influx
of calcium ions into the cell during depolarization
(Bicknel1f1988;Zhao,Chapman and Bicknel1,1988?
The x—opioid receptor agonist U50,488H is found to
decrease the entry of Ca2'" into rat cortical
synaptosomes by inhibition of N but not L type calcium
channels (Xiang,Adamson et al,1990).
OPIOID RECEPTORS
The three main opioid receptor subtypes can be viewed
as initiators in a physiological signal transduction
mechanism within the neuronal cell membrane and
cytoplasm. In some cell culture systems and discrete
brain areas opioid receptors have been linked with
negative coupling to adenylate cyclase but it is often
difficult to quantify a second messenger response.
In common with muscarinic and adrenergic receptor
subtypes,opioid receptors are associated with the
specific guanine nucleotide binding protein G,: 1/0)
which accomplishes the first stage of signal
transduction through hydrolysis of GTP
Haynes,1988).
In the general model that has been proposed, ligands
which interact with G(.L/.....) proteins can be negatively
coupled to adenylate cyclase (vs. G(ra> which
stimulates adenylate cyc1ase). A 1 though a decrease in
intracellular cAMP may account for some of the
physiological effects associated with opioid receptor
binding some other mechanisms may contribute to the
physiological responses seen via adeylate cyclase
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independent mechanisms, Ionic conductances,particularly
K""~ and Ca2"" have been shown in some neurones to play
an important role in cell depolarization and may do so
in oxytocin neuronal activity.
So, how do G proteins couple opioid receptor binding
to ionic channels ?
G—PROTEINS
GTP binding proteins are heterotrimers consisting of
an a-subunit and a g'y-d imer. There is conflicting
evidence as to which subunit plays an active role in
signal transduction flLutz Birnbaumer,1987).
Initial experiments carried out on embryonic chick
atrial cells showed that coupling of acetylcholine
<ACh> binding to muscarinic receptors resulted in an
increased potassium conductance from the atrial cells
and hence slowing of pacemaker activity and that this
required intracellular GTP.Changes in cAMP and cGMP
were found not to affect the potassium channel or its
response to muscarinic agonists and hence imply that
cyclic nucleotide second messengers are not involved.
Pretreatment of GTP binding proteins with islet
activating protein (IAP) from the bacterium Bordetel1 a
Pertussis leads to ADP-ribosy1 ation of two GTP binding
proteins and prevents the coupling of ACh binding to
ionic channel activation <Pfaf f inger, Mart in et
al, 1985 >.
Following this finding,attempts were made to determine
whether it was the a or the By subunits which
activated ion channels. The effects of purified G(.±/.z,>
subunits from bovine cerebral cortex on muscarinic K"'
channels in chick embryonic atrial cells was examined.
The By-subunit was found to cause activation of single
K"1" channels whilst the a-subunit did
not.Additionally,a-subunits added in excess to the By
fraction inhibited inactivation by the By dimer.This
suggests that dissociation of the aBy trimer is
necessary for G-protein activation.
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Magnesium ions are necessary for activation and
dissociation of the G protein through binding and
hydrolysis of GTP but is not required for
activation of the K'" channel.
The role of the a-subunit was not discounted, it was
noted that in this system its action could not be
demonstrated (Logothetis,Kurachi et al,1987>. The a—
subunit of the GTP binding protein Gb,; has been found
to open K"" channels in mammalian atrial myocytes
(Codina,Yatani et al,1987)
Somatostatin is found to reduce the voltage dependent
Ca;:;:"" current IC„K and intracellular free Ca2+ in cells
cultured from a pituitary cell 1ine.Treatment of cells
with pertussis toxin supressed the ability of G:ii/..... to
couple inhibitory receptors to adenylate cyclase and
abolished the effect of somatostatin on calcium influx
and intracellular calcium concentration.
However,intracellular application of cAMP did not
alter the inhibitory effects of somatostatin implying
that the GTP-binding protein is directly involved in
the cAMP-independent receptor-mediated inhibition of
voltage dependent Ca:::"" channels (Lewis, Weight &
Luini,1986;Koch & Schonbrunn,1988>
The active form of guanine nucleotide binding proteins
is with GTP bound to the protein.Inactivation occurs
by the slow hydrolysis of GTP to GDP which is mediated
by the GTP-ase activity of the G protein itself.It is
accepted that low Km GTP-ase stimulation is a post
receptor event mechanism resulting from binding of the
effector mo1 ecu1e.U50 , 488H, a kappa opioid receptor
agonist was found to stimulate low Km GTP-ase activity
which was antagonized by MR2266 <a q/x antagonist) but
not by naloxone <a q-an t agon i s t) at 100 times the
concentration of MR2266.DAG0 (a q-agonist) was found
to stimulate low Km GTP-ase activity in a sodium
dependent and fully naloxone reversible manner.Sodium
is necessary for high-affinity agonist binding to the
receptor (Ueda, Misawa et al,1987).
-177-
It has been accepted that enhancement of low Km GTP-
ase activity is followed by the automatic termination
of signal transduction and hence opioid—receptor
agonists would manifest an inhibitory response.The
type of response following this,which ultimately leads
to an inhibitory effect on the neurone has yet to be
elucidated (Ueda,Misawa et al, 1987)
However,the key feature is the nature of the G-protein
involved.GTP-ase stimulation indicates that the
receptor-G-protein interaction is in progress,which in
the case of opioid receptors will lead to inhibition
of cell events.For other G-proteins,for example G(m>
binding of an agonist leads to stimulation of cell
mechanisms by the stimulation of adenylate cyclase
(Sternweis & Pang,1990).By treating rats with i.e.v.
pertussis toxin it was hoped to inactivate brain
G<1/0)-proteins by ADP-ribosy1 ation including those
coupled to opioid-receptors.Fo11owing this we
intended,to test the effectiveness of morphine on
1)basal oxytocin secretion and 2) on the stimulation
of oxytocin secretion by hypertonic saline
(Shibuki,Leng & Way, 1988;Landgraf,Neumann &
Schwarzberg,1989).In this way it was intended to
demonstrate a role of G,:i/C,> in signal transduction
from the p-opioid receptor subtype to oxytocin
secretion.
The evidence cited has demonstrated G<:,proteins to
be involved in the regulation of ion currents in that
they can open K"~ channe 1 s, mod i f y IC(1> and hence alter
[ Ca2 '" j. 1 .
These factors are all part of the neurosecretory event
and it is possible that the actions of endogenous
opioids on oxytocin neurone cell bodies and/or nerve
terminals may involve G(i/O)_protein mediated
mechanisms.
7. 1 EXPERIMENT 1 : Effects of pertussis toxin given
at a low or high dose 24hrs prior to terminal
experiment.
7.1.1. METHOD
7. 1. 1 <i> Animals
Virgin female rats housed under conditions described
in 1. 1 were used.Three groups of experimental animals
were set up:-contro1s, 1ow dose pertussis toxin treated
and high dose pertussis toxin treated rats.
The rats were housed individually in metabolism cages
for the duration of the experimental period.
The water bottle and food hopper were easily removed
for daily weighing and hence measurement of food and
water consumption.The rats were also weighed daily to
monitor any weight changes.
The base of the cage comprised a wire mesh so that
urine and faecal matter fell into a collecting
funnel.The outlets of this funnel were arranged so
that urine and faeces fell into separate
bott1es.Faeces were discarded but the urine was
collected under a layer of liquid paraffin to prevent
evaporation , the volume was measured gravimetrica11y
and a sample of approximately 2mls withdrawn for
Na"1", K"" and osmolarity analysis.
Weighing and volume measurements were carried out at
the same time each day (8.50—10.50 a.m.)
The day the rats were placed in the metabolism cages
was designated day —3. Measurements were taken on days
—2,— 1 and 0,administration of toxin taking place on
day O.The rats were kept in metabolism cages for 24hrs
after the toxin administration and measurements taken
on day +1.
7.1.1 <i1) Surgery
On day 0,the animals were anaesthetized with ether and
the head immobilized in a stereotactic frame. A
midline skin incision exposed the skull surface and a
hole drilled with a dental burr 1.6mm lateral and
0.6mm posterior to the skull sutures at bregma.The
skull was levelled between lambda and bregma by
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adjustment of the height of the incisor bar so that
the hole drilled through the skull and the track of
the drug delivery needle would be vertical.A 21 gauge
needle attached to a 25pl through the needle Hamilton
syringe was lowered vertically by a micromanipulator
attached to the stereotactic frame to a depth of 4.5mm
below the skull thickness via the drilled hole.
Vehicle (isotonic sterile sal ine, 5j.il) or pertussis
toxin (0. 7p.g/5p. 1 or 7pg/5pl) was injected slowly into
the lateral ventric1e. After closing the skin incision
with sutures,the animals were immediately returned to
their metabolism cages - the whole surgical procedure
lasted 10—15 minutes.
7.1.1 (iii> Terminal experiment (blood sampling)
Blood sampling took place 24hrs after the pertussis
toxin or vehicle injections (day +1).
On the morning following i.e.v. injection the rats
were anaesthetized by intraperitoneal injection of
urethane (25% solution w/v, 1.25mg/kg).Each animal was
fitted with a femoral arterial and femoral venous
cannula for blood sampling into heparinized syringes
and drug injection.The animals were left for 2hrs
before sampling started,the sampling protocol being
that shown in Fig. 7.1. (a).
Blood samples 1 and 9 were 0.6ml, the plasma being
divided into two a 1 i quots,200p1 for oxytocin
radioimmunoassay and the rest for sodium analysis.The
rest of the samples (2-8) were 0.3ml, the plasma used
for oxytocin determination only.Blood samples were
'withdrawn from the femoral ar ter y; samp 1 e 1 being
replaced with an equivalent volume of isotonic saline
into the femoral vein.Subsequent samples were replaced
with resuspended red blood cells made up to a volume
of 0.3ml in isotonic sa1ine,P1asma aliquots were
immediately cooled over ice and then stored at -20°C
un til assayed.
Morphine sulphate or naloxone hydrochloride was
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Plasma sample 1 t= O mlns
Plasma sample 2 t—10 mlns
Morphine <500pg/kg,lmg/ml l.v.> t=15 mlns
Plasma sample 3 t=20 mlns
Plasma sample 4 t=30 mlns
Naloxone <50pg/kg,O.lmg/ml i.v.) t=34 mlns
Plasma sample 5 t=40 mlns
Plasma sample 6 t=50 mlns
Plasma sample 7 t=60 mlns
Hyperosmotic stimulus t=60 mlns
<1.5M NaCl, 4ml/kg>
Plasma sample 8 t=80 mlns
Plasma sample 9 t=90 mlns
Fig 7.1. <a>
Summarized protocol of the blood sampling and drug
administration procedure for rats treated 24hrs
previously with i.e.v. pertussis toxin <0.7pg/5pl and
7pg/5pl saline) or control rats treated with 5pl
sterile sa 1 ine. Samp 1 es 1 and 9 were divided into two
aliquots for oxytocin assay and sodium content
analysis,all other samples were assayed for oxytocin
on 1 y .
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injected via the femoral vein
(0.5mg/kg;lrag/ml),Naloxone was given a) to antagonize
any effects of morphine and b) to test for inhibitory
endogenous opioid action acting on oxytocin neurones.
After blood sample 7 was taken,all the animals
received a hyperosmotic stimulus by means of an
intraperitoneal injection of hypertonic saline
<4ml/kg,1.5M NaCl);to compare the responsiveness of
the oxytocin system in the three treatment groups.
Radioimmunoassay of oxytocin in the plasma samples
were carried out by Mr.C.Chapman at A.F.R.C.Institute
of Animal Physiology and genetics Research,Babraham.
Plasma osmolality measurements were carried out by
Mr.B.McGrory , Dept. of Physiology,University of
Edinburgh Medical School.
Once the blood sampling schedule was completed, the
animals were killed by injection of 0.6ml Sagatal
(60mg/ml> and the brains removed so that the position
of the needle track to the lateral ventricle where the
toxin or vehicle had been injected could be confirmed
by dissection (see Fig 7.1 <b)> .
7.1.2 RESULTS
7. 1.2. <i> Rat Body Weight
The body weight data obtained is shown in Fig 7. 1
(c).The mean initial weights (± sem) of the treatment
groups of rats were 219.63 ± 7.23g (controls),225.81 ±
3.48g (low dose pertussis toxin) and 225.11 ± 5.10g
(high dose pertussis toxin).There was no significant
difference in the initial weight of the rats between
gr oups.
All three groups gained weight up until day 0 when
they underwent surgery for i.e.v. injection of toxin
or vehicle.On day +1 both toxin treated groups lost
weight but only those receiving 7pg/5pl dose showed a
significant decrease with respect to the previous days
weight and the mean weight of the other two groups
(p<0.05 with respect to weight on day 0, paired t —
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Fig. 7.1 (b)
Coronal section of the brain at 600|im posterior to the intersection
of skull sutures at bregma,the area confined between the two
parallel lines demarkates the acceptable area for needle tracks to
the lateral ventricle.
[ CC corpus callosum;DF dorsal fornix;LV lateral ventricle;
F fornix;BNST bed nucleurs of the stria terminalis;MPO medial




^ Day of experiment
i.c.v. injection of 0.7|i.g/5pJ or





^ Day of experiment
i.c.v. injection of 0.7pg/5|il
or 7pg/5|i.l pertussis toxin
or 5p.l isotonic saline
Fig. 7.1 (d)
Histograms representing the daily weight change (7.1c)
and food consumption (7. Id) in three groups of rats
(n=6 rats per group).Solid bars represent control animals,
striped bars 0.7|ig/5|il pertussis toxin treated and
hatched bars 7|ig/5|il pertussis toxin treated.
Statistical comparisons:
* p<0.05,** p<0.02,paired t-test with respect to previous
days weight/food consumed.
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test;p<0.05 with respect to weight of control group on
day +1,unpaired t-test).
7.1.2. <ii> Food and water consumption.
Food and water consumption data are shown in Figs.
7.1. <d> and 7.1 <e> respective1y.There were no
significant differences in food or water consumption
until day +1 (24hrs post surgery) . On this day food
intake was decreased,compared to day 0 in the low dose
toxin treated group (p<0.05,paired t-test) and in the
high dose toxin treated group (p<0.02,paired t—
test);water consumption was also significantly lower
in the high dose toxin treated group p<0.05,pal red t —
test).
7.1.2.(ill) Urine output.
There was no significant change in urine output in any
of the three experimental groups over the four days of
sampling (Kruskal-Wal1 is) .
Changes in urine electrolyte balance are shown in
Figures. 7.1 <f),7.1 <g).
Urine osmo 1 a 1 i ty, Fig. 7.1<f) in the high dose
pertussis toxin treated group was significantly
decreased 24hrs post toxin injection <p<0.0015,pal red
t—test).Urine sodium content was not significantly
changed but there was a significant decrease in urine
[ K + l on day 1 <24hrs post i.e.v. toxin injection)
p<0.001,paired t-test (Figure 7.1 <g>).
Urine osmolality in the low dose pertussis toxin
treated group and control group was not significantly
changed during the experimental period (paired t-
test).Individua11y,neither sodium nor potassium
content of urine samples was changed in either group
before or after i.e.v. injection (paired t-test).
7.1.2.(iv) Plasma oxytocin.
Graphs representing plasma








^ Day of experiment
i.c.v. pertussis toxin
0.7pg/5pl or 7pg/5|il
or 5|il isotonic saiine
Fig. 7.1 (e)
Histogram representing daily water consumption in three
experimental groups of animals,controls:solid bars,0.7|ig/
5|il pertussis toxin: striped bars, 7p,g/5|il pertussis toxin:
hatched bars (n=6 rats per group).
Statistical comparisons:
*












Histograms depicting urine osmolality (7.1(f) and urine [K+] in
three groups of experimental rats.Solid barsrcontrols,striped bars:
0.7pg/5|il pertussis toxin,hatched bars 7(ig/5jal pertussis toxin.
(n=6 rats per group).
Statistical comparisons:
* p<0.015,** p<0.001,paired t-test, with respect to previous days
value.
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7.1. (h—j > .
Basal oxytocin levels were not significantly different
in the toxin treated groups 20.85 ± 3.52 pg/ml (low
dose),27. 48 ± 7.46 pg/ml (high dose) compared to the
controls (17.95 ± 2.81 pg/ml).
Plasma oxytocin concentration in the control
group, Fig. 7.1(h), remained unchanged from basal
values after injection of morphine (500jjig/kg i.v.) and
there was no statistically significant elevation of
plasma oxytocin after naloxone injection (500jj.g/kg
i .v.),a 1 though this was expected from several previous
experiments (Chapters 3, 4, and 5) , and is likely to be
due to large variation in this experiment.
After the hyperosmotic stimulus of an intraperitoneal
injection of 1.5M NaC1 plasma oxytocin was elevated to
217.38 ± 84.44 pg/ml 20 minutes after the stimulus in
sample 8 (p<0.05,paired t—test) compared to basal
oxytocin secretion (17.95 ± 2.81 pg/ml). A1though
oxytocin levels continued to rise in sample 9,30
minutes after the stimulus ,the large error makes this
non-significant (paired t-test).
In the low dose pertussis toxin treated group of
rats, Figure 7. l<i>, there was no change in plasma
oxytocin after morphine administration but a
significant elevation of oxytocin was measured in
sample 6 (62.61 ± 12.24 pg/ml) and 7 (56.85 ± 11.21
pg/ml),16 and 26 minutes after intraveous injection of
naloxone repectively compared to basal measurements of
plasma oxytocin (20.85 ± 3.52pg/ml) (p< 0.01 and
p=0.01,paired t-test). In sample 6 this elevation was
also significant with respect to oxytocin measured in
the previous sample (p<0.05>0.01,paired t—test).
A hyperosmotic stimulus led to elevation of plasma
oxytocin in sample 8 (236.37 ± 65.85 pg/ml),20 minutes
after i.p. injection of 1 . 5M NaCl (p=0.01 paired t —
test).This rise was also significant with respect to
oxytocin levels measured in the previous sample




Plasma oxytocin (pg/ml) in serial samples withdrawn from the
femoral artery of rats given 5|al isotonic saline i.c.v. 24hrs
previously .The values shown are mean ± sem.
Statistical comparisons:





Plasma oxytocin (pg.ml) in serial samples withdrawn from the
femoral artery of rats given 0.7p.g/5p.l pertussis toxin i.c.v.
24hrs previously.Values shown are mean ± sem.
Statistical comparisons:
* p<0.01,paired t-test with respect to basal values
f p<0.05>0.01,paired t-test with respect to sample 5




Plasma oxytocin (pg/ml) in serial samples withdrawn from the
femoral artery of rats given 7|ig/5|il pertussis toxin i.e.v. 24hrs
previously.Values shown are mean ± sem.
Statistical comparisons:
* p<0.05>0.01,f p=0.05, paired t-test with respect to basal values
** p=0.05,tt P< 0.05,paired t-test with respect to sample 7
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rise in oxytocin measured in sample 9,30 minutes after
the hyperosmotic stimulus but due to the large
variation of responses within the experimental group
and hence the large standard error this was not
statistically signi f i cant. P1 asma C Nameasured in
samples 1 and 9 showed an increase in [ Na""'l indicative
of a successful hypertonic stimulus (ca.5-lOmm/L>.
Plasma oxytocin in the high dose pertussis toxin
treated group of rats appeared to be decreased after
i.v. injection of morphine and this was found to be
statistically significant when comparing samples 3
<24. 76 ± 5.09 pg/ml) and 4 <20.98 ± 4.14 pg/ml>, 10 and
20 minutes after morphine administration respectively
to basal values <27.48 ± 7.46
pg/ml>, <p<0.05>0.01,paired t-test).After naloxone
injection there appeared to be an elevation of
oxytocin levels measured but this could not be
demonstrated significantly.
After the hyperosmotic stimulus an elevation of plasma
oxytocin was measured which was of similar magnitude
to that seen in the control group of animals. With
respect to the basal value <27.48 ± 7.46 pg/ml) the
increase was significant in both samples 8 <187.84
±63.68 pg/ml> and 9 <322.14 ± 114.63 pg/ml) ,20 and 30
minutes post osmotic stimulus respectively <p=0.05 and
p=0.02,paired t-test).The rise in oxytocin was also
significant when compared to the pre-st irnulus levels
recorded in sample 7 <p<0.05,paired t-test).
Changes in oxytocin in plasma samples 3 and 4 (post
morphine injection),5,6, and 7 (post naloxone
injection) and samples 8 and 9 in response to the
hyperosmotic stimulus were compared between the
control and low dose pertussis toxin group,contro 1 and
high dose pertussis toxin group and between the two
pertussis toxin treated groups.No significant
difference in the measured oxytocin responses was
detected at any stage of the experiment between any of
the groups (Kruska1-Wa11 is) .
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7.2. Experiment 2 : The effects of pertussis toxin
given at a high dose 72hrs before experiment.
7.2.1 METHOD
7.2.1 ( i > Anima1s
The rats used were of the same sex and strain as in
experiment 1.They were housed under the same
conditions and had free access to food and tap
water.There were two experimental groups,contro1s
<i.c.v. saline) and pertussis toxin treated (i.e.v.
0.7pg/5pl saline),n=12 rats per group.
The rats were housed in individual cages (not
metabolism cages) for the duration of this experiment
but were weighed daily and had their water bottles
weighed to determine water consumption
gravimetrica11y.The experiment was carried out over 8
days - 4 days prior to surgery,day 0 when the animals
underwent i.e.v. injection of saline or toxin and
72hrs post-surgery (day 1-3).
7.2.1 <ii) Surgery
The surgical procedure was the same as described in
experiment l.Only one dose of pertussis toxin was
administered 0.7p.g/5pl saline plus an equal number of
saline control animals .The rats were returned to
their cages and weighed and monitored for 72hrs.
7.2.1 (ill) Terminal experiment (blood sampling)
72hr post—surgery the rats were anaesthetized with
urethane as before and fitted with femoral arterial
and venous cannulae.The protocol was changed in this
experiment so that morphine and the hyperosmotic
stimulus were administered concommitant1y at t=10 rnins
to study the effects of morphine on a stimulated,high
secretion rate of oxytocin rather than on a basal
seeretion.The amended protocol is summarized in Fig.
7.2 (a).
Blood samples 1 and 7 were 0.6ml and the plasma
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Plasma sample 1 t=0 mlns
Plasma sample 2 t=10 mlns
Hyperosmotic stimulus t=10 mins
<1.5M NaCl,4ml/kg> +
morphine 500p.g/kg (lmg/ml)
or 0.5ml/kg O. 97. NaCl i.v.
Plasma sample 3 t=20 mins
Plasma sample 4 t=30 mins
Plasma sample 5 t=40 mins
Naloxone 5mg/kg <10mg/ml) t=44 mins
Plasma sample 6 t=50 mins
Plasma sample 7 t=60 mins
Fig. 7.2 (a>
Summarized protocol of blood sampling schedule
followed in experiment 2.Blood volumes withdrawn were
the same as in experiment 1. Oxytocin content was
detected by radioimmunoassay.
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obtained divided into two aliquots for oxytocin
radioimmunoassay and measurement of sodium content.All
other samples were 0.3ml and were for oxytocin
radioimmunoassay only.Blood volume was maintained by
reinfusing resuspended red cells in an appropriate
volume of isotonic sterile saline except the first
sample which was replaced by 0.6ml isotonic saline.At
the end of the protocol as in experiment 1,the
position of the needle track made when delivering
i.c.v. injections was checked by dissection.
7.2.2 RESULTS
7.2.2 <i> Rat Body Weight
Daily body weights are shown in Fig 7.2 (b) . The mean
initial weight of the control animals was 253.6 ± 4.5g
and the pertussis toxin treated group 249.9 ± 8.2g
(n.s.,paired t—test).
In the control group bodyweight increased daily
throughout the experiment so that by day 0 it was
significantly elevated above initial bodyweight
<p=0.006,paired t test).In the pertussis toxin group
body weight increased daily until day 1, the first day
after pertussis toxin i.c.v. admin i strat. i on. On day 0
bodyweight was significantly above initial starting
weight <p<0.01,paired t—test) but on day 1 it
decreased from 255.4 ± 7. 6g to 239.2 ± 6. 3g
<p<0.0001,paired t—test).On days 2 and 3 the rats
gained weight as before and weighed 258.5 ± 5. 3g
compared to 266.0 ± 4. 8g in the control group on day
3.
There was no significant difference between the daily
mean weights of the two groups of animals except on
day 1,the day after surgery when only the toxin
treated group lost weight <p=0.02,unpaired t test.
7.2.2 (ii) Water consumption.
Water consumption was also measured daily,the results









Histograms depicting rat bodyweight (7.2b) and water consumption
(7.2c) in two groups of rats (n=12 per group).Control animals are
shown by solid bars and pertussis toxin treated animals (0.7|ig/5pl
i.c.v.) by the striped bars.
Statistical comparisons:
* p<0.005,** p<0.001,*** p<0.0001,paired t-test with respect to
previous days values.
f p=0.02,tt p<0.005,unpaired t-test,with respect to control group.
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daily water consumption did not change
significantly.In the pertussis toxin group water
consumption decreased between day — 2 and -1
<p<0.005,paired t—test) when it fell from 32.0 ±
1.7mls to 26.2 ± 1.Orals and between day 0 and day 1
<p<0.001 , paired t-test) when it fell from 27.3 ±
1.6mls to 16.4 ± 2.9rnls.
The second decrease in water intake corresponded to
that in the initial 24hrs after pertussis toxin
administration.Water consumption subsequently returned
to pre— toxin administration values on days 2 and
3.There was only a significant difference in water
intake between the two groups on day 1 after surgery
(p<0.005,unpaired t-test).
7.2.2 <iii> Plasma oxytocin.
The plasma profiles of oxytocin in control animals and
pertussis toxin treated animals are shown in Fig. 7.2
<d) . & (e)
Mean basal oxytocin in the plasma of control animals
was 8.93 ± 1.80 pg/ml and in the pertussis toxin
treated group 12.34 ± 2.82 pg/ml (n.s.unpaired t—
test).
At t=10 minutes both groups of animals received an
intraperitoneal injection of 1 . 5M NaCl (4mls/kg) to
provide a hyperosmotic stimulus. [Na""] determination in
plasma samples 1 and 7 showed a change in [ Na""l (ca 5 —
lOmrn/L) sufficient to indicate a successful
hyperosmotic stimulus.Immediate1y after this,half the
animals in each group (0=6) were given i.v. morphine
(500pg/kg) ,the other half an i.v. injection of
isotonic saline (0.5ml/kg).
In the control rats (i.e.v. NaCl) treated with saline
(i.v. ) , p1asma oxytocin rose slightly from 8.93 ± 1.80
to 24.52 ± 8.24 pg/ml (sample 4,t=30 mins) but this
rise was not significant with respect to basal values
(paired t-test).
In the i.v. morphine injected control animals plasma
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saline treated rats (n=6)
or isotonic saline 0.5ml/kg
Fig 7.2 (d)
300 t O - saline treated rats (n=6)






Hypertonic NaCl (1.5M) i.p.
4ml/kg + morphine 500jig/kg
or isotonic NaCl 0.5ml/kg
Fig 7.2 (e)
Plasma oxytocin in two groups of rats (n=12 per group),treated with
0.7|ig/5[il i.c.v pertussis toxin (7.2 d) or 5|il i.c.v. isotonic NaCl (7.2 e)
72hrs previously.Six animals in each group were given either isotonic
NaCl or morphine i.v. with hypertonic NaCl i.p. at t=10 mins.All
animals received naloxone at t=44 mins.
Statistical comparisons:
t p<0.05,tt p<0.02,ttt p=0.009,paired t-test with respect to pre-
naloxone values.
*p <0.05,** p< 0.01,paired t-test with respect to pre-naloxone values.
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oxytocin remained almost constant with respect to
basal values (8.93 ± 1.81 pg/ml),rising to 13.72 ±
5.95 pg/ml in sample 5 <t=40 minutes).
There was no significant difference in response to the
hyperosmotic stimulus In terms of oxytocin secretion
between the i.e.v. vehicle treated rats subsequently
injected with morphine or isotonic saline i.v.
(unpaired t-test).
In the pertussis toxin treated groups, the i.v.saline
injected animals showed a smal1,non-significant
elevation of plasma oxytocin to 16.05 ± 4.39 pg/ml
from basal values (12.34 ± 2.82 pg/ml).
The morphine injected i.e.v. pertussis toxin treated
animals followed almost exactly the same trend
resulting in a non-significant rise in plasma oxytocin
to 16.43 ± 3.38 pg/ml from basal values of 12.34 ±
2.82 pg/ml at sample 5.
There was no difference in the response to a
hyperosmotic stimulus between the two pertussis toxin
treated groups.
At t=44 minutes all animals in the experiment were
given an i.v. injection of naloxone.
In the i.v. saline treated control animals plasma
oxytocin was elevated following naloxone.Samples 6
and 7 showed oxytocin concentrations of 82.27 ± 17.74
pg/ml and 92.82 ± 19.17 pg/ml, which were found to be
significant with respect to the pre—naloxone value of
24.52 ± 8.24 pg/ml (p < 0.05,paired t-test).
In the morphine treated control animals, a large
elevation in plasma oxytocin was seen following
injection of the opioid antagonist. Samp 1es 6 and 7
taken 6 and 16 minutes after naloxone showed a
significant rise with respect to pre-naloxone values
of 13.72 ± 5.95 pg/ml to 123.35 ± 48.6 pg/ml and
172.75 ± 66.02 pg/rnl (p = 0.009 and p = 0.01, paired t —
test ) .
There was no significant difference between the
response to naloxone in the i.v. morphine and saline
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treated control groups (unpaired t-test),
In the i.c.v. pertussis toxin treated group,the i.v.
saline injected animals showed the greater response to
naloxone in terms of oxytocin secretion.There was an
immediate rise in sample 6 from 16.05 ± 4.39 pg/ml to
216.25 ± 78.4 pg/ml falling to 127.40 ± 34.19 in
sample 7.These values were significantly elevated with
respect to pre—naloxone levels (p < 0.05,p <
0.02,paired t-test).
Morphine injected animals showed an initially
lesser response,an elevation from 16.43 ± 3.38 to
62.02 ± 11.67 pg/ml in sample 6 but this steadily
increased to 163.63 ± 37.51 pg/ml in sample 7.Both
these values were significantly higher than pre-
naloxone oxytocin levels (p < 0.02,p = 0.009,paired t-
test).
Once again there was no significant difference in
oxytocin secreted as a response to naloxone between
morphine and saline treated pertussis toxin animals.
Overall there was no difference between pertussis
toxin treated or saline treated animals in magnitude
of the oxytocin secretory response to a hyperosmotic




In tr ac erebroven tricular (i.c.v.) injection of
pertussis toxin caused a significant weight loss in
the group of rats treated with the highest dose of
toxin (7pg/5p1).These animals decreased both their
food and water consumption significantly in the 24hrs
following toxin administration compared to the vehicle
trated control animals.The animals in this group
looked unwell from their external appearance following
surgery-tending to sit in a hunched position with
their fur standing on end rather than exploring their
cages like the rats in the other two treatment
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groups.Urine output volume was not significantly
changed in any of the three treatment groups but in
the high dose pertussis toxin treated group,urine
electrolyte balance was disrupted with urine [ KJ"1
falling significantly in the 24hrs post injection.This
effect is probably as a result of the decreased food
intake seen in this group of rats.
Intravenous morphine sulphate has been shown to
decrease basal oxytocin (Chapter 3) and silence
continuously firing putative oxytocin neurones
recorded in the supraoptic nucleus (SON)
(P i ttman,Hatton & Bloom, 1980;Waker1ey,Noble &
Clarke,1983).Morphine binding to hypothalamic p-opioid
receptors may lead to alteration of potassium and
calcium ionic conductances to favour the unresponsive
state of oxytocin neurones,inhibiting cell body
electrical activity and firing rate and decreasing
oxytocin neurosecretion.Pretreatment of the rats with
pertussis toxin was expected to inactivate the G(i.^.-.,)
proteins involved in ionic conductance regulation and
hence negate the inhibiting effect of morphine.
The results obtained from this experiment are
inconclusive since it was in the control and low dose
pertussis toxin experimental groups that morphine
injection was ineffective and the high dose toxin
treated group where morphine effectively lowered basal
plasma oxytocin.The controls behaved unexpectedly as
morphine was expected to lower basal plasma oxytocin
(see chapter 3).
The opioid receptor antagonist naloxone is most
potent at the p—opioid receptor subtype.However.it
also antagonizes,at the dose used here,x-opioid
inhibition of oxytocin secretion at the level of the
posterior pituitary,in i.v. morphine treated rats it
would thus have dual actions.If morphine inhibition of
oxytocin secretion is interrupted by the action of
pertussis toxin on the receptor G ( w.....)
proteins,then,na1oxone binding which would normally
-201-
elevate plasma oxytocin and restore putative cell body
firing ,may also act through modification of ion
fluxes via G protein action.
In this experiment there was no statistically
significant difference in response to naloxone between
the three treatment groups due to the large standard
errors from individual variations in response.Both the
high and the low dose pertussis toxin treated groups
displayed a significant elevation in basal oxytoxin
following naloxone injection implying that the
integrity of the G<.i.y,z>') proteins is not required for
naloxone mediated action endogenous opioid inhibition
of oxytocin secretion or,as the response to morphine
implies that the pertussis toxin had not affected G
protein interactions.
There are several reasons that could account for the
lack of results.
i> The dose of pertussis toxin may have been
insufficient for inactivation of central G (iy)
proteins.
ii) The time delay of 24hrs before the terminal
experiment may have been insufficient for inactivation
of central G<;P. ,,,..,) proteins.
iii> The i.e.v. route of administration of the toxin
into a lateral cerebral ventricle may have only given
poor access to sensitive sites modifying oxytocin
secretion.
iv) The G(:lprotein may not be involved in
morphine actions on oxytocin neurones.
Administration of an intraperitoneal injection of
hypertonic saline increases plasma osmotic pressure
and produces a sustained activation of both oxytocin
and vasopressin neurones (Brimble & Dyball) resulting
in elevated plasma oxytocin levels (Shibuki,Leng &
Way, 1988 ; I.andgraf, Neumann & Schwarzberg, 1988;
RusselI,Blackburn & Leng,1988).
This stimulus to oxytocin secretion was given to check
the responsiveness of the oxytocin system in animals
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treated with pertussis toxin.
In all three groups an elevation of plasma oxytocin
was noted after hypertonic saline but a difference in
magnitude of this response between the three groups
was not seen.
7.3.2: Experiment 2
The aim of this experiment was to see whether leaving
the animals for 72hrs post i.e.v. toxin injection
would increase protein disruption in the light
of the results from Experiment 1 and give more clear
cut resuIts.
The pertussis toxin treated rats experienced weight
loss in the 24hrs following surgery and i.e. v. toxin
injection whereas the control rats did not. This could
be attributed to non—opioid receptor linked actions of
the toxin disrupting food and water intake — effects
which only lasted for 24hrs after toxin treatment.
In experiment 1 the hyperosmotic stimulus was given
towards the end of the blood sampling protocol <Fig
7.1.<a>>.In experiment 2 this was amended so that the
hyperosmotic stimulus could be given concommitant1y
with either a morphine or a saline injection. It was
hoped that by giving these treatments close together
that it could be determined whether the inhibition by
morphine of the usually marked oxytocin response to a
hyperosmotic stimulus could be mediated by receptor
G < 1....) prote i ns . Once again the plasma oxytocin data
proved disappointing with control animals unable to
provide a significant oxytocin secretion in response
to hypertonic saline,thus making it difficult to
demonstrate any inhibitory effects of morphine or show
that pertussis toxin pretreatment had any effect.
In the vehicle treated animals given saline i.v.
followed by a hyperosmotic stimulus of 1 . 5M NaCl i.p.
did not consistently show the rise in plasma oxytocin
expected CShi buk i , Leng & Way, 1988) and it was
therefore difficult to say if morphine injection had
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suppressed a response since there was no significant
difference in plasma oxytocin between the two groups.
Following i.v. naloxone injection at t = 44 mins both
the morphine and saline treated control animals
experienced a significant rise in plasma oxytocin with
respect to pre-naloxone values.
The morphine treated group appeared to experience a
greater elevation implying that antagonism of
endogenous opioids regulating oxytocin secretion as
well as morphine binding to p-receptors had been
achieved but this difference between the groups was
not significant.
In the animals that had received i.c.v, pertussis
toxin C0.7pg/5pl) 72hrs previously neither animals
injected with saline or with morphine showed a
significant increase in plasma oxytocin following i.p
hypertonic saline therefore confounding comparison
between the two treatment groups with respect to
morphine effects..Following naloxone,both the morphine
and saline treated animals experienced a significant
elevation in plasma oxytocin levels.It appears that
the saline treated animals experienced an initially
greater elevation than the morphine treated
group.However there was no statistical significant
difference between oxytocin secretion in morphine
injected or saline injected animals and therefore no
definite conclusions can be drawn from this.
Since the morphine treated i.c.v. pertussis toxin
treated rats showed a similar elevation of plasma
oxytocin as the morphine treated i.c.v. vehicle
treated rats following naloxone suggests that the
actions of both exogenous and endogenous opioid
antagonists have been reversed i.e. both morphine and
endogenous opioids are normally effective.
Another possibility for the lack of effect of the
pertussis toxin was that the toxin was no longer
active although changes in only the toxin treated
animals following i.c.v. injection would imply that it
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was active. These exper i rrrendt-s gave inconclusive results
as to whether a pertussis toxin sensitive G- protein
(Gi/..,) is the signal transduction mechanism for jjl-
opioid receptor subtype binding.
In contrast,i.c.v. pertussis toxin (7pg/5pl>
pretreatment attenuates morphine inhibition of
electrical activity of putative oxytocin neurones in
the SON.Oxytocin neurone electrical activity in i.e.v.
pertussis toxin treated rats was found to be fully
inhibited by i.v. U50,488H, at similar doses to
control animals.Morphine however,showed a
significantly decreased ability to inhibit oxytocin
neurone cell firing in these pertussis toxin treated
rats compared to control i.e.v. vehicle infused
anima1s.
Other results indicate that morphine but not U50.488H
inhibit oxytocin neurones by a mechanism involving a
pertussis toxin sensitive G:l y.... :> protein and that it
is p-opioid receptors not x-opioid receptors that
involve a G < ^....protein in their modification of
oxytocin secretion (Russell.Pumford & Leng,1991>.
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CHAPTER EIGHT
THE EFFECT OF PETHIDINE (MEPERIDINE),A SYNTHETIC
OPIATE,ON OXYTOCIN RELEASE AND UTERINE CONTRACTILITY
IN THE RAT.
Chapter 8 : The effect of pethidine (meperidine),a
synthetic opiate,on oxytocin release and uterine
contractility during parturition in the rat.
INTRODUCTION
A pregnant female rat will give birth to between 6 and
14 pups on the afternoon of day 21 or 22 following
detection of a vaginal plug (day 0) , taken as an
indication of fertile mating.The pups are normally
born over a period of 60—90 minutes provided the
mother rat remains undisturbed (Leng,Mansfield et
al,1988).
In the rat,oxytocin is known to have a regulatory role
in the progress of parturition.Oxytocin secretion
steadily increases once parturition has been initiated
and reaches a plateau some time after the 4th or 5th
pup (Higuchl, Honda et a 1, 1985;HIguch1,Takadoro et
al,1986).
Superimposed upon this slightly elevated basal
secretion are bolus releases of oxytocin associated
with periodic high frequency bursting of supraoptic
neurones similar to milk-ejection activity
(Summer 1ee, 1981).
Oxytocin is a potent uterotonic agent but is unable to
initiate contraction of the pre-parturient uterus and
hence precipitate parturition earlier than 4-6 hours
prior to expected de1ivery.Sinee plasma oxytocin does
not increase dramatically during parturition and the
uterus is unresponsive until just beforehand it would
appear that it is a change in sensitivity of the
uterine receptors to oxytocin rather than the
modification of oxytocin secretion that initiates
parturition (Fuchs,Periyasami e t a 1, 1983;Fuchs, 1985) .
Morphine administered intracerebroventricularly
(i.c.v.) or intravenously (i.v.) interrupts
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established parturition for up to several hours with a
depression in circulating oxytocin .This effect is
fully reversible by naloxone and can also be overcome
by i.v. infusion of oxytocin (Cutting,Fitzsimons et
al,1985).
The bolus release of oxytocin just prior to the
appearance of a pup is thought to be responsible for
the uterine contractions which propel the foetuses
from their implantation site along the uterus - this
is known as the foetus-ejection reflex.The foetal-
expulsion reflex which finally moves the pup through
the birth canal is dependent upon abdominal and
respiratory movement' and compliance of the cervix
<Higuchi,Uchide et al,1987>.
In rats where parturition has been held up by morphine
administration, the foetuses remian adjacent to their
implantation sites implying that depression of
oxytocin has interrupted the foetus-ejection reflex.
Pethidine (meperidine) is a synthetic opiate used as
an obstetric analgesic in humans.Pethidine is believed
to act as a p-opioid agonist (Clarke & Wright, 1984)
and also to have atropine—1ike properties.
In the following experiments,the effect of pethidine
on parturition in the rat and upon uterine
contractility of the post-partum uterus in—vitro were
examined to establish whether it had central or
peripheral actions.Co-administration of naloxone was
used in an experimental group of animals to see
whether pethidine was acting via opioid receptors.In
these experiments blood samples were taken at timed
intervals during delivery of the litter to determine
the effect of pethidine or pethidine and naloxone on
plasma oxytocin.
Observations were also on maternal behaviour in which
oxytocin may play an important role (Pederson &
Prange, 1979;Pederson,Ca1dwe11 et
al, 1985;Fahrbach, Morrel1 & Pfaff,1985>.
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The effect of pethidine on osmotically stimulated
plasma oxytocin levels was also investigated.This was
to determine whether pethidine was able to depress
oxytocin secretion by a central action,since the
hyperosmotic stimulus acts both directly on
magnoce11u1ar neurones and on central osmoreceptors in
the AV3V region or subfornical organ <SFO)
(Leng,Blackburn et al, 1989) .
8.1. METHODS
8. 1. Cii> ANIMALS
Female Sprague Dawley rats were placed in individual
mating cages with wire mesh floors, with males, during
late afternoon (~ 4pm) and left overn i gh t. The
following morning,the removable tray beneath each cage
floor was checked for the presence of a vaginal plug —
an indication that a fertile mating had taken
p1 ace. Fo11owing detection of a plug, the female was
removed and caged individually.The day of vaginal
plugging was designated day 0 and parturition
estimated for the afternoon of day 21.All pregnant
females were kept under conditions of controlled
photoperiod <13hrs light:1lhrs dark,lights on at
8a.m. > and constant temperature.Food and water were
freely available.
From day 16 of pregnancy onwards, the animals were
weighed daily at the same time each morning <8.30-9.30
a.m.) to
a) check that they were pregnant from their daily
weight gain,
b) accustom the animals to being handled and removed
from their cages.
8. 1 <ii> Experiment 1 : The effect of subcutaneous
pethidine injection on the timecourse of parturition
in the undisturbed Sprague—Dawley rat.
On the morning of expected delivery the rats were
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observed from the time of lights on.All signs of
impending delivery were noted
i) nest building
ii> appearance of blood on bedding
iii> straining and muscular contraction of the abdomen
iv) excessive body grooming and licking of perineum.
The time of delivery of each pup was noted and whether
they were born alive or dead. After the birth of the
second pup pethidine or 0.9% isotonic saline was
injected subcutaneously into the hind flank of the
mother rat and the timecourse of continuing
parturition noted.The time delay between the first and
second pup is generally longer than subsequent inter-
birth intervals and extremely variable between animals
hence the drug/saline injection was not given until
after pup 2 so that any effects on established
paturition could be more reliably interpreted.
Pethidine was administered subcutaneously in one of
three doses 60,30 and 10 mg/kg (taken from 120,60 and
20 rng/ml stock solut ions) . The control animals were
injected subcutaneously with isotonic sterile saline
<vehicle,0.5ml/kg).
All injections were performed by the same person so
that variation in restraining the animal and the
initial site of drug entry was minimized.
8.1 <iii> Experiment 2 : effect of pethidine,pethidine
and naloxone, or vehicle on the timecourse of
established parturition and levels of plasma oxytocin
during parturition in the undisturbed Sprague-Dawley
rat.
Early in the morning of expected delivery under ether
anaesthesia a cannula was implanted via the jugular
vein into the right atrium to allow withdrawal of
timed blood samples in an unrestrained conscious rat
during parturition (Leng,Mansfield et al,1988>.
The cannula tubing was silicon and thus
extremely flexible which allowed it to be taken up
over the shoulder under the skin to exit through a
small incision at the base of the neck.The cannula was
fed through a tightly coiled spring which was attached
to the rat via two loose skin sutures at the base of
the neck and tied to the cage lid at the other end.The
cannula was thus protected from the animal chewing it
by being encased in the spring whilst still allowing
the rat free access to all parts of its cage since the
spring allowed it complete freedom of movement. The
cannula was filled with heparinized saline (Heparin
50U/ml saline) and was periodically flushed through
to prevent blood clots.
An initial blood sample for basal oxytocin was taken
2hrs after completion of surgery and the other samples
according to the protocol shown in 8.1(a).
Signs of impending delivery as previously described
were noted and the times of each pup de 1 i ver y. Af ter
the birth of the second pup, the rats were given a
subcutaneous injection of pethidine <lOmg/kg,20mg/ml)
or vehicle (isotonic saline 0 . 5ml/kg).B1ood samples
were withdrawn as described in 8.1(a) and the time
course of continuing parturition noted. In n=10 rats, an
intravenous injection of 5mg/kg naloxone preceded
pethidine administration to determine whether the
effects of pethidine are naloxone reversible and hence
opioid receptor mediated.
Blood samples (0.3ml) were immediately placed over ice
and then centrifuged to obtain p1asma.P1asma aliquots
were stored frozen at —20°C until assayed.The method
of radioimmunoassay used to measure oxytocin was that
described by Dr.T.Higuchi (T. Higuchi,K.Honda et
al, 1985) .
All oxytocin assays in this experiment were carried
out at AFRC Institute of Animal Physiology and
Genetics Research,Babraham, Cambridge CB2 4AT. The
detection limit of the assay was 5pg/ml plasma.The
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Sample 1 2hrs post surgery (basal oxytocin)
Sample 2 After delivery of pup no. 2
Subcutaneous injection of pethidine (lOmg/kg) or
saline.For method II (ii) naloxone (5mg/kg i.v.)
preceded pethidine injection.
Sample 3 10 minutes post injection
Sample 4 20 minutes post injection
Sample 5 30 minutes post injection
•>,. Sample 6 60 minutes post injection
Sample 7 90 minutes post injection
Sample 8 120 minutes post injection
Sample 9 After birth of pup 3 in animals
delayed for >120 minutes.
Figure 8.1(a)
Protocol for the blood sampling procedure in
cannulated rats receiving either subcutaneous
vehic1e,pethidine or pethidine preceded by intravenous
na1oxone.
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intra- and inter- assay coefficients of variation were
9.5% and 3.3% respectively.
8. 1 (iv) Experiment 3: Does pethidine affect maternal
behaviour ?
During the course of parturition in experiments 1 and
2,maternal behaviour was monitored before and after
drug administration.
<a> During parturition
Maternal behaviour comprised of Ci) cleaning the pups
immediately they were born <ii) gathering the pups
together into a nest and Ciii) eating newly delivered
placentae Cplacentophagy) Civ) not eating the newly
delivered pups.
Cb) Post—parturn
Maternal behaviour involved Ci) construction of a nest
area Cii) keeping the pups together as a litter in the
nest Ciii) keeping the pups warm and Civ) nursing the
pups.
Since the mother usually moved from the nest if the
cage was disturbed these observations were usually
made early in the morning before moving the cage from
the rack.The presence of milk-spots and litter weight
gain were taken as an index of whether the pups were
suck 1ing.
8. 1 Cv) Experiment 4 : Does pethidine affect
spontaneous contractions in the immediate Cor <24hr)
post—parturient isolated uterus muscle bath
preparation ?
Animals from experiment 1 which had littered overnight
without receiving any drug treatment and a few mated
up at a later date and allowed to deliver without any
disturbance were used in this experiment.
The rats were killed by stunning followed by cervical
d i s1ocation.The uterine horns were ligated and removed
from the abdominal cavity .The horns were suspended in
a 40ml muscle bath containing de Jalon's solution
gassed with 95% 0::r,/5% CO:2 maintained at 37'C by an
external water bath.Each horn was suspended from a
strain gauge and secured to a metal hook at its lower
end (see Fig 8.1(b)).The muscle was initially tensed
to lOg and contractile activity measured
isometrica11y .
Once spontaneous contractile activity had attained a
steady state,a control period of nine minutes was
observed prior to introduction of drugs into the
bathing medium. All drug solutions were made up in de
Jalon's medium. Effects of the drugs were determined by
measuring the mean amplitude of the last three
contractions in the control period and the first three
A.- contractions in the series immediately post drug
administration (excluding those occuring in the first
30 seconds except in the case of acetylcholine (see
later).
Drug effects were expressed as the ratio of the mean
amplitude of contractions pre— and post- drug
additions.When the drug caused complete cessation of
spontaneous contractions the trace was assigned a
minimum scale value so that all ratios would be
finite.Since the water bath accommodated two muscle
baths,simultaneous recordings of contractile activity
could be made from two uterine horns at the same
time.This allowed time controls to be carried out,
when one horn was not exposed to any drug, at the same
time another horn was undergoing a drug addition
protoco1.
8. lv (a) Effect of pethidine on spontaeous uterine
contractile activity.
A nine minute control period of spontaneous
contractile activity was recorded after which
pethidine was added to the bath.The doses tested were
5. 16x10~"eM, 0 . 3x10 *'M, 2. 06x10 ®M, 6. 19x10 ®M and
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5% COi/ 95% 02
for gassing medium
stock







In- vitro muscle bath preparation set up.The uterine muscle
was kept at 37°C in gassed de Jalons medium.Drugs were
added directly to the medium bathing the muscle in the bath
(volume of bath ca. 40ml).The medium in the bath was changed
by a system of draining and filling the bath with pre-warmed
fresh de Jalons medium.
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2.47xlO""4M which were administered singly in random
order. These doses were calculated to be of the same
order of magnitude as the range of pethidine used in
Experiment 1 once distributed in the rats
extracellular fluid volume.After four minutes the
fluid in the bath was drained twice and replaced with
fresh stock solution;the test cycle was then repeated
with another dose of pethidine.
8.lv <b> Effect of pethidine on oxytocin stimulated
contractions of uterine muscle.
Nine minutes of control spontaneous activity was
measured as before after which oxytocin was added to
the bath.The doses of oxytocin used were 0.875 mU/ml
CI. 75x 10"eM) , 0. 218mU/ml (4 . 375x1and 0.109mU/ml
<2 . 9x10""7M) .
After three minutes the bath was drained and refilled
with fresh medium twice and a further nine minutes of
spontaneous activity recorded.Pethidine was then added
to the bath <6. 19xlO'""-JM) and four minutes after this
the same dose of oxytocin as previously administered
was added and uterine contractions measured over a
further three minutes.The bath was then drained and
refilled twice with fresh medium and the whole cycle
repeated using another dose of oxytocin.
Thus, the effects of different doses of oxytocin on
uterine contractility before and after a fixed dose of
pethidine compared to the control period of activity
were examined.
8.lv (c> Interaction of naloxone with pethidine
After a nine minute control period oxytocin (middle
dose: 4. 375xlO~'7M) was added to the bath and after
three minutes was washed out.After a further nine
minutes control period , pethidine (6. 19xl0""'3M) was
added to the bath and its effect recorded for three
minutes before being washed out wi th fresh stock de
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Jalon's.This established the effect of oxytocin or
pethidine alone on uterine contractions as compared to
the control period.
Next,after another nine minute control period these
doses of oxytocin and pethidine were added
simultaneously and their combined effects recorded for
three minutes before replacing the bathing medium with
fresh solution.
F ina11y,after nine minutes of control
ac t i v i ty , na 1 oxone at or 10 ,SM was added to the
bath to determine its effect on uterine contractions
alone then two minutes later pethidine <6. 19xlO~sM>
was added and lastly oxytocin <4. 375 x 10-'7M) after
three minutes. This allowed comparison of naloxone
p alone and naloxone effects on pethidine or pethidine
and oxytocin combined effects as compared to control
spontaneous activity.
8.1v <d> Pethidine effects on acetylcholine <ACh>
stimulated contractions.
After a nine minute control period,ACh was added to
the bath in doses of 10""eM, 5 x 10~ yM, 10""7M and 5xl0~"e:,M
administered singly in random order.After three
minutes the medium was replaced twice and the cycle
repeated with the next dose. From the dose response
curve constructed 10""'SM was chosen to test against
pethidine and after nine minutes of control activity
this dose was added to the bath and the contraction in
the next two minutes recorded. In the previous
experiments,the first thirty seconds of activity after
a drug addition was disregarded but since ACh acts and
is degraded so quickly,the immediately following
contractions were studied.After a further nine minutes
of control activity,pethidine was added to the muscle
bath in one of the doses 5. 16 x 10~"SM, 1.03x10"
6M, 2. 06x 10'~SM and G. 19x10 and three minutes later
ACh added. After two minutes the bath was drained
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and refilled twice with fresh stock solution and
cycle repeated with a different dose of pethidine
the same dose of ACh.
the
but
All drug concentrations given are those in the baths
in which the uterine horns were suspended.Tests were
carried out only once on each horn but each horn
experienced several different tests but always
received a thorough wash-out and adequate recovery
t ime.
8. 1 (vi) Experiment 5 : Does pethidine affect elevated
plasma oxytocin concentration in osmotically
stimulated virgin female Sprague—Dawley rats ?
Virgin female Sprague—Dawley rats in this experiment
were caged separately under the same conditions as the
rats in 8.1 <ii> and 8.1.<iii).
On the evening of day 1 the rat and its water bottle
were weighed at 8pm. On day 2 the rat and water bottle
were weighed at 8am ( to monitor normal overnight
water consumption) and the rats implanted with a
jugular cannula under ether anaethesia.At 12 noon the
water was replaced with 2% saline and the bottles
weighed at 8pm.
On day 3 the rats and water bottles were weighed at
8am to monitor overnight saline consumption.[If the
rats continued to drink as normal they would be
osmotically stimulated from the 2% saline solution but
if they chose not to drink for the 24hrs exposure to
saline they would be osmotically stimulated from water
depriva tion. 1
Blood samples were taken according to the protocol
shown in Fig 8. 1 (c) . Samples of 0.3ml were withdrawn
for oxytocin radioimmunoassay,those of 0.6ml for
radioimmunoassay and plasma osmolality and C Na'*"l
measur emen ts.
After 24hrs exposure to 2% saline the rats were
DAY 1:
Weigh rat and water bottle 4pm
Weigh water bottle 8pm
DAY 2:
Weigh rat and water bottle 8am
Implant venous cannula
Sample 1 <0.6ml> 2hrs post surgery
Replace drinking water with 2% saline
Sample 2 <0.3ml> 8pm
Weigh water bottles
DAY 3:
Sample 3 <0.3ml> 8am
Weigh water bottles
Sample 4 <0.6ml> 12 noon
Subcutaneous pethidine <10mg/kg> or saline
Sample 5 <0.3ml> 10 mins post injection
Sample 6 <0.3ml) 20 mins post injection
Sample 7 <0.3ml) 30 mins post injection
Sample 8 <0.6ml> 60 mins post injection
Figure 8. 1Cc >
Blood sampling protocol for cannulated virgin female
rats during exposure to 2% saline drinking water as an
osmotic stimulus and subsequently injected
subcutaneously with pethidine or vehicle
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injected subcutaneously with either pethidine
(lOmg/kg,20mg/ml > or vehicle and serial blood samples
withdrawn.
8.2 RESULTS
8.2 <i> Experiment 1 : The effect of subcutaneous
injection of pethidine on the timecourse of
parturition.
The first rat to deliver in this experimental group of
animals was given 60mg/kg pethidine s.c. following the
birth of its second pup.Acute respiratiory depression
ensued resulting in death of the animal.This dose was
subsequently rejected for use in this study.
The timecourse of parturition following s.c. pethidine
(30 & lOmg/kg) and vehicle is shown in Figure
8.2(a).Cumu1 ative birth-time against pup number has
been plotted.Both doses of pethidine (lOmg/kg &
30mg/kg) significantly increased the cumulative time
of delivery with respect to vehicle treated animals
<p<0.05,0.002 and 0.005,Kruska1-Wa11is)
For more detailed statistical comparisons,the time to
deliver pups 2-6 and 6—10 were compared between the
three experimental groups <see table 8.2<I>>
For the rats that received pethidine <30mg/kg>
inhibition of the progress of parturition was severe
enough to prevent reinitiation of parturition before
lights out and therefore the data for these animals
into the later stages of parturition has not been
collec ted.
Injection of pethidine slowed parturition
significantly compared to vehicle treated rats. The
action had rapid onset,lengthening the interbirth
intervals between pups 2-5 (lOmg/kg pethidine s.c. )
and between pups 2-3 <30mg/kg pethidine s.c.).Once
parturition had been re-established it continued at a





Graph depicting cumulative time of parturition against pup no.
for three experimental groups of rats (vehicle,open circles;
pethidine (10mg/kg),open squares;pethidine (30mg/kg),filled-
squares.Subcutaneous administration of vehicle or pethidine
was after pup no.2.
Statistical comparisons:
* p<0.05,** p<0.02,*** p<0.005 with respect to both groups
of pethidine treated rats (Kruskal-Wallis),
The cumulative time to the delivery of pup 8 in the 30mg/kg
pethidine treated group ranged from 62-1 126 mins,therefore the
































Summary of statistical comparisons on the progress of
parturition in uncannulated rats treated with
pethidine <10/30mg/kg> or vehicle s.c.
** p<0.005(Kruska1-Wa11is w.r.t. vehicle)














Summary of statistical comparisons on the progress of
parturition in cannulated rats treated with vehicle or
pethidine (lOmg/kg) s.c. or pethidine <10mg/kg) s.c.
preceded by naloxone (5mg/kg i.v)
** p<0.001 w.r.t pethidine, * p<0.005 w.r.t vehicle
(Wi1coxon)
t p<0.05 w.r.t pethidine, tt p<0.02 w.r.t vehicle
<Wilcoxon)
1 p<0.01, 'z p<0.02 w.r.t interval 2 — 6 (Wilcoxon signed
rank test)
INTERBIRTH INTERVAL (min)




184.3 ** 52.8 ft 1
28.4 7.3
15 9




8.2 (ii) Experiment 2 : Effect of pethidine <10mg/kg>
s.c. on plasma oxytocin during parturition.
The timecourse of parturition in rats that received
s.c. vehicle,s.c. pethidine (lOmg/kg) or s.c.
pethidine preceded by 5mg/kg naloxone i.v. is shown in
Figure 8.2 (b).The same statistical comparisons were
made as in the uncannulated rats and are summarized
in Table 8.2 <II>.The cannulation procedure and blood
sampling protocol did not affect the progress of
parturition in these animals.The cumulative time to
delivery of pup 10 was not different to that in the
uncannulated group (unpaired t-test),
Pethidine (lOmg/kg) s.c. was once again followed by a
slower progress of parturition.The interbirth
intervals between pups 2-6 were significantly
lengthened compared to the vehicle injected group
<p<0.001 Wilcoxon). In both groups the interval between
pups 6-10 was significantly less than that between
pups 2-6 (p<0.02 vehicle,p<0.01 pethidine Wilcoxon)
indicating that the interbirth intervals between pups
decreased as parturition progressed.
Naloxone (5mg/kg i.v.) given prior to pethidine
increased the rate of delivery of the four pups
immediately after treatment (pups 3-6) compared to the
group treated with pethidine alone (p<0. 005,Wi1coxon
rank sum test).There were no significant differences
between the rate of delivery of the pups in the
naloxone/pethidine treated group compared to those
rats treated with vehicle.
Basal plasma oxytocin concentration in the pregnant
and parturient rats was significantly elevated
compared to the virgin rats used in 8.1 (vi) (33.95 ±
3.82 vs 17.37 ± 2.40pg/ml,p<0.05 Wi1coxon).The plasma
oxytocin profile obtained from the serial blood
samples taken from each group of rats is shown in
Figure 8.2(c).This graph represents the change in
plasma oxytocin with respect to that measured in
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or Naloxone + Pethidine
Figure 8.2 (b)
Graph depicting cumulative time of parturition against pup no.
for three groups of experimental animals (vehicle,open circles;
pethidine (10mg/kg),open squares;pethidine (lOmg/kg) +
naloxone (5mg/kg i.v.),filled squares.Subcutaneous administ¬
ration of vehicle or pethidine or naloxone/pethidine took place
after delivery of pup 2.
Statistical comparisons:
* p<0.02,** p<0.005,*** pcO.OOl (with respect to vehicle
treated group,Wilcoxon).
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Change in plasma oxytocin in serial blood samples taken
from rats during the course of parturition which were
treated with pethidine (lOmg/kg s.c.) or pethidine (lOmg/kg
s.c.) + naloxone (5mg/kg i.v.).The drugs were administered
after the birth of pup no.2,immediately after sample 2.
Sample 9 was taken from rats that resumed delivery after
120 mins and only occured in the pethidine treated group.
Values shown are mean ± sem.
Statistical comparisons:
* p<0.03,** p<0.006,*** p<0.007 unpaired t-test,with respect
to pethidine + naloxone group.
f p<0.01 ,paired t-test,with respect to value at sample 2.
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sample 2,immediately after pup no. 2 and preceding any
drug administration.
Following pethidine injection,plasma oxytocin in the
timed samples decreased with respect to its initial
value to a maximum change of —13.68 ± 6.97 pg/ml
(sample 7).When pethidine was co-administered with
na1oxone,p1asma oxytocin was elevated during the
course of parturition to a maximum increase of 23.6 ±
14.4 pg/ml (sample 5).Statistica1 comparisons at
sample times where significant,are shown in Figure
8.2 <c).
8.2 <iii) The effect of pethidine injection upon
maternal behaviour.
During the course of parturition,fema1e rats will
clean their pups as they are born, gather the newborn
into a nest and will eat the newly delivered
p1acentae.A1 though the pups will gather beneath the
mother, mi lk let down does not usually occur until
about 2hrs after the completion of
parturition.Oxytocin is believed to play an important
role in prolactin secretion and milk-ejection
(Bisset,C1ark et al,1967>.
Following injection of pethidine,the female rats
appeared much quieter than those injected with saline
or pethidine preceded by naloxone.In general they were
disinterested in their increasing litter and made
little or no attempt to clean or gather the pups
together.However, this effect was short-lived and
generally within two hours of completing parturition
their interest in the litters had returned.No signs of
dystocia were noted amongst, the pethidine treated rats
and despite the long delays apparent in producing the
next pup after pethidine i nj ec t i on, there was a high
pup survival rate.Details of litter size and perinatal
pup viability with relevant statistical comparisons
are summarized in tables 8.2 (III) & 8.2 (IV).
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Litter size and pup viability data from uncannulated
rats that received vehicle or pethidine <10 or 30mg/kg
s. c . ) .
* p<0.05 (unpaired t-test,w.r.t. vehicle group).






























Litter size and pup viability data in cannulated rats
that received either vehicle or pethidine (lOmg/kg)
s.c. or pethidine (lOmg/kg) preceded by naloxone
(5mg/kg i . v. )
* p<0.05 (unpaired t test,w.r.t vehicle group).
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8.2 Civ) Effect of pethidine on uterine contractility
In vitro
Pethidine inhibited spontaneous contraction of the
post-partum uterus in a dose-dependent manner;the IDso
was approximately 2.6x10"sM <Fig 8.2<d)) . Pethidine
also inhibited uterine contractions stimulated by
oxytocin.This inhibition was not reversed by addition
of oxytocin up to 1.8xlO""sM.
The stimulatory effect of acetylcholine on spontaneous
uterine contractions is shown in Figure 8.2(e).
Acetylcholine <10~"®M) had no effect on pethidine
mediated inhibition of uterine contractions as shown
in Figure 8.2 Cf).
Naloxone alone had no effect on spontaneous uterine
t-. contractility and was not able to reverse pethidine
mediated inhibition of spontaneous or oxytocin
stimulated contracti1ity. These results are summarized
in Figure 8.2(g).
8.2 (v) Experiment 5 : Effect of pethidine on plasma
oxytocin elevated by an osmotic stimulus.
The results of fluid i n t ake, p 1 asma C Na""l and plasma
osmolality measurements are shown in Table 8.2
(V).F1 uid intake was reduced significantly once water
had been replaced with 2% sa1ine.Subsequent 1y,p1asma
[ Na'1"] and osmolality were elevated by 24hrs either
from the rats drinking the saline or by not drinking
and elevating these parameters by water deprivation.
Following pethidine injection,plasma oxytocin was
decreased in the serial blood samples withdrawn
between 10 and 60 minutes post pethidine.Fo1 lowing
injection of saline (vehicle),plasma oxytocin
continued to rise from its post-osmotic stimulation
values throughout the blood sampling protocol.The
plasma oxytocin profiles from both groups of rats is
shown in Figure 8.2(h).

































Dose response curves for pethidine (8.2 (d)) and acetylcholine
(8.2 (e)) to demonstrate the inhibitory and facilitatory effects
they show on spontaneous contractile activity of the immediate


















Change in contractile activity of the post-parturient uterus
in vitro in the presence of pethidine (filled circles) , at
various doses , and pethidine in the presence of acetylcholine
at 10-6M (filled squares).Values are mean ± s.e.m.The open
square symbol represents the change in force of contraction
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The effects of pethidine,oxytocin and naloxone on the
force of contractions recorded from the post-parturient
uterus in vitro.The drugs were given alone or in
combination at the following doses;pethidine 6.2 xlO-5M,
oxytocin 4.4 x 10-7M and naloxone at 10-5M.The effects
were recorded from the spontaneously contracting uterus,
oxytocin stimulated contracting uterus or naloxone
stimulated contracting uterus.All points represent mean ±
s.e.m. values.
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Day 1 Day 2 Day 3




Mean fluid Day 1—2 (water) Day 2—3 <2% NaCl)
intake (ml) 20.6 ± 1.3 12.2 ± 1.6A
8pm—8am <n=22> <n=25)
Mean Day 2 <8pm> Day 3 (12am) Post injection
Plasma veh peth
1 Na~"l 143.7 146.2* 145.7 145.8
mm/L ± ± ± ±
O. 5 0.5 0. 8 O. 6






















Summary of the effects of substitution of 2% saline
for drinking water for 24hr on body weight,fluid
intake, plasma [ Na"'~l and osmolality in virgin female
rats fitted with jugular venous cannulae for blood
samp 1ing. Va1ues shown are mean ± sem.
Statisical comparisons:
A p< 0. 001 with respect to Day 1 value (paired t-test)
Ap<0.001 with respect to Day 1 value (paired t-test)
•p<0.001 with respect to Day 2 value (paired t-test)
•&p<0.05 with respect to Day 2 value (paired t-test)
■*Wfp<0.01 with respect to Day 2 value (paired t-test)
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2% NaCl Vehicle or
pethidine
Fig 8.2 (h)
Change in plasma oxytocin concentration in blood
samples withdrawn from the jugular vein of conscious
rats which had been osmotically stimulated by replacing
their drinking water with 2% NaCl for 24hrs (stippled
symbols).The rats were then divided into two treatment
groups,pethidine (filled circles) or vehicle (open circles)
injected.The blood sampling protocol is shown in Figure
Statistical comparisons:
* p<0.01, ** p<0.001 paired t-test with respect to basal
value (t=0 h).
t p<0.05,paired t-test with respect to value at (t=0 min)
# p<0.05,unpaired t-test with respect to vehicle treated
group at t=30 and t=60 min.
Mean plasma oxytocin at t=0h , 18.8 ± 2.1 pg/ml and at
t=24h/0min , 26.5 ±3.7 pg/ml.
8.1(c).
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respect to basal values at t=20hrs and
t = 24hrs.Fo11 owing pethidine inject ion,plasma oxytocin
concentration was decreased in samples withdrawn from
the jugular vein at t=20,30 and 60 minutes after drug
injection with respect to plasma oxytocin
concentration at t =0 rains. At t= 30 and 60 minutes
plasma oxytocin concentration in the pethidine treated
group was significantly lower than that of the saline
injected contro1s.Statistica 1 comparisons are shown in
Figure 8.2 <h>.
8.3 DISCUSSION
The reported effects of pethidine,when used as an
obstetric analgesic,on the progress of labour in women
are conf1icting. A significant prolongation (Gallen &
Prescott, 1944) and an acceleration (Filler,Hall &
Fi Her, 1967 > of labour have been documented.
In the experiments described here,pethidine acted to
substantially prolong parturition at the two doses
tested (30 & 10 mg/kg) . Examination of delivery times
of the rats show that this was through a lengthening
of interbirth intervals.The effect of pethidine was
rapid in onset and generally apparent within one to
two pups after injection.For the low dose of pethidine
(lOmg/kg) there appeared to be an increase in the
first four interbirth intervals following injection of
the drug.Parturition then resumed to the rate observed
in control animals.In the rats treated with the higher
dose of pethidine (30 mg/kg) there appeared to be an
increase in one interbirth interval,usual ly
immediately after pethidine injection but this was for
a considerable length of time and parturition
continued at the normal rate on appearance of the next
pup.This indicates a dose related effect dependent
upon the half life of pethidine in the circulation.
There was little or no increase in perinatal mortality
despite the interruption, oft en for several hours, to
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the progress of parturition.ThIs implies that the
foetuses remained at their implantation sites on the
uterus with foetal transport along the uterine horns
rather than the foeta 1-expu1sion reflex from the birth
canal being affected (Higuchi,Uchide et
al,1987).Foetal-ejection relies in secretion of
oxytocin and its uterotonic action,therefore pethidine
may have an inhibitory action on oxytocin action at
this stage of labour (Higuchi,Uchide et al,1986).
Morphine acts centrally to inhibit oxytocin secretion
(by its actions as an agonist at p-opioid receptors)
and hence prolong parturition. This effect is reversed
by naloxone which is a potent p—opioid receptor
antagonist or by infusion of oxytocin (Russel1,Gosden
et al,1989).
Pethidine has considerably less affinity for p—opioid
receptors than morphine so naloxone would be expected
to completely reverse its effects and that of any
endogenous opioids acting to regulate oxytocin
secretion.Subcutaneous injection of pethidine reduced
plasma oxytocin during the course of parturition,as
seen in 8.2(c).
Na1oxone,when co-administered with pethidine elevated
plasma oxytocin considerably,presumably through
antagonism of pethidine and endogenous opioids
(Hartman,Rosella—Dampman et al, 1986;Leng,Mansfield
etal,1988).Parturition was not accelerated in these
ra ts, a 1 though when naloxone is given to rats in the
early stages of labour it increases plasma oxytocin
and shor tens the duration of part urition
(Leng,Mansfield et al, 1987) . Pethidine is known also to
have atropine like properties and it may be partly due
to these non-opioid rnechan i sms that parturiti on i s
de1ayed.
In—vitro,pethidine profoundly inhibited spontaneous
and oxytocin-stimulated uterine contractions as well
as rendering the muscle insensitive to
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aceylcho1ine.These results contrast with the results
of previous studies on uteri from late pregnant rats
in which pethidine increased both the frequency and
amplitude of uterine contractions (Fazackerley &
P1euvry,1987;Sivalingham & P1euvry,1985>Na1oxone was
not able to reverse the inhibition, implying that it
was not mediated by opioid-receptors.Since the effects
of acetylcholine are negated by pethidine it would
appear that its actions at the uterus are due to its
atropine-1ike properties.A consequence of this direct
action on the uterus would be to prevent entry of the
foetuses into the birth canal via the cervix and hence
remove the Ferguson reflex stimulation of oxytocin
seeretion.Thus,pethidine probably interrupts
parturition by this inhibitory action on the
uterus,periphera11y and indirect1y,as well as reducing
oxytocin secretion possibly by a central route.
It is difficult to monitor the effects of pethidine on
uterine contractility in women since administration of
other drugs such as oxytocin and prostaglandins during
labour makes interpretation of any effects seen
difficult.Pethidine has been reported to both
stimulate (Sica-Blanco,Rozada & Remedio,1957) and
inhibit (Petrie,Wu,Miller,Sacks et al,1976) uterine
contrac ti1ity.
Immediate post-partum maternal behaviour was disrupted
by pethidine injection,in that the mother rats did not
clean or gather their pups together in a
nest.However, the litter sizes in the pethidine and
pethidine/na1oxone treated animals were not
significantly different from the vehicle treated
groups.There was a small significant decrease <p<0.05
with respect to the vehicle group) in pup viability 1
hour post-partum following lOmg/kg pethidine
Cexperiment 1) or lOmg/kg pethidine + 5mg/kg naloxone
(experiment 2).
It has been postulated that the hormonal changes at
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the termination of pregnancy induce the rapid onset of
maternal behaviour.Centra 1 oxytocin is also thought to
have a role in the induction of maternal behaviour
(Pederson & Prange,1979) but that oestrogen priming is
necessary for oxytocin receptor sensitization
(Pederson & Prange, 1985) .Centra 1 oxytocin is known to
be elevated in the SON and PVN at the end of pregnancy
(Russel1, 1980;Fuchs, 1985).
Central injection of an oxytocin antagonist,d(CH2) 5—
8—ornithine vasotocin inhibits post-partum maternal
behaviour (van Leengoed,Kerker & Swanson, 1987) and the
partial inhibition of this central oxytocin by
pethidine may account for the slight disruption of
maternal behaviour seen.
Rats with raised plasma oxytocin secretion from
drinking 2% saline for 24hrs experienced a decrease in
plasma oxytocin following pethidine injection
(10mg/kg>.Oxytocin secretion is elevated in response
to an osmotic stimulus by central mechanisms,implying
that pethidine acts centrally to depress oxytocin
secretion (Leng,Mason & Dyer, 1982).Hyperosmo1 a 1ity
stimulates oxytocin secretion by actions at osmo¬
receptors located in the AV3V (region anterior and
ventral to the third ventricle) (Leng,Blackburn et
al,1989) and this may be the site for the central
effects of pethidine on oxytocin since there are
opioid receptors in this region and the sub—fornical
organ (SFO) (Sharif & Hughes,1989 ; Sumner, Coombes et
al,1990).
However,parturition is not prolonged by lesion of the
AV3V region which would be expected to resemble
opioid inhibitory action,so pethidine may not impede
parturition by acting at this site (Russel1,Blackburn
& Leng,1989).Pethidine may.like morphine,also act on
the cell bodies of magnocellular oxytocin neurones,but
this has not been investigated.
In the rat,pethidine profoundly prolongs parturition
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by depression of oxytocin secretion possibly by p—
opioid agonist activity and by abolision of uterine
contracti1ity.Since the effect on the uterus is not
reversible by naloxone and renders acetylcholine
ineffective at the isolated uterus,this may be by
atropine like actions.These effects delay the movement
of pups down the uterus and consequently prevent
positive feedback secretion of oxytocin from the
Ferguson—reflex.Pethidine severely affects both the
secretion and action of oxytocin during parturition
resulting in lengthening of labour.
It is not yet known,whether, when used in women as an
obstetric analgesic,pethidine compromises the
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ABSTRACT
The effects of morphine dependence and abrupt
opiate withdrawal on the release of oxytocin and
corticotrophin-releasing factor-41 (CRF-41) into
hypophysial portal vessel blood in rats anaesthetized
with urethane were investigated. Adult female
Sprague-Dawley rats were made dependent upon
morphine by intracerebroventricular infusion of
morphine for 5 days; abrupt opiate withdrawal was
induced by injection of the opiate antagonist naloxone.
The basal concentrations of oxytocin in portal or
peripheral plasma from morphine-dependent rats did
not differ significantly from those in control, vehicle-
infused rats. In rats in which the pituitary gland was
not removed after stalk section, the i.v. injection of
naloxone hydrochloride (5 mg/kg) resulted in a large
and sustained increase in the concentration of oxy¬
tocin in both portal and peripheral plasma in control
and morphine-dependent rats. The i.v. injection of
naloxone resulted in a threefold increase in the
secretion of oxytocin into portal blood in acutely
hypophysectomized rats infused with morphine, but
did not alter oxytocin secretion in vehicle-infused
hypophysectomized rats. The concentration of oxy¬
tocin in peripheral plasma in both vehicle- and
morphine-infused hypophysectomized rats was at the
limit of detection of the assay and was unchanged by
the administration of naloxone. There were no signifi¬
cant differences in the secretion of CRF-41 into portal
blood in vehicle- or morphine-infused hypophysecto¬
mized rats either before or after the administration of
naloxone. These data show that, as for oxytocin release
from the neurohypophysis into the systemic circulation,
the mechanisms which regulate oxytocin release into
the portal vessel blood can also be made morphine
dependent. The lack of effect ofmorphine or naloxone
on the release of CRF-41 or other stress neuro¬
hormones suggests that the effect of opiate dependence
and withdrawal is selective for oxytocin and is not
simply a non-specific response to 'stress'.
Journal ofEndocrinology (1990) 124, 141-150
INTRODUCTION
Oxytocin is secreted in high concentrations into hypo¬
physial portal blood (Gibbs, 1984; Sarkar & Gibbs,
1984; Horn, Robinson & Fink, 1985). The role of
oxytocin released into portal blood has not been
established, but it has been suggested that under
some conditions it may act synergistically with
corticotrophin-releasing factor-41 (CRF-41) and
vasopressin in the regulation of adrenocorticotrophin
(ACTH) secretion (Antoni, 1986) and may be involved
in prolactin secretion (Sarkar & Gibbs, 1984).
Many studies have shown that opioids inhibit the
secretion of oxytocin into the systemic circulation
from the neurohypophysis under several physiological
and experimental situations including suckling (Clarke,
Wood, Merrick & Lincoln, 1979; Russell & Spears,
1984), parturition (Leng & Russell, 1989) and electrical
stimulation of the neurohypophysis (Bicknell &
Leng, 1982) or neuropharmacological manipulation
(Haldar, Hoffman & Zimmerman, 1982; Keil, Rosella-
Dampman, Emmert etal. 1984). Themilk ejection reflex
is initially blocked by long-term continuous infusion of
morphine into the cerebroventricular system, but this
effect is rapidly lost as tolerance develops to morphine
(Russell, 1984; Rayner, Robinson & Russell, 1988).
Continuous or repeated administration of opiates re¬
sults in opiate dependence, as shown by a withdrawal
response to the i.v. injection of the opiate antagonist
naloxone. In urethane-anaesthetized lactating rats in
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which morphine had been infused into the lateral ven¬
tricles continuously for 5 days, injection of naloxone
resulted in a sustained increase in intramammary
pressure, an increased firing rate of continuously
firing cells (presumed oxytocinergic) in the supraoptic
nucleus and a greater than 25-fold increase in the
concentration of oxytocin in systemic plasma (Russell,
1984; Bicknell, Leng, Lincoln & Russell, 1988; Rayner
et al. 1988). Morphine withdrawal by naloxone
administration also results in increased firing of oxyto¬
cinergic neurones and hypersection of oxytocin from
the posterior pituitary gland in non-lactating rats
(Bicknell, Grossmann, Leng & Russell, 1987).
The aim of the present study was to determine the
effects of long-term morphine administration and of
naloxone-induced withdrawal on the secretion of
oxytocin from the median eminence into hypophysial
portal blood. Because opiate withdrawal is considered,
in conscious rats, to constitute a marked stress, the
release of CRF-41 into portal blood in the same ani¬
mals was also measured in order to determine whether
any effect on oxytocin release could simply be due to
non-specific stress. Some aspects of this study have
been reported previously in abstract form (Bicknell,
Coombes, Fink et al. 1988).
MATERIALS AND METHODS
Adult female Sprague-Dawley rats (200-300 g body
weight) supplied by Bantin and Kingman, Hull,
Humberside, U.K. were maintained under controlled
conditions of lighting (12 h light: 12 h darkness) and
temperature (22 °C) and allowed free access to food
(pelleted breeder diet) and tap water. Rats were anaes¬
thetized with ether and implanted stereotaxically with
a cannula positioned with its tip in the lateral cerebral
ventricle. The cannula was connected by way of a
coiled length of polythene tubing to an Alzet 2001
osmotic minipump (Alza Corp., San Diego, CA,
U.S.A.) implanted s.c. By this means the animal
received a continuous intracerebroventricular (i.c.v.)
infusion of either morphine sulphate (supplied by the
Pharmacy, Royal Infirmary ofEdinburgh, Edinburgh,
U.K.; 10 pg/h for 40 h, 20 pg/h for the next 40 h and
50 pg/h for the remainder of the experiment, all infused
at 1 pl/h; Rayner et al. 1988) or vehicle (distilled water).
Five days after the start of infusion of morphine or
vehicle the rats were anaesthetized with urethane (ethyl
carbamate; Sigma, Poole, Dorset, U.K.; 1 -2 g/kg body
weight administered i.p. as a 20% (w/v) solution in 0-9%
(w/v)NaCl) and the hypophysial portal vessels exposed
by the transpharyngeal approach (Worthington, 1966;
Fink & Sheward, 1989). Once the dura overlying the
pituitary gland and median eminence was exposed,
each rat was left undisturbed for h. The purpose
of this delay period was to enable the establishment of
stable baseline concentrations of oxytocin and CRF-
41 in portal blood after surgery. Throughout the
experiment the body temperature was monitored con¬
tinuously and maintained at 37 + 1 °C with the aid of
an electric warming blanket. At the end of the delay
period, the dura mater was cut and the exposure of the
hypophysial portal vessels completed. The pituitary
stalk was cut as close as possible to the pituitary gland
which was removed in its entirety by aspiration. After
a brief delay (less than 5 min) to achieve haemostasis,
heparin (Multiparin; C.P. Pharmaceuticals,Wrexham,
Clwyd, U.K.; 2500 IU) was injected byway of the exter¬
nal jugular vein, and the hypophysial portal vessels re-
cut for the collection ofportal blood (Fink & Sheward,
1989). In some animals the pituitary stalk was cut im¬
mediately after injection of heparin, and the pituitary
gland was left in situ throughout the period of portal
blood collection. The blood which issued from the cut
pituitary stalk in the first 5min was discarded to prevent
the contamination ofblood with tissue fragments from
the cut stalk; thereafter, hypophysial portal blood was
collected into ice-cold plastic tubes for a total of six
consecutive 15-min collection periods. A proteinase
inhibitor (Trasylol; Bayer UK, Newbury, Berks, U.K.;
500 Kallikrein inactivator units/ml blood) was added
to prevent peptide degradation (Fink, Robinson &
Tannahill, 1988). At the end of the third collection
period either 0-9% NaCl (0-5 ml/kg) or naloxone hy¬
drochloride (Sigma; 5 mg/kg in 0-9% NaCl; 0-5 ml/kg)
was injected i.v. by way of the external jugular vein.
Samples of peripheral blood (0-3 ml) were also with¬
drawn periodically from the external jugular vein as
follows: (a) after removal of the pituitary gland and
immediately before the injection of heparin, (b) at the
end ofthe third period ofportal blood collection (50min
after the first sample), (c) 5 min after the i.v. injection
of naloxone or saline and (d) at the end of the final
period of portal blood collection (45 min after i.v.
injection of naloxone or saline). In some animals
which were infused with morphine or vehicle, the pitu¬
itary gland was left in position throughout the exper¬
iment and only 0-9% NaCl (0-5 ml/kg) was injected
i.v. after 45 min of blood collection. At the end of each
experiment, animals were killed by decapitation and
the brain was removed rapidly, placed on an ice-cold
slide and the pituitary stalk-median eminence (SME)
dissected out (Sheward, Watts, Fink & Smith, 1985).
For animals in which the pituitary had remained in
position throughout the portal blood collection, the
pituitary gland was removed from its dural capsule
and the neurointermediate lobe (NIL) dissected away
from the anteror pituitary gland. Samples of SME and
NIL tissue were homogenized in 200 pi ice-cold
0-1 mol HC1/1. All plasma and tissue samples were
stored frozen at —40 °C until radioimmunoassay.
Journal ofEndocrinology (1990) 124, 141-150
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table 1. Mean ± s.e.m. concentrations of oxytocin (pmol/1) in the peripheral plasma of female rats anaesthetized and prepared
for the collection ofhypophysial portal blood after long-term administration ofmorphine sulphate or vehicle into the lateral
ventricle of the brain (i.e. v.). The numbers of animals in each treatment group are shown in parentheses
Concentration of oxytocin (pmol/1)
P, p2 P3 P.
Treatment
Pituitary intact
Vehicle i.c.v. +naloxone i.v. (n= 13) 258 + 69 224+113 1168 + 582*tt 896 + 254f
Morphine i.e.v. + naloxone i.v. (« = 13) 172 + 39 183 + 82 1149+ 192*tt 808 + 299)
Vehicle i.e.v. + saline i.v. (n = 7) 71+20 28 + 13 32+13 134 + 89
Morphine i.e.v. + saline i.v. (« = 7) 110 + 48 101+56 108 ±56 79 + 21
Pituitary removed"
Vehicle i.e.v.-(-naloxone i.v. (n= 11) 12 + 2 5+1 5+1 4+ 1
Morphine i.c.v. +naloxone i.v. (« = 11) 12 + 2 6± 1 5+ 1 5+1
*P<0 05 compared with saline-injected controls (Mann-Whitney U test); f/><0-05, tt/'cO Ol compared with preinjection concentration (p,) (Wilcoxen signed
matched pairs test).
The assay limit for these samples was 3 pmol/1.
The sample p, was withdrawn from the external jugular vein at the start of the first portal blood collection period; 45 min after p, a further sample (p2) was taken
(immediately before the i.v. injection of naloxone hydrochloride, 5 mg/kg, or saline) and sample p3 was taken 5 min later. The final peripheral blood sample (p4)
was taken at the end of the experiment, 45 min after i.v. injection.
Plasma concentrations of oxytocin were determined
by radioimmunoassay of unextracted plasma samples
as described previously (Higuchi, Honda, Fukuoda
et al. 1985). The lower limit of detection of the assay
was 3 0 pmol/1 and inter- and intra-assay coefficients
of variation were 7 and 11% respectively. For deter¬
mination of CRF-41, plasma samples were first
extracted with ice-cold methanol and subsequently
assayed by double-antibody radioimmunoassay using
anti-rat-CRF-41 (IgG Corporation, Nashville, TN,
U.S.A.) as described previously (Fink et al. 1988). All
plasma concentrations of CRF-41 were determined in
a single assay. The lower limit of detection of the
assay was 7-4 pmol/1 and the intra-assay coefficient of
variation was 7-2%. The significance of differences
between groups was determined by theMann-Whitney
U test and Wilcoxon matched pairs signed rank test.
RESULTS
Oxytocin was present in hypophysial portal blood
in higher concentrations than in peripheral blood
(Table 1 and Fig. 1) and there was no significant
difference between the concentration or the content
(concentration x plasma volume collected/15 min) of
oxytocin in portal blood collected from intact rats or
rats in which the pituitary gland was removed at the
time of blood collection (Fig. 1). In contrast, the
concentration of oxytocin in peripheral plasma was
reduced by hypophysectomy to concentrations close to
the detection limit of the radioimmunoassay (Table 1).
In animals in which the pituitary gland was not
removed before portal blood collection, there was
no significant difference in the baseline secretion of




figure 1. (a) Concentration of oxytocin in hypophysial por¬
tal vessel plasma and (b) the total amount released from in¬
tact female rats (hatched bars) or rats in which the pituitary
gland had been removed immediately before the collection
ofportal blood (open bars). Hypophysial portal blood was
collected under urethane anaesthesia for four consecutive
15-min periods. Values are means + s.e.m. for six animals in
each treatment group.
plasma from rats infused with vehicle compared with
rats infused with morphine (Fig. 2). In both morphine-
and vehicle-infused rats the injection of naloxone
resulted in a prompt and sustained increase in the
portal plasma concentration of oxytocin and in the
total amount of oxytocin secreted during each 15-min
Journal ofEndocrinology (1990) 124, 141-150
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figure 2. (a) Mean + s.e.m. concentration of oxytocin in hypophysial portal
blood and (b) the amount ofoxytocin secreted during each of six consecutive
15-min periods ofportal blood collection under urethane anaesthesia from
female rats after 5 days of continuous intracerebroventricular infusion with
either morphine sulphate or distilled water (vehicle). The pituitary gland was
not removed during blood collection. At the end of the third collection period
(arrows) animals were injected i.v. with 5 mg naloxone hydrochloride/kg or
with 0-9% (v/v) NaCl (control). Rats were infused with vehicle and injected
with naloxone (open bars; n= 13), infused with morphine and injected with
naloxone (hatched bars; n— 13), infused with vehicle and injected with saline
(cross-hatched bars; n = 7) or infused with morphine and injected with saline
(shaded bars; n = l).*P< 0-05 compared with control rats (Mann-Whitney U
test); t-P<0 01, tt^><0 005 compared with preinjection values (Wilcoxon
matched pair signed rank test).
collection period, with no significant differences
between the i.e.v. treatment groups (Fig. 2). Similarly,
there was a significant increase in the concentration of
oxytocin in peripheral plasma withdrawn from the ex¬
ternal jugular vein 5 and 45 min after the injection of
naloxone in both vehicle- and morphine-infused rats,
with no significant difference between the two i.e.v.
Journal ofEndocrinology (1990) 124, 141-150
treatment groups (Table 1). Injection of saline, instead
of naloxone, did not result in any significant alteration
in the output of oxytocin into portal blood or the
concentration of oxytocin in peripheral blood in
vehicle- or morphine-infused rats (Fig. 2 and Table 1).
In vehicle- and morphine-infused rats in which the
pituitary gland was removed immediately before the
Effects ofmorphine on oxytocin and CRF-41 secretion w. j. sheward and others
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figure 3. (a) Mean ± s.e.m. concentration ofoxytocin and (b) oxytocin content in
hypophysial portal vessel blood during each of six consecutive 15-min periods of
blood collection from urethane-anaesthetized female rats after 5 days ofcontinu¬
ous intracerebroventricular infusion ofmorphine sulphate (open bars) or vehicle
(hatched bars). The entire pituitary gland was removed by aspiration immediately
before the start of the first period of blood collection. Naloxone hydrochloride
(5 mg/kg) was injected i.v. at the end of the third period ofcollection (arrows).
There were 13 animals in each treatment group. *P< 0 005, **jP< 0-001 compared
with vehicle-infused rats (Mann-Whitney U test); t-f< 0-01, ff.P< 0-005 com¬
pared with preinjection value (Wilcoxon matched pairs signed rank test).
start of hypophysial blood collection, there was no
significant difference in the secretion of oxytocin into
either portal or peripheral blood before the injection
of naloxone (Table 1). However, in morphine- but not
vehicle-treated rats, the injection of naloxone resulted
in a significant increase in both the concentration of
oxytocin and the total amount of oxytocin in portal
plasma during each successive 15-min collection period
(Fig. 3). In both vehicle- and morphine-infused rats,
the concentration of oxytocin in peripheral plasma
after hypophysectomy was close to the lower limit of
detection of the assay (3-0 pmol/1) and was not affected
by the i.v. injection of naloxone (Table 1).
Table 2 shows the oxytocin content of the median
eminence and neurointermediate lobeofmorphine- and
vehicle-infused rats. Although in morphine-dependent
rats in which the pituitary gland remained in situ
throughout the blood collection period the content
of oxytocin in the median eminence was apparently
depleted by administration of naloxone; this finding
was not confirmed in hypophysectomized rats. The
content of oxytocin in the neurointermediate lobe was
not altered significantly by administration ofmorphine
or naloxone.
Figure 4 shows that CRF-41 was present in hypo¬
physial portal plasma collected from acutely hypo¬
physectomized rats; concentrations were high relative
to those reported in peripheral plasma, and with
the assay system used the concentrations of CRF-41
in peripheral plasma from the rats anaesthetized
with urethane were below the limit of detection
(<7-4 pmol/1). The secretion of CRF-41 into hypo¬
physial portal plasma did not differ significantly
between morphine- and vehicle-infused rats and was
not affected by administration of naloxone.
There were no significant differences in the volumes
of portal blood collected from rats with intact pitu-
itaries or hypophysectomized rats infused with either
vehicle or morphine and the portal blood flow was not
appreciably altered by the i.v. injection of naloxone or
Journal ofEndocrinology (1990) 124, 141-150
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table 2. Mean + s.e.m. content ofoxytocin in the median eminence (pmol/median eminence) or
neurointermediate lobe (nmol/neurointermediate lobe) of female rats after long-term infusion
ofmorphine sulphate or vehicle into the lateral cerebral ventricle (i.e. v.) and i.v. injection of
naloxone hydrochloride or saline. The numbers of animals in each treatment group are shown in
parentheses
Content of oxytocin
Median eminence (pmol) Neurointermediate lobe (nmol)
Treatment
Pituitary intact
Vehicle i.e.v. + naloxone i.v. 12-0+ l-8*f 1 -8 + 0-2f
(" = 1D ("= 11)
Morphine i.c.v. + naloxone i.v. 5-9 + 0-4* 1-6 + 0-3
("=H) (" = H)
Vehicle i.c.v. + saline i.v. 7-0+1-0 0-9 + 0-1
(n = 6) (« = 7)
Morphine i.c.v. + saline i.v. 8-5 + 0-9 1-1+0-1
(" = 7) (« = 7)
Pituitary removed
Vehicle i.c.v. + naloxone i.v. 9-7 + 0-8 —
(" = 13)
Morphine i.c.v. + naloxone i.v. 9-9 + 0-9 —
(" = 13)
*P< 0-05 compared with vehicle-saline group; f/><0-01 compared with morphine-saline group; ZP < 0-001 compared with
morphine-naloxone group (Mann-Whitney U test).
saline. The mean (± s.e.m.) volume of portal blood
collected from the various treatment groups ranged
between 123+14 and 267 ± 64 pi/15 min.
DISCUSSION
Ourmajor finding was that the release of oxytocin into
hypophysial portal blood, like the release of oxytocin
into the systemic circulation, can be made morphine
dependent. We have also confirmed that hypophysial
portal plasma contains high concentrations ofoxytocin
(Gibbs, 1984; Sarkar & Gibbs, 1984; Horn et al. 1985)
and CRF-41 (Plotsky, Otto & Sapolsky, 1986; Fink
et al. 1988) relative to peripheral plasma, and that the
output of oxytocin is unaffected by the removal of the
pituitary gland immediately before portal blood col¬
lection (Sarkar & Gibbs, 1984; Horn et al. 1985). The
source of the oxytocin in portal blood is most likely to
be a projection from the paraventricular nuclei of the
hypothalamus to the portal vessels, but the possibility
cannot be excluded that, as suggested for vasopressin
(Holmes, Antoni, Aguilera & Catt, 1986), oxytocin
may be released from oxytocinergic fibres passing
through the internal layer of the median eminence.
Ultrastructural studies suggest that oxytocin may be
released collaterally from axons or axon swellings of
magnocellular neurones (Buma & Nieuwenhuys, 1988;
Morris & Pow, 1988).
The present results show that there was no significant
difference between the secretion ofoxytocin into portal
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blood of morphine- and vehicle-treated rats, suggest¬
ing the rapid development of tolerance to the effects of
morphine on oxytocin release. Such tolerance to the
effects of continuous administration of morphine
develops rapidly (within the first 2-3 days) in the
neurohypophysial oxytocin system (Russell, 1984;
Bicknell et al. 1987). The immediate increased release
of oxytocin into portal blood following administration
of the opiate antagonist, naloxone, shows that the
oxytocin neurones which project to the median
eminence have been made morphine-dependent by
long-term administration of opiates. In morphine-
infused rats in which the pituitary gland was left in situ
during the portal blood collection, concentrations of
oxytocin in peripheral plasma were increased markedly
following administration of naloxone. Antagonism of
endogenous opioids released within the neurohypo¬
physis is probably responsible for this effect, since
neurohypophysial opioid receptors are of the K-type
and insensitive to p-opioid agonists such as morphine
(Coombes & Russell, 1988; Zhao, Chapman & Bicknell,
1988). This interpretation is supported by the finding
of a similar rise in peripheral oxytocin seen following
administration of naloxone in the pituitary-intact rats
infused with vehicle. Previous in-vitro studies have also
demonstrated a lack of opiate dependence at the level
of the neurohypophysis in morphine-treated animals
(Bicknell, Chapman, Leng & Russell, 1985). The
increase in oxytocin concentration in portal blood, in
response to naloxone in vehicle-treated animals from
which the pituitary gland was not removed, may be




























figure 4. (a) Mean + s.e.m. concentration and (b) content of
corticotrophin-releasing factor-41 (CRF-41) in hypophysial
portal blood from female rats under urethane anaesthesia
after intracerebroventricular infusion of either vehicle
(hatched bars) ormorphine sulphate (open bars) for 5 days.
Data shown are concentration and content ofCRF-41
for the third, fourth and fifth of six consecutive 15-min
periods of blood collection; after the third collection period
(arrows) animals were injected i.v. with 5 mg naloxone
hydrochloride/kg. The entire pituitary gland was removed
immediately before starting the blood collection. There were
13 animals in each treatment group.
due to oxytocin in backflow blood from the pituitary.
Alternatively, endogenous opioids from the pituitary
gland could conceivably inhibit oxytocin release, an
effect blocked by naloxone. In contrast, in hypophy-
sectomized rats infused with vehicle, administration
of naloxone did not stimulate any increase in oxytocin
output into portal blood, suggesting that whilst the
oxytocinergic neurones which project to the neuro¬
hypophysis and those which project to the median
eminence are sensitive to the actions of morphine
these neurones differ from one another with respect
to their sensitivity to endogenous opioids. In the case
of the oxytocinergic neurones which project to the
neurohypophysis, it is evident that, under urethane
anaesthesia, it is their terminals in the posterior pitu¬
itary that are under endogenous opioid tone and not
their cell bodies (Bicknell et al. 1988). Clearly, with
respect to the neurones which project to the median
eminence, neither their cell bodies nor their terminals
in the median eminence are under endogenous opioid
inhibition, at least during urethane anaesthesia.
Although the present results demonstrate that the
secretion of oxytocin into portal blood can be modi¬
fied by naloxone after pretreatment with morphine,
the site of action and nature of the opioid receptor
involved has yet to be elucidated. Naloxone may act
directly on receptors on the cell bodies of oxytocinergic
neurones in theparaventricular (or supraoptic) nucleus,
on the afferent input to these neurones or, alternatively,
on the oxytocinergic terminals in themedian eminence.
In lactating rats, opiate withdrawal following long-
term administration ofmorphine resulted in a 25-fold
increase in plasma oxytocin concentration together
with a three- to fourfold increase in the firing rate of
oxytocin neurones in the supraoptic nucleus, whereas
in vehicle-infused rats injection with naloxone also
resulted in increased secretion of oxytocin, but no
change in the firing rate. Such an effect on the electrical
activity of the oxytocinergic neurones which project
to the median eminence could explain the increased
secretion of oxytocin into portal blood after naloxone-
induced withdrawal in morphine-dependent rats. It
is the effect on electrical activity, together with the
reversal of endogenous opioid inhibition in the pos¬
terior pituitary, which accounts for the increased
secretion of oxytocin from the posterior pituitary
into peripheral blood in morphine-dependent rats.
Although the lack of effect of naloxone on oxytocin
secretion into portal blood in i.e.v. vehicle-treated rats
indicates lack of endogenous opioid influence on these
neurones under urethane anaesthesia, the enhanced
secretion ofoxytocin induced by naloxone in morphine-
dependent rats indicates nonetheless that opioid
receptors are available to influence these neurones,
and that endogenous opioids could inhibit their
activity. In particular, these receptors are likely to be
p-type opioid receptors (Leng, Russell & Grossman,
1989). As discussed above, there may be actions of
opioids on the inputs to these neurones, or on their
terminals in the median eminence. P-Endorphin,
dynorphin(l-17) and the enkephalins are all present
in portal blood (Wardlaw, Wehrenberg, Ferin et al.
1980; Castanas, Giraud, Drissi et al. 1984; Sarkar &
Yen, 1985). Dynorphin(l-17) could be co-released
from vasopressinergic neurones which synthesize this
opioid (Anhut & Knepel, 1982; Watson, Akil, Fischli
et al. 1982; Fiston & Rossier, 1984); there is some evi¬
dence that oxytocinergic neurones themselves produce
[Met]-enkephalin (Martin, Geis, Holl et al. 1983;
Vanderhaeghen, Fotstra, Fiston & Rossier, 1983); p-
endorphin in portal blood presumably is secreted by
arcuate nucleus neurones. Similarly, this range of
Journal ofEndocrinology (1990) 124, 141-150
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opioids could act after central release at the level of the
cell bodies. Further studies are necessary to identify the
endogenous opioids which regulate the secretion of
oxytocin into portal blood.
Despite the greater release of oxytocin from the
median eminence after injection with naloxone in
morphine-dependent rats in comparison with vehicle-
infused rats, there was no consistent evidence of
greater depletion of median eminence oxytocin in the
former (Table 2). In morphine-dependent hypophy-
sectomized rats the injection of naloxone resulted in
an increase of 150fmol oxytocin released in 45 min,
which represents approximately 1-5% of the total
median eminence content of oxytocin. Similarly,
naloxone did not significantly deplete the neurohypo¬
physis of oxytocin (Table 2), despite the large and sus¬
tained increase in peripheral blood concentration of
oxytocin (Table 1). It can be concluded that the stores
of oxytocin in both the neurohypophysis and median
eminence are adequate to meet major acute demands
for increased secretion. Long-term i.c.v. infusion of
morphine had no detectable effect on oxytocin con¬
tent in the neurohypophysis or median eminence
(Table 2); similarly, the oxytocin mRNA content of
neurones in the supraoptic nuclei is not affected
(Sumner, Kawata & Russell, 1989).
In the present experiments, insufficient plasma
remained after assay of oxytocin and CRF-41 to
enable the assay of arginine vasopressin (AVP). How¬
ever, Bicknell et al. (1985) showed, that in contrast to
oxytocin, there were only small and transient
increases in the peripheral plasma concentration of
AVP in morphine-treated rats after i.v. injection of
naloxone.
One possible interpretation of the present and pre¬
vious findings is that the oxytocin reponse to naloxone
in morphine-dependent rats is a non-specific stress
response. However, several measures of so-called
stress hormones argue against this. First, naloxone did
not stimulate ACTH release in morphine-dependent
rats anaesthetized with urethane (Russell, Antoni,
Coombes & Robinson, 1988/)). Secondly, we found no
significant difference between the baseline secretion of
CRF-41 into portal blood of morphine- and vehicle-
treated rats, and CRF-41 output was unaffected by the
injection of naloxone. Thirdly, although adminis¬
tration of opiates increases the secretion of prolactin
and growth hormone (Deyo, Swift, Miller & Fang,
1980; Wehrenberg, Bloch & Ling, 1985), and stress¬
ful stimuli increase prolactin secretion (Samson,
McDonald & Lumpkin, 1985) and decrease growth
hormone secretion (Terry, Willoughby, Brazeau et al.
1976), the plasma concentrations of these hormones
are not altered by naloxone-induced opiate withdrawal
in the model used in the present experiments (Russell,
Antoni, Bicknell et al. 1988a; Russell et al. 1988/)).
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Thus it appears that the hypersecretion of oxytocin
after administration of naloxone is a specific effect on
this system and not a general 'stress response' caused
by abrupt withdrawal of opiates.
The present experiments and those of Russell et al.
(1988/)) show that the in-vivo secretion of CRF-41
and ACTH in morphine-dependent rats anaesthe¬
tized with urethane was not affected by adminis¬
tration of naloxone. This would appear to conflict
with the finding of other groups, who reported that
ACTH release was increased by naloxone treatment
(Buckingham & Cooper, 1987; Donnerer & Lembeck,
1988). However, it must be stressed that changes in
ACTH release may be mediated by factors other than
CRF-41, such as AVP and/or adrenaline (Antoni,
1986). Plotsky (1986) reported that naloxone increased
CRF-41 release into portal blood, but in contrast to our
i.v. administration, Plotsky infused naloxone by the
i.c.v. route. Administration of naloxone to morphine-
dependent rats also increased the content of CRF-41
mRNA in the parvocellular division of hypothalamic
paraventricular nuclei (Lightman & Young, 1988);
however, there is not necessarily a close relationship
between neuropeptide mRNA concentration and
neuropeptide release.
It is possible that the secretion ofCRF-41 in animals
prepared for portal blood collection might be maximal
after surgery in both morphine- and vehicle-infused
rats, and this could explain the lack of a response by
CRF-41 to naloxone. However, this is an unlikely
explanation since it is possible to use the portal blood
collection technique to demonstrate increases in the
secretion of CRF-41 in response to long-term adrenal¬
ectomy or hypophysectomy (Fink et al. 1988; W. J.
Sheward & G. Fink, unpublished data). Fink et al.
(1988) have shown that rats anaesthetized with
urethane have increased plasma concentrations of
ACTH and corticosterone in comparison with ani¬
mals anaesthetized with pentobarbitone. However, in
the present experiments, in rats anaesthetized with
urethane, and with a 3-4 h delay period before collect¬
ing portal blood, the portal plasma concentration and
content of CRF-41 did not differ from the values
reported in animals anaesthetized with sodium pento¬
barbitone (Fink et al. 1988). Our findings on CRF-41
secretion into hypophysial portal blood, therefore,
provide an important positive controlwhich shows that
the effect ofnaloxone on oxytocin release is specific and
not simply a general stress effect on neuroendocrine
systems.
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OPIOID RECEPTOR SUBTYPES IN THE SUPRAOPTIC
NUCLEUS AND POSTERIOR PITUITARY GLAND OF
MORPHINE-TOLERANT RATS
B. E. H. Sumner,* J. E. Coombes, K, M. Pumford and J. A. Russell
Department of Physiology, University Medical School, Teviot Place, Edinburgh EH8 9AG, U.K.
Abstract—Morphine, given acutely, inhibits oxytocin secretion in adult female rats, but chronic
intracerebroventricular infusion for five to six days induces tolerance and dependence in the mechanisms
regulating oxytocin secretion. One explanation for tolerance could be that there is a loss of opioid
receptors.
To test this hypothesis cryostat sections of selected brain regions and the pituitary, from six control
and six intracerebroventricular morphine-infused rats, were processed for quantitative in vitro receptor
autoradiography. [3H]Etorphine or [3H]( — )-bremazocine were used as ligands, and DAGO, DPDPE and
U50,488H as selective displacers from /t-, 5-, and K-receptors, respectively. Control incubations had
naloxone determined specificity. The supraoptic nucleus (site of oxytocin-secreting magnocellular
perikarya) contained both n- and k-receptors in control rats (mean + S.E.M. binding of //-selective
[3H]etorphine was 91.8 ± 25.4 fmol/mg of tissue, and of k-selective [3H](—)-bremazocine was
130.4 + 25.6 fmol/mg). Chronic morphine treatment caused a 83.9% decrease in binding in //-selective
conditions (P <0.05). but no significant change in k-selective binding. In the median preoptic nucleus
(which projects to the supraoptic nucleus) mean + S.E.M. binding of [3H]etorphine decreased by 77.0%
(P <0.01) in chronic morphine-treated rats, from the control value of 76.2 ± 9.8 fmol/mg of tissue. In the
posterior pituitary gland (site of the terminals of the oxytocin-secreting magnocellular perikarya) binding
with [3H]( — )-bremazocine in controls was over 90% lower than in the supraoptic nucleus. No changes
followed chronic morphine treatment.
Thus chronic morphine exposure reduces the numbers of available //-receptors in the supraoptic
nucleus, and of opioid receptors in the median preoptic nucleus, perhaps accounting for morphine-
tolerance in relation to oxytocin secretion.
The inhibitory effects of opiates on oxytocin secretion
were first demonstrated only a decade ago.18 Since
then inhibitory actions of both exogenous opiates and
endogenous opioids have been shown in a range of
studies on the oxytocin system, mainly in the rat (e.g.
see Refs 20, 48, 50). Morphine acts centrally by
inhibiting the firing rate of continuously firing (puta-
tively oxytocin-secreting) neurons in the supraoptic
nucleus (SON).6'58 Endogenous opioids act also on
oxytocin-releasing nerve terminals in the posterior
pituitary (PP) gland.3'5'6 Opioids can also inhibit
vasopressin secretion in vivo,2 but their effects on
perikaryal electrical activity are inconsistent,58 and
their action on vasopressin release from the PP is less
striking,35'17'58 except for a dose-dependent inhibition
by ethylketocyclazocine,55 and U50,488H.60'61
*To whom correspondence should be addressed.
Abbreviations'. AV3V region, region anterior and ventral to
the third ventricle; DAGO, Tyr-D-Ala-Gly-MePhe-
NH(Ch2)2OH, a //-type opioid receptor agonist;
DPDPE, [d-Pen2, d-Pen5]-enkephalin, a <5-type opioid
receptor agonist; G;, inhibitory guanine nucleotide-
binding protein; MPN, median preoptic nucleus; PP,
posterior pituitary; SON, supraoptic nucleus; U50, 488H
trans-( ± )-3,4-dichloro-A'-methyl-A'-(2-[l-pyrrolidinyl]-
cyclohexyl) benzeneacetamide, methane sulphonate salt,
a K-type opioid receptor agonist.
The actions of opioids in brain are mediated by
three principal opioid receptor subtypes, classified by
agonist selectivity.U2,63 Mansour et al.2A~36 and Tem-
pel and Zukin57 have surveyed the distribution of //-,
3- and k-type opioid receptors in the rat brain, using
in vitro receptor autoradiography. In the SON, k-
type receptors but not //-or 5-receptors were found,
yet both //- and k-opioid receptor agonists inhibit
the electrical activity of SON neurons.49 In the PP,
k-type receptors predominate, with few //-receptors
and no <5-receptors;12'25 k-selective, but not //- or
3-selective, agonists inhibit oxytocin secretion at this
site.7'19
Chronic morphine exposure leads to tolerance (loss
of opiate effect, or a requirement for a larger dose to
achieve the initial effect) and dependence (revealed as
hyperexcitation on withdrawal). Both changes are
seen in the mechanisms regulating oxytocin secretion
in the rat after i.e.v. infusion of morphine for five
days.6-43-54 In contrast, dependence does not develop
in the vasopressin system.6
One possible explanation for opioid tolerance is
that the number of opioid receptors on tolerant
neural elements diminishes. Previous in vitro autora¬
diographic studies on cryostat sections of morphine-
tolerant rat brain found either no change in total
opioid receptor numbers,21 or an up-regulation of
// -receptors,10 but with no observations on the SON
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or PP. Studies on 3H-ligand-binding to other brain
preparations have also yielded conflicting results in
morphine-tolerance.8,27,28,42,45,46,52,56,59 However, most
of these studies did not distinguish between opioid
receptor subtypes, and none focused on the SON and
PP. The aims of the present study were to measure the
densities of p- and x-opioid receptor subtypes in the
SON and PP in normal and morphine-tolerant female
rats, to try to explain morphine-tolerance in relation
to oxytocin neurons.
We also measured opioid receptor density in the
median preoptic nucleus (MPN), which is part of the
region anterior and ventral to the third ventricle
(AV3V region) that projects to the supraoptic




The following were used as probes for opioid receptors
in vitro, (i) [3H]Etorphine (50 Ci/mmol = 1.85 TBq/mmol
Amersham);12,33 (ii) [3H](—)-bremazocine (21.3 Ci/mmol =
0.79 TBq/mmol, NEN).9,38
The following were used as competitive displacers of the
3H-ligands from individual opioid receptor subtypes, (i)
Tyr-d-Ala-Gly-MePhe-NH(CH,), OH. or DAGO (cat. No.
PB2000A, Cambridge Research Biochemicals), for displace¬
ment from p-receptors;34 (ii) [d-Pen2, d-Pen5]-enkephalin, or
DPDPE (cat. No. E-0260, Sigma), for displacement from
<5-receptors;34,40 (iii) trans-( + )-3,4-dichloro-7V-methyl-N-
(2-[l-pyrrolidinyl]cyclohexyl) benzeneacetamide, methane
sulphonate salt, or U50,488H, (cat No. D-0908, Sigma) for
displacement from k-receptors.16,38 To test specificity, nalox¬
one hydrochloride (cat. No. N-7758, Sigma) was used.
Intracerebroventricular infusion
Adult virgin female albino Sprague-Dawley rats were
implanted stereotaxically under ether anaesthesia with a
cannula in a lateral cerebral ventricle, for continuous infu¬
sion from a subcutaneous osmotic minipump (Alzet, 2001)
of either morphine sulphate (10 p g/h for 40 h increasing to
20 /z g/h, and then 50 g/h, each for 40 h), or vehicle (sterile,
pyrogen-free distilled water, 1 /tl/h).43 There were six rats in
each group, and the mean + S.E.M. body weights were
274.8 + 5.1 g in the morphine group and 288.8 + 8.7 g in the
vehicle group.
Tissue preparation
After five days of i.e.v. infusion, the rats were decapitated,
their brains removed, and from each a thick coronal slice
was cut extending from approximately 1 mm anterior to the
optic chiasma, to the posterior limit of the mammillary
body. Each slice was frozen onto a pre-cooled layer of
Tissue-Tek II OCT compound (Miles Laboratories) on a
cryostat chuck, in crushed dry ice. The pituitary gland
containing the PP was frozen similarly after orientation for
coronal sectioning.
Cryostat sections were cut at 10 /im, and thaw-mounted
onto acid-cleaned, chrome alum-gelatine-subbed slides.
From each rat for each incubation category there were four
sections containing two SON profiles each, four sections of
the MPN, and four sections of the PP. Mounted sections
were stored at — 20°C for up to three weeks before incu¬
bation.
Detection of opioid receptors
An incubating medium containing a broad-spectrum 3H-
ligand (2 nM), without additional agonists, was used for
total opioid receptors, but for receptor subtypes two unla¬
beled selective agonists were included (2/jM each)57 with
the 3H-ligand, with the intention of competitively displacing
the 3H-ligand from all but the third receptor subtype. In
pilot studies, higher concentrations of displacer (up to
50 pM) did not reduce 3H-ligand-binding further. The auto¬
radiographic images from different incubation categories
(see Results) suggested that at 2^M the displacers were
effective and selective in the protocol for either 3H-ligand.
[3H]Etorphine (with displacers) was used for /r-receptors
in brain, but [3H]( — )-bremazocine (with displacers) was
used for k-receptors, since pilot studies showed more bind¬
ing by [3H](—)-bremazocine than by [3H]etorphine in brain
sections when DAGO and DPDPE were present. Only
[3H](—)-bremazocine (with or without displacers) was used
for the pituitary, since we obtained negligible specific la¬
belling with [3H]etorphine, even after long exposure. Neither
3H-ligand gave measurable binding in the presence of
DAGO and U50, 488H at either site, or elsewhere in brain
sections, so quantitative analysis of this category was omit¬
ted. Control sections were incubated with 2 nM 3H-ligand
and 2pM naloxone hydrochloride to antagonize all binding
to opioid receptors. In pilot studies, higher concentrations
of naloxone (up to 20 /iM) did not further reduce binding.
Further control sections were incubated with 3H-ligand
containing all three displacers to control for possible direct
chemical interaction between naloxone and [3H]etorphine,
and this reduced binding like naloxone; the effects of
naloxone were used to calculate specific binding (see below).
Other control sections were incubated without 3H-ligand to
test for chemography. None of these sections produced
autoradiographic images. The incubation categories and
protocols are shown in Tables 1 and 2. Sections were
brought to room temperature and then preincubated to
detach and wash out endogenous opioid or exogenous
opiate. We used procedures optimized for each 3H-ligand by
others;9,12 Na+ was not included in the incubating medium
with [3H]etorphine to seek to distinguish high/low affinity
binding to p -receptors.13 The preincubating and incubating
solutions, made up in deionized double-distilled water, were
applied as a 40- or 20-/H puddle to each brain or pituitary
section, respectively, on slides in moist chambers. After
ice-cold immersion washes, the slides were air-dried, and
stored desiccated at 0-A°C for less than 48 h before auto¬
radiography. All the slides from a pair of control and
morphine-treated rats were processed identically at the same
time.
Autoradiography
Slides at room temperature were apposed to Hyperfilm-
3H (Amersham), keeping similarly incubated slides from
each pair of rats adjacent. A 5-/rm section of a tritium
standard (3H-microscales, Amersham) was applied to each
film. The loaded films were clamped between mirror-coated
glass plates with adhesive tape, sealed in light-tight wrap¬
pers, and exposed in the dark at 0-4=C.
The optimum exposure periods (determined empirically
to produce grain densities over tissue that were below
saturation for all positive incubations) were nine weeks for
brain sections and 16 weeks for pituitary sections. The
exposed films were separated from the slides, developed at
18°C in Kodak D19 developer (5 min), rinsed in tap water,
fixed in Ilford Hypam rapid fixer (two changes, 5 min each,
of 1:4 fixer:tap water), washed for 30 min in running water,
then air-dried. The sections were fixed for 10 min in acetic
acid:absolute ethanol:commercial formalin (1:17:2 by
volume), dehydrated, rehydrated, stained for 15 min in
1% aqueous Cresyl Fast Violet, dehydrated, cleared, and
mounted in DPX.
Image analysis
Pieces of film were first cut out and attached to slides.
Subjective assessment. Autoradiographs were matched
with the stained sections in a Wild M3 binocular dissecting
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Table 1. Incubation categories for the detection of opioid receptor subtypes in the different
tissue regions
Intended selectivity for different Tissue region(s)
Incubation category opioid receptor subtypes probed
[3H]Etorphine alone All subtypes SON and MPN
(without displacers) (non-selective)
[3H]Etorphine + DPDPE //-receptor selective SON
+ U50.488H
[3H]Etorphine + naloxone No naloxone-sensitive SON and MPN
opioid receptors detected
[3H]Etorphine + DAGO No //-, <5-, or K.-receptors SON and MPN
+ DPDPE + U50,488H detected
No 3H-ligand, but No receptors of any kind SON and MPN
['Hjetorphine protocol detected
[3H](—)-Bremazocine alone All subtypes SON and PP
(without displacers) (non-selective)
[3H](—)-Bremazocine + // -receptor-selective PP
DPDPE + U50,488H
[3H] — )-Bremazocine + k -receptor-selective SON and PP
DAGO + DPDPE
[3H]( — )-Bremazocine + No naloxone-sensitive SON and PP
naloxone opioid receptors detected
[3H](—)-Bremazocine + DAGO No //, 6-, or k -receptors SON and PP
+ DPDPE + U50.488H detected
No 3H-ligand, but No receptors of any kind PP
[3H](—)-bremazocine protocol detected
microscope (magnification: x 16), to identify appropriate
brain regions.41 Regional silver-grain density was graded on
a subjective scale of 0, +, ++, + + +, and + + ++
(none, weak, moderate, moderately strong, strong).
Quantitative assessment of autoradiographs. The
boundaries of the SON, MPN, and PP profiles were first
scored with a needle-point on the film under the dissecting
microscope. Silver-grain density in these regions was
measured with a Joyce-Loebl //Magiscan image-analysing
computer, receiving video input from a Philips black and
white Video 40 camera (with a Newvicon tube) mounted on
a Vickers M17 microscope.54 Microscope magnification was
x 10 (objective), and xl.6 (intermediate lens); the video
monitor scale factor was 1.1878 pm per pixel. The rectangu¬
lar counting frame (201.63 x 133.04 //m) was set to be
smaller than the average area of the SON, to make measure¬
ments in the dorsal SON, where oxytocin perikarya predom¬
inate.44-54 The same counting frame was used for both MPN,
and for the PP where separate central and peripheral
measurements were made because more opioid receptors
have been found in the oxytocin terminal-rich periphery.9-25
Silver-grain density was calculated from the fraction:
total area of silver deposit
, as justified previously.
total area of counting frame
Grain densities over tissue were corrected by subtraction
of a background count (measured over nearby tissue-free
film). For each rat the mean grain density was determined
for each tissue region (eight, four and four images of SON,
MPN, or PP, respectively) in each incubation category. The
mean grain density representing specific binding to opioid
receptors was obtained by subtraction of the mean grain
density over the corresponding naloxone control sections, if
significantly above background (paired /-test). Then, since
tissue from morphine- and vehicle-treated rats was co-
processed in pairs, the mean grain densities in each incuba¬
tion category were compared by the paired /-test.
For conversion to absolute values, grain densities were
measured similarly, in triplicate, and backgrounds sub¬
tracted, for each step of the standard scale on each sheet of
film. A mean standard curve of grain density against
radioactivity in terms of its brain-gray matter-tissue equiv¬
alent (calibrated by Geary and Wooten for Amersham), was
computed for the SON and MPN analysis (nine weeks
exposure) and for the PP analysis (16 weeks exposure), and
fitted to a power function (y = 0.27 a0'23 and r = 0.97, for
the SON and MPN standard curve, and y = 0.34 a:014 and
r = 0.96, for the PP standard curve). Tissue radioactivity
values (nCi/mg of tissue), were then calculated from the
mean grain densities, and were converted to fmol of 3H-
ligand bound per mg of tissue, by reference to the specific
activity of the 3H-ligand. Specific binding to opioid recep¬
tors was obtained by subtracting binding in the presence of
naloxone.
I.c.v. morphine and control group mean 3H-Iigand-
binding values were compared by Student's /-test.
Preincubation tests
To test the efficiency of the preincubation wash procedure
in detaching opioids or opiates from the tissue, brain
sections were preincubated for 0, 1, 10, 15, 30, 45, 60, 75,
or 90min, incubated with [3H]etorphine (//-selective for
SON; non-selective for MPN), and then processed and
analysed as above.
Blood plasma analysis
Trunk blood was collected from each rat into heparinized
tubes, plasma separated immediately by centrifugation, and
stored at — 20°C. Measurements were made of (i) oxytocin
concentration by radioimmunoassay (Higuchi et al.26) to
assess tolerance; (ii) glucose concentration (using a
Boehringer Kit; Glucosa GOD-Perid) since morphine raises
blood glucose concentration, but tolerance develops;23 (iii)
osmolality and sodium concentration43 to assess hydro-




Subjective assessment. Representative autoradio¬
graphs of the SON in a control rat are shown in
Fig. 1. Using [3H]etorphine alone the SON was
moderately strongly labelled (+ + +), as was adja-
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cent gray matter in the hypothalamus and thalamus.
White matter gave only a feeble image (0 to +). The
strongest labelling was in patches in the caudate-
putamen, and in the amygdala (+ + + +). Elsewhere
in the caudate-putamen, amygdala, and cerebral
cortex, labelling was moderate (++)■ The pattern
and intensity of labelling was similar in sections
probed with [3H]etorphine and DPDPE and
U50,488H. Sections probed in the presence of DAGO
and U50.488H gave only weak images (0 to +) in the
SON and elsewhere.
Sections probed with [3H]( — )-bremazocine alone
gave strong images in which the pattern of labelling
resembled that shown by pH]etorphine, except that
the cerebral cortex and caudate-putamen were more
heavily labelled (+ + to + + + ). The SON was
moderately strongly labelled (+ + +). Sections
probed with pEI](— )-bremazocine and DAGO and
DPDPE gave moderate images in the SON and
elsewhere in the hypothalamic gray matter (++).
The intense patches in the caudate-putamen and the
amygdala, probed with either 3H-ligand alone, or
with [3H]etorphine and DPDPE and U50,488H, were
absent from sections probed with pH]( — )-brema-
zocine and DAGO and DPDPE.
Specificity control sections, incubated with 3H-
ligand either with naloxone, or with all three
unlabelled displacers, gave extremely faint images.
In morphine-treated rats, the pattern of labelling
was similar to control rats, but there was a decrease
in intensity in sections incubated with p3H]etorphine
and DPDPE and U50,488H.
Quantitative assessment. The results for the SON
are shown in Table 3, and Fig. 2. Specific (naloxone-
displaceable) binding was over 97% of the total
binding in SON sections probed by 3H-ligand alone.
The grain density over the SON incubated with
p3H]etorphine alone was reduced by 26.9% in the
chronic morphine group (P < 0.05; Student's paired
t-test). With [3H]etorphine, DPDPE and U50,488H
the decrease was 46.9% (P < 0.02). There was no
significant difference between morphine- and vehicle-
treated rats for any other incubation category. In the
SON of control and morphine-treated rats the group
mean (+S.E.M.) specific binding of [3H]etorphine
alone was 102.0 ± 10.5 and 51.7 ± 25.4 fmol per mg
of tissue, respectively (not significant). Over SON
profiles probed by [3H]etorphine and DPDPE
and U50,488H, mean binding was 91.8 + 25.4 and
14.8 ± 7.5 fmol per mg of tissue in the control and
morphine groups, respectively (83.9% decrease,
P < 0.05, Student's r-test).
Specific binding of [3H]( — )-bremazocine alone in
the SON was not significantly altered by i.e.v. mor¬
phine treatment. In the control and morphine groups
the means were 125.7 ± 35.0 and 70.9 + 24.8 fmol per
mg of tissue, respectively. Similarly, treatment group
means for SON probed with [3H]( — )-bremazocine
and DAGO and DPDPE showed no significant





Fig. 1. (Top row) S is part of a 10-/rm coronal section of rat brain, incubated with [3H]etorphine, apposed to Hyperfilm-3H
for nine weeks, then fixed in acetic acid-ethanol-formalin, and stained with Cresyl Fast Violet. The SON is the small
dark-staining area between the black triangles. The upward-pointing arrow is on the midline. A is the autoradiographic
image corresponding to S, processed on the Hyperfilm-3H after separation of S from the film. The position of the SON
is indicated as in S, and the downward-pointing arrow is on the midline. Magnification x 6. (Second and third rows)
Autoradiographic images of sections incubated with [3H]etorphine alone (Et), or with [3H]etorphine and DPDPE and
U50,488H (Eu), or with [3H]( — )-bremazocine alone (Bt), or with [3H](— )-bremazocine and DAGO and DPDPE (Bk), or
with [3H]( — )-bremazocine and naloxone to antagonize all binding to opioid receptors (Bn). In [3FI]etorphine alone (Et),
the SON is between the black triangles, and the arrow indicates intense patches of labelling in the caudate-putamen. For
further neuroanatomical details, see Paxinos and Watson.41 Magnification x 4. (Fourth and fifth rows) Autoradiographic
images of sections from an i.e. v. vehicle-infused rat (V), and an i.e. v. morphine-infused rat (M), incubated with [3H]etorphine
and DPDPE and U50,488H following 0, 15, or 90 min preincubation as indicated. Magnification x 4.
640 B. E. H. Sumner et at.
Table 3. Treatment group means (+ S.E.M.) of mean grain densities in autoradiographs of the supraoptic nucleus, median















[3H]Etorphine + DPDPE + U50.488H
[3H](— )-Bremazocine alone













MPN [3H]Etorphine alone 0.36 + 0.01 0.25 ± 0.02 P < 0.05
PP [3H](— )-Bremazocine alone
[3H]( — )-Bremazocine + DAGO + DPDPE










Data are expressed in pm2 of silver deposit per pm2 of field; specificity control values subtracted, n.s., not significant.
(means + S.E.M. were 130.4 + 25.6 and 95.5 +
16.0 fmol per mg of tissue).
Without the preincubation step, the mean binding
of [3H]etorphine with DPDPE and U50,488H in
chronic morphine-treated tissue was not significantly
different from the binding after incubation with
[3H]etorphine and all three selective agonists. With
only 1 min of preincubation, the mean binding in the
presence of DPDPE and U50.488H in morphine-
treated tissue had risen to 15.1% of the value in
vehicle-treated tissue, and thereafter, up to the
longest preincubation time tested (90 min), there
was no further rise. Typical sections are illustrated in
Fig. 1.
Median preoptic nucleus
Subjective assessment. Regional silver-grain distri¬
bution in sections containing the MPN, probed with
pHjetorphine alone, was similar to sections contain¬
ing the SON. Assessed subjectively, in control rats,
the relative intensities were: white matter, 0 to +;
MPN, + + +; patches in the caudate-putamen,
+ + + +; elsewhere in the caudate-putamen and in
the cerebral cortex, + +. Specificity control sections,
incubated with [3H]etorphine and either naloxone or
all three displacers, gave very weak images.
In i.c.v. morphine-treated rats the pattern of silver-




Fig. 2. Treatment group means ( + S.E.M.) of 3H-ligand binding to the SON of i.c.v. vehicle-infused rats
(□) and i.c.v. morphine-infused rats (0), in each incubation category. The values shown represent specific
binding to opioid receptors since specificity control values have been subtracted. Values are expressed in
fmol of 3H-ligand per mg of tissue. Etorph alone, binding after incubation with [3H]etorphine alone
(without displacers). E + DPDPE + U50, binding after incubation with [3H]etorphine and DPDPE and
U50,488H. Bremaz alone, binding after incubation with [3H](—)-bremazocine alone (without displacers).
B + DAGO + DPDPE, binding after incubation with [3H](—)-bremazocine and DAGO and DPDPE.
*P < 0.05 (Student's /-test).
Opioid receptor subtypes in morphine-tolerant rats 641
was similar to the control group, but the silver-grain
density appeared lower in the MPN and elsewhere.
Quantitative assessment. Chronic morphine treat¬
ment significantly decreased grain density over MPN
after incubation in ['HJetorphine (by 29.7%,
P < 0.05; Student's paired r-test, Table 3). Mean
specific [3H]etorphine-binding in the MPN was re¬
duced by 77.0% in morphine-treated rats. In the
control and morphine-treated groups the means
( + S.E.M.) were 76.2 + 9.8 and 17.5 + 5.2 fmol per
mg of tissue, respectively (P < 0.01, Student's Mest).
Prolonged preincubation, for 90 min, before incuba¬
tion in [3H]etorphine did not affect the difference
between control and morphine-treated rats.
Posterior pituitary
Subjective assessment. Whole pituitary sections
were apposed to film, but only the PP gave an
autoradiographic image. Typical autoradiographs are
shown in Fig. 3. No consistent differences between
central and peripheral parts of the posterior pituitary
were found in any incubation category. Using
)-bremazocine alone or with DAGO and
DPDPE an intense image was obtained (+ + +).
Inclusion of DPDPE and U50.488H in the incubating
medium gave a less intense image (+ +). Incubation
in the presence of DAGO and U50.488H resulted in
a very weak image (0 to +). Specificity control
sections, incubated with [3H](—)-bremazocine and
naloxone, also gave very weak images (0 to +), and
chemography control sections, incubated without
3H-ligand, gave no images at all.
Images from the posterior pituitaries ofmorphine-
treated rats were similar to those from vehicle-treated
controls.
Quantitative assessment. Whether the quantitative
results from the posterior pituitary were expressed as
mean grain densities, or as mean binding, no statisti¬
cally significant differences were found between the
centre, and the periphery, of the PP for any incuba¬
tion category so central and peripheral data have
been combined.
In control rats, the mean grain densities were
highest after incubation with [3H](—)-bremazocine
alone (Table 3). Chronic morphine treatment had no
significant effects (Table 3). Results from PP sections
of control rats probed with [3H](—)-bremazocine
alone or with naloxone, showed that specific binding
averaged 79% of the total. Mean ( + S.E.M.) specific
binding after incubation with [3H]( — )-bremazocine
without displacers, was 11.6 + 6.30 and 18.0 +
8.46 fmol per mg of tissue in control and i.c.v.
Fig. 3. (Top row) S is a 10-/rm section of rat pituitary, incubated with [3H]( — )-bremazocine, apposed to
Hyperfilm-3H for 16 weeks, then fixed in acetic acid-ethanol-formalin, and stained with Cresyl Fast Violet.
The PP is the pale-staining area. A is the autoradiographic image of S. Note that only the PP has produced
an image. This image shows binding to opioid receptors after incubation in ['H](—)-bremazocine alone
(without displacers) (Bt). Magnification x 8. (Second row) Autoradiographic images of sections incubated
with [3H]( — )-bremazocine and DAGO and DPDPE (Bk), or with [3H](— )-bremazocine and DPDPE and
U50.488H (Bu), or with [3H](— )-bremazocine and naloxone to antagonize all binding to opioid receptors
(N). Magnification x 8.
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morphine-infused rats, respectively. In control rats
binding was only 9.2% of that in the SON in the same
incubation category. In the presence of DAGO and
DPDPE the mean ( + S.E.M.) values were 3.25 ± 2.09
and 2.72+ 1.42 fmol of 3H-ligand bound per mg of
tissue in control and morphine groups, respectively.
For control rats, this binding was only 2.5% of the
level in the SON in similar conditions. Mean
( + S.E.M.) specific binding after incubation with
[3H](—)-bremazocine and DPDPE and U50,488H
was 2.00 + 1.21 fmol (control group), and
1.07 + 0.73 fmol (morphine group) per mg of tissue.
There were no significant differences between control
and morphine-treated rats for any incubation cate¬
gory.
Blood plasma analysis
There were no significant differences between the
control and i.e. v. morphine groups for any of the par¬
ameters measured, i.e. trunk blood plasma oxytocin,




Control rats. Unlike some previous studies on male
rats35,36 we found 3H-ligand-binding in the SON of
female rats in conditions designed to be selective for
//-type opioid receptors. We suggest that this repre¬
sents binding to //-type opioid receptors, for the
following reasons. Firstly, [3H]etorphine is a broad
spectrum 3H-ligand for opioid receptors, but with a
1000-fold molar excess of the unlabelled agonists,
DPDPE and U50,488H, known to have high relative
affinity for 5- and K-type receptors, respectively,16-40
competition for binding sites would be expected to
leave predominantly //-receptors available for [3H]-
etorphine. Although U50,488H is a stronger dis-
placer at K-type opioid receptors of the guinea-pig
(postulated type 1 k-receptors) than at k-receptors of
the rat (postulated type 2 receptors),62 it nonetheless
blocks in situ [3H]( — )-bremazocine-binding to rat
k-receptors.38,39 Secondly, incubation with DAGO
(which has a high relative affinity for //-receptors), in
addition to DPDPE and U50.488H, reduced
[3H]etorphine-binding in the SON to a very low level.
Thirdly, elsewhere in the sections containing SON
profiles were intense patches of labelling, present after
incubation in media designed to demonstrate //-
receptors, but absent after incubation in media de¬
signed to show 5- or /c-receptors. Other authors have
claimed these intense clusters in the caudate-putamen
to be //-receptors.57 Fourthly, the change in the SON
during chronic morphine treatment was confined to
//-selective binding. This suggests that the subtype
demonstrated by this selective incubation differs from
the others, and that it is uniquely responsive to a
known //-selective agonist (morphine). Lastly, the
demonstration of //-type opioid receptors in the SON
is consistent with the inhibitory action of morphine
on the electrical activity of oxytocin neurons when
applied close to their cell bodies.49,58
Specific binding to opioid receptors was also
demonstrated in the SON after incubation with
[3H]( — )-bremazocine in the presence of DAGO and
DPDPE, a procedure designed to be selective for
K-receptors. In the caudate-putamen, this type of
incubation did not show the intense patches of bind¬
ing shown by 3H-ligand alone, or by incubation in
conditions intended to be //-selective; it seems likely
that DAGO and DPDPE prevented binding to the
receptor subtype(s) at these clustered sites. Addition
of U50,488H. a known k-receptor-selective agonist,16
to the other two unlabelled selective agonists reduced
[3H]( — )-bremazocine-binding to a low level both in
the SON and caudate-putamen, supporting the as¬
sumption that /c-receptors were predominantly in¬
volved. Demonstration of k-receptor in the SON is in
agreement with previous reports,35'36 and with electro¬
physiological studies showing inhibitory actions of
U50,488H on oxytocin (and vasopressin) neurons in
the SON.49 Indeed, suppression of electrical activity
by U50.488H, and by morphine, has even been
achieved on the same supraoptic neuron (Russell et
al., unpublished observations).
With the low resolution of the techniques used, we
were unable to determine the distribution of //- and
k-receptors on or between neurons,24 or indeed
whether they had been internalized.29 It is possible, by
analogy with the PP gland,12-33 that some of the
receptors were on glial cells, especially astrocytes.
Effects of intracerebroventricular morphine infusion.
In the SON, binding of [3H]etorphine in conditions
designed to be //-selective was reduced by over 80%
by chronic morphine treatment compared with con¬
trol rats. Morphine did not affect k-selective [3H](—)-
bremazocine-binding.
One possible explanation for decreased binding of
[3H]etorphine to the SON after chronic morphine
treatment could be that morphine still in the tissue
Table 4. Means (+ S.E.M.) of data from blood plasma samples
Oxytocin Glucose Sodium
Treatment concentration concentration concentration Osmolality
group (pg/ml) (mM/1) (mM/1) (mOsmol/kg)
i.c.v. vehicle-infused 13.23 + 5.06 7.82 + 0.43 138.29 + 2.23 270.00 + 5.63
(n =6)
i.c.v. morphine- 8.67+ 1.77 7.31 +0.24 142.71 + 1.41 268.29 + 5.99
infused (n = 6)
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competes with [3H]etorphine. Morphine is remark¬
ably persistent in brain after peripheral adminis¬
tration, [14C]morphine still being detectable three
weeks after a single injection,37 however, morphine
can be washed out in vitro,55 Similarly, altered release
of endogenous opioid in i.e.v. morphine-infused rats
might compete with [3H]etorphine. However, etor-
phine has a high affinity for opioid receptors,22 and
5'-guanylylimidodiphosphate was included in the
preincubating medium to encourage dissociation of
receptor-bound opioids,12 and we showed that pre¬
incubation for much longer than the 15 min used did
not result in any increase in 3H-ligand binding. It
seems reasonable to conclude that in vivo, the number
of /(-receptors in the SON is reduced by chronic i.e. v.
infusion of morphine, and that this reduction ex¬
plains the decreased binding of 3H-ligand. However,
a possible wash-resistant blockade by some of the
i.e.v. infused morphine, cannot be ruled out. A
significant reduction in [3H]etorphine-binding was
found also in the MPN, though not resolved to a
particular opioid receptor subtype.
A reduction in number of available /(-receptors
might allow SON oxytocin neurons, and their inputs,
to function normally in morphine-treated rats, as
indicated by similar concentrations of oxytocin in
trunk blood plasma from the i.e.v. morphine- and
vehicle-treated rats in the present study. Normal
functioning has also been inferred in previous
studies.6-43 The consequence of a partial loss or block¬
ade of /(-type receptors would be to decrease the pool
of spare receptors.I4-32-53 Thus, even if the affinity of
the receptors for morphine were unaffected, this
would decrease the number of receptors which could
be activated at a given concentration of morphine.
This effect would contribute to tolerance, and the
extent of the loss of binding we have measured might
almost be great enough to explain morphine-toler¬
ance15 in the female rat oxytocin system. We found
no evidence after i.e.v. morphine infusion for changes
in trunk blood plasma glucose or sodium concen¬
trations, or osmolality, that might stimulate the
oxytocin system through osmoreceptor mechan¬
isms,47 and perhaps alter opioid receptor density in
the SON.
Posterior pituitary
Control rats. In common with earlier work,51 we
found a much lower density of opioid receptors in the
PP than in the brain. Longer exposures were required
to produce autoradiographic images. Most binding
was obtained after incubation with [3H]( — )-brema-
zocine alone, or in the presence of DAGO and
DPDPE, which was intended to be selective for
K-receptors. Since addition of U50,488H to DAGO
and DPDPE reduced [3H](—)-bremazocine-binding
to a low level, it is probable that k-receptors were
indeed responsible for most of this binding. Other
authors have also suggested that opioid receptors in
the PP are predominantly of the k -receptor sub¬
type.9I2'25 In the presence of DPDPE and U50,488H,
which was intended to be /(-selective, there was still
some binding by [3H](—)-bremazocine, but there was
less binding in pilot studies with [3H]etorphine so the
presence of the /(-receptor subtype in the PP remains
controversial.
We did not find any differences in opioid receptor
density between the central and peripheral zones of
the PP of female rats, unlike the studies of Herken-
ham et al.25 and Brady and Herkenham9 on male
rats.
Effects of intracerebroventricular morphine infusion.
Although i.e.v.-infused morphine reaches the PP,43 we
detected no change in [3H]( — )-bremazocine binding
in any incubating conditions. The lack of effect of
morphine on k-receptors in the PP is consistent with
the persistence of endogenous opioid- (probably
dynorphinj-inhibition of oxytocin secretion in iso¬
lated PPs from i.c.v. morphine-infused rats in vitro?
Thus, chronic morphine treatment neither affects the
number of K-receptors, nor induces cross-tolerance to
the endogenous ligand in the PP. However, the
density of K-receptors in the PP can show plasticity:
during dehydration for five days the number of
K-receptors decreases by about 40% without a
change in affinity."
CONCLUSION
The data we have on the oxytocin and oxytocin
mRNA content of SON neurons, their firing rate, and
the responsiveness of their terminals in the PP to
electrical stimulation, all indicate that the synthesis of
oxytocin and the coupling of electrical activity to
secretion are not altered in morphine-tolerance.3'6'43'54
This leaves opioid-receptor interaction, and early
post-receptor events regulating electrical excitability,
as likely sites for tolerance. We have provided evi¬
dence in this study for a decrease in number of
available /(-receptors in the SON, and of available
opioid receptors in an input pathway, the MPN,
which regulates oxytocin neurons, but we have not
distinguished intracellular forms from surface forms
of the receptor. There may also be reduced effective¬
ness of remaining receptors available for binding to
ligand because of attenuated coupling of receptor to
a Gi/0-like protein, as has been described for mor¬
phine-tolerant locus coeruleus neurons,15 but this has
not been investigated in SON neurons.
Morphine-dependence in the oxytocin system, re¬
vealed by injection of naloxone, is expressed as with¬
drawal excitation of oxytocin hypersecretion result¬
ing from a large increase in the firing rate of oxytocin
neurons.6,30 This phenomenon is mediated through
/(-receptors,31 which the present study has shown to
remain available in the SON at about 20% of the
number in morphine-naive rats. It is difficult to
explain withdrawal excitation of oxytocin neurons in
terms of a reduced number of available /(-receptors.
Adaptive changes in post-receptor mechanisms regu-
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lating ionic fluxes seem more likely. There may also
be compensatory changes in non-opioid pathways.
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